

CITATION REPORT

List of articles citing

Imaging brain amyloid in Alzheimerts disease with
Pittsburgh Compound-B

DOI: 10.1002/ana.20009

Annals of Neurology, 2004, 55, 306-19.

Source: <https://exaly.com/paper-pdf/37101880/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2282	Brain imaging investigation of chemotherapy-induced neurocognitive changes. 19-32		9
2281	Following are the abstracts from the Third Annual Meeting of the Society for Molecular Imaging. The nature of author relationships of financial interests or affiliations with organizations with a direct and substantial interest in the subject matter of the following presentations are numbered accordingly at the bottom of each abstract: 1 = Grant/research support; 2 = Consultant; 3 = Speakers bureau; 4 = Stockholder; 5 = Employment; 6 = Other financial or material support; or none of the above. 2004, 3, 1535-1540		
2280	Quantitative and statistical analyses of PET imaging studies of amyloid deposition in humans. 2004, 3, 1535-1540		2
2279	Functional-anatomic correlates of memory retrieval that suggest nontraditional processing roles for multiple distinct regions within posterior parietal cortex. 2004, 24, 10084-92		224
2278	Protein chemistry. In the footsteps of alchemists. 2004, 304, 1259-62		64
2277	Amyloid angiopathy-related vascular cognitive impairment. 2004, 35, 2616-9		243
2276	Advances in the early detection of Alzheimer's disease. 2004, 10 Suppl, S34-41		332
2275	PET imaging of amyloid in Alzheimer's disease. 2004, 3, 519-27		358
2274	Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. 2004, 1025, 98-105		116
2273	Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. 2004, 24, 55-62		53
2272	Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection. 2004, 24, 333-6		3
2271	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. 2004, 31, 1539-40		3
2270	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. 2004, 31, 1540-3		4
2269	The proteomics of positron emission tomography. <i>Annals of Neurology</i> , 2004, 55, 303-5	9.4	11
2268	In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. 2004, 52, 1263-71		154
2267	High-field magnetic resonance imaging of brain iron: birth of a biomarker?. 2004, 17, 433-45		269
2266	Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. 2004, 4, 831-49		34

2265	Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. 2004 , 56, 670-6	155
2264	Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose. 2004 , 42, 1033-53, viii	32
2263	Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. 2004 , 44, 195-208	1128
2262	A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. 2004 , 23, 724-38	905
2261	Pathological aging of the brain: an overview. 2004 , 15, 369-89	48
2260	Targeting prion amyloid deposits in vivo. 2004 , 63, 775-84	28
2259	SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease. 2004 , 13, 1369-73	2
2258	Emission tomography in dementia. 2005 , 26, 189-96	40
2257	Dementia update 2005. 2005 , 19, 100-17	44
2256	Biomarkers for neurodegenerative diseases. 2005 , 18, 698-705	55
2255	Imaging in neurodegenerative disorders: recent studies. 2005 , 18, 640-6	8
2254	Healthy and pathological processes in adult development: new evidence from neuroimaging of the aging brain. 2005 , 18, 740-7	72
2253	[Probes for diagnosis of Alzheimer's disease]. 2005 , 126, 199-206	
2252	[Molecular imaging techniques for research on brain function using PET]. 2005 , 126, 347-52	0
2251	Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer's Disease with PET. 2005 , 62, 591-5	50
2250	Techniques for brain imaging in vivo. 2004 , 6, 65-78	25
2249	Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology. 2005 , 10, 11007	21
2248	Amyloid beta-peptide(1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. 2005 , 95, 715-23	157

2247	Current concept and future research directions of mild cognitive impairment. 2005 , 5, 83-88	5
2246	Aggregating interests in aggregates: mechanistic, diagnostic and therapeutic implications of brain amyloidosis in neurodegenerative disorders among the elderly. 2005 , 5, 117-121	
2245	Bringing amyloid into focus. 2005 , 23, 552-4	4
2244	In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. 2005 , 23, 577-83	270
2243	Alzheimer disease, in living color. 2005 , 8, 404-5	14
2242	¹⁹ F and ¹ H MRI detection of amyloid beta plaques in vivo. 2005 , 8, 527-33	304
2241	Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. 2005 , 25, 1528-47	566
2240	The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials. 2005 , 4, 129-33	14
2239	Brain aging: reorganizing discoveries about the aging mind. 2005 , 15, 245-51	400
2238	Dementia: finding the signals in the noise. 2005 , 4, 10-1	6
2237	Alzheimer's amyloid immunotherapy: quo vadis?. 2005 , 4, 452-3	9
2236	Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. 2005 , 26, 231-9	589
2235	In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. 2005 , 44, 5452-6	254
2234	In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. 2005 , 117, 5588-5592	34
2233	¹⁸ F-FESB: synthesis and automated radiofluorination of a novel ¹⁸ F-labeled pet tracer for amyloid plaques. 2005 , 48, 983-996	6
2232	PET imaging of brain with the beta-amyloid probe, [¹¹ C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. 2005 , 32, 593-600	108
2231	Imaging in cell-based therapy for neurodegenerative diseases. 2005 , 32 Suppl 2, S417-34	12
2230	Human gene therapy and imaging in neurological diseases. 2005 , 32 Suppl 2, S358-83	14

2229	A computational positron emission tomography simulation model for imaging beta-amyloid in mice. 2005 , 7, 69-77	8
2228	Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development. 2005 , 7, 59-68	11
2227	Problems associated with biological markers of Alzheimer's disease. 2005 , 30, 1501-10	29
2226	The role of Amyloid in Alzheimer's disease. 2005 , 452-458	
2225	Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics. 2005 , 445-458	2
2224	Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. 2005 , 4, 2000-9	96
2223	F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. 2005 , 48, 5980-8	132
2222	Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. 2005 , 1, 96-105	17
2221	Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. 2005 , 280, 23599-604	82
2220	Nigrostriatal dysfunction in familial Alzheimer's disease-linked APP ^{swe} /PS1 ^{DeltaE9} transgenic mice. 2005 , 25, 10220-9	67
2219	Neuroimaging in dementia. 2005 , 67, 43-72	1
2218	Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease. 2005 , 5, 277-84	22
2217	In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. 2005 , 25, 10041-8	142
2216	Antecedent biomarkers of Alzheimer's disease: the adult children study. 2005 , 18, 242-4	28
2215	Use of laboratory and imaging investigations in dementia. 2005 , 76 Suppl 5, v45-52	10
2214	Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. 2005 , 25, 10857-62	172
2213	Clinical observations with AN-1792 using TAPIR analyses. 2005 , 2, 273-6	16
2212	Positron Emission Tomography Agents for Central Nervous System Drug Development Applications. 2005 , 40, 49-68	4

2211	Multiple ligand binding sites on A beta(1-40) fibrils. 2005 , 12, 5-14	77
2210	Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). 2005 , 1, 55-66	652
2209	Amyloid imaging: from benchtop to bedside. 2005 , 70, 171-213	37
2208	Commentary on "Diagnosis of Alzheimer's disease: two decades of progress". 2005 , 1, 107-8	
2207	Role of biomarkers in studies of presymptomatic Alzheimer's disease. 2005 , 1, 145-51	21
2206	Translational research in central nervous system drug discovery. 2005 , 2, 671-82	80
2205	Positron emission tomography diagnosis of Alzheimer's disease. 2005 , 15, 837-46, x	37
2204	A clinical perspective of mild cognitive impairment: what radiologists should know. 2005 , 15, 779-88, x	2
2203	Mild Cognitive Impairment. 2005 , 13, 645-655	81
2202	Clinical aspects of inflammation in Alzheimer's disease. 2005 , 17, 503-14	97
2201	Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. 2005 , 280, 7677-84	174
2200	Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. 2005 , 12, 221-30	46
2199	Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity. 2005 , 65, 123-37	28
2198	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. 2005 , 26, 104-11	114
2197	Biphenyls labeled with technetium 99m for imaging beta-amyloid plaques in the brain. 2005 , 32, 171-84	52
2196	Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. 2005 , 32, 337-51	34
2195	F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. 2005 , 32, 799-809	196
2194	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. 2005 , 2, 226-36	85

2193	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. 2005 , 2, 348-60	124
2192	Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. 2005 , 2, 612-26	72
2191	Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. 2005 , 48, 7253-60	65
2190	The use of biomarkers in the elderly: current and future challenges. 2005 , 58, 272-6	30
2189	Neuroimaging as a marker of the onset and progression of Alzheimer's disease. 2005 , 236, 55-64	91
2188	Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. 2005 , 25, 7709-17	1550
2187	The RRC mandate for residency programs to demonstrate psychodynamic psychotherapy competency among residents: a debate. 2005 , 29, 339-49	17
2186	Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. 2005 , 25, 10598-606	322
2185	Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. 2006 , 26, 10222-31	533
2184	Very small and soft scorpionates: water stable technetium tricarbonyl complexes combining a bis-agostic (k(3)-H, H, S) binding motif with pendant and integrated bioactive molecules. 2006 , 128, 14590-8	53
2183	Noninvasive Brain Imaging for Experimental Medicine in Drug Discovery and Development. 2006 , 20, 167-175	1
2182	Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. 2006 , 2, 131-9	27
2181	Neuroimaging in Parkinson's disease. 2006 , 241-248	7
2180	Alzheimer's disease. 2006 , 368, 387-403	2621
2179	The role of biomarkers in clinical trials for Alzheimer disease. 2006 , 20, 6-15	167
2178	A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies--clinical brain studies using [11C]-GR205171, [11C]-L-deuterium-deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11C]-L-DOPA and Pittsburgh Compound-B. 2006 , 33, 588-98	20
2177	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. 2006 , 33, 94-102	105
2176	Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. 2006 , 2, 36-42	42

2175	Commentary on "The NIH Cognitive and Emotional Health Project. Report of the Critical Evaluation Study Committee". 2006 , 2, 33-5	3
2174	Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. 2006 , 2, 263-71	37
2173	Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". 2006 , 2, 272-4	7
2172	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. 2006 , 77, 714-8	422
2171	Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. 2006 , 49, 6111-9	162
2170	Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. 2006 , 2, 43-55	86
2169	Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?. 2006 , 59, 940-7	22
2168	Oxorhenium(V) and oxotechnetium(V) [NN][S]3 complexes of 2-phenylbenzothiazole derivatives. 2006 , 45, 902-9	27
2167	Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. 2006 , 19, 180-5	21
2166	Positron emission tomography of the brain. 2006 , 16, 591-603, viii	4
2165	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. 2006 , 49, 2841-4	23
2164	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. 2006 , 49, 2725-30	89
2163	Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. 2006 , 28, 991-1001	132
2162	A quantitative near-infrared spectroscopy study: a decrease in cerebral hemoglobin oxygenation in Alzheimer's disease and mild cognitive impairment. 2006 , 61, 189-94	63
2161	Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. 2006 , 347, 669-77	18
2160	Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. 2006 , 27, 1604-12	195
2159	A hundred years of Alzheimer's disease research. 2006 , 52, 3-13	365
2158	Synthesis and evaluation of benzothiophene derivatives as ligands for imaging beta-amyloid plaques in Alzheimer's disease. 2006 , 33, 811-20	25

2157 Syndromic approach to Parkinson's disease: role of functional imaging. **2006**, 2, 83-91

2156 Imaging Brain Amyloid in Alzheimer's Disease With Pittsburgh Compound-B. **2006**, 2006, 190-191

0

2155 La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. **2006**, 19, 453-74

11

2154 Visual association pathology in preclinical Alzheimer disease. **2006**, 65, 621-30

116

2153 Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. **2006**, 33, 6-26

14

2152 Introduction to Neurotherapeutics and Neuropsychopharmacology. **2006**, 1, 1-12

2151 Development of a population-based questionnaire to explore psychosocial determinants of screening for memory loss and Alzheimer Disease. **2006**, 20, 182-91

11

2150 Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. **2006**, 20, S12-8

92

2149 High-field magnetic resonance imaging of brain iron in Alzheimer disease. **2006**, 17, 41-50

59

2148 The natural history of Alzheimer disease dissected through multiphoton imaging of transgenic mice. **2006**, 20, 206-9

1

2147 Seeing is believing: neuroimaging adds to our understanding of cerebral pathology. **2006**, 19, 564-9

20

2146 New developments in mild cognitive impairment and Alzheimer's disease. **2006**, 19, 552-8

17

2145 Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. **2006**, 19, 299-306

17

2144 Reporters of Amyloid Structure. **2006**, 287-302

2143 Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. **2006**, 24, 2530-42

81

2142 Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. **2006**, 97, 1700-25

190

2141 Disease modifying therapy for AD?. **2006**, 99, 689-707

105

2140 Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. **2006**, 5, 69-79

67

2139	Pinpointing plaques with PIB. 2006 , 12, 753-4; discussion 754	19
2138	In vivo imaging of the diseased nervous system. 2006 , 7, 449-63	152
2137	Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents. 2006 , 14, 8599-607	89
2136	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. 2006 , 16, 1350-2	39
2135	QSAR and primary docking studies of trans-stilbene (TSB) series of imaging agents for β -amyloid plaques. 2006 , 763, 83-89	19
2134	Alzheimer 100--highlights in the history of Alzheimer research. 2006 , 113, 1603-23	91
2133	Memory-provoked rCBF-SPECT as a diagnostic tool in Alzheimer's disease?. 2006 , 33, 73-80	8
2132	NeuroAIDS, drug abuse, and inflammation: building collaborative research activities. 2006 , 1, 351-99	20
2131	Frontotemporal dementia. 2006 , 6, 481-9	16
2130	Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B. 2006 , 6, 496-503	20
2129	Current treatment of mild cognitive impairment and Alzheimer's disease. 2006 , 6, 365-71	24
2128	Imaging Alzheimer's disease pathology: one target, many ligands. 2006 , 11, 1093-9	50
2127	Biomarkers for the early diagnosis of Alzheimer's disease. 2006 , 5, 198-9	17
2126	Aspirin after intracerebral haemorrhage: probably safer than we thought. 2006 , 5, 288-9	2
2125	Plasma Abeta in Alzheimer's disease--up or down?. 2006 , 5, 638-9	30
2124	Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. 2006 , 19, 655-68	48
2123	Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. 2006 , 27, 888-96	54
2122	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. <i>Annals of Neurology</i> , 2006 , 59, 512-9	9.4 1009

2121	Reply: To PMID 16374827. <i>Annals of Neurology</i> , 2006 , 59, 432	9.4	16
2120	Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. <i>Annals of Neurology</i> , 2006 , 60, 145-7	9.4	163
2119	Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. <i>Annals of Neurology</i> , 2006 , 60, 688-95	9.4	114
2118	Dementia epidemiology research: it is time to modify the focus of research. 2006 , 61, 1314-8		11
2117	Interventions for heart disease and their effects on Alzheimer's disease. 2006 , 28, 630-6		31
2116	Regional cerebral blood flow reductions, heart failure and Alzheimer's disease. 2006 , 28, 579-87		34
2115	The role of neuroimaging in elucidating delirium pathophysiology. 2006 , 61, 1287-93		50
2114	Noninvasive brain imaging for experimental medicine in drug discovery. 2006 , 1, 111-21		1
2113	Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. 2006 , 412, 144-60		34
2112	Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. 2007 , 78, 356-62		60
2111	Mild cognitive impairment should be considered for DSM-V. 2006 , 19, 147-54		46
2110	X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. 2006 , 412, 123-44		42
2109	Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40. 2006 , 318, 17-25		10
2108	The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. 2006 , 26, 6069-76		129
2107	Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease. 2006 , 15, 209-13		21
2106	The frontal assessment battery does not differentiate frontotemporal dementia from Alzheimer's disease. 2006 , 22, 125-31		60
2105	PET of brain amyloid and tau in mild cognitive impairment. 2006 , 355, 2652-63		573
2104	Biomarkers in the diagnosis of Alzheimer's disease: are we ready?. 2006 , 19, 172-9		44

2103	The Generic Nature of Protein Folding and Misfolding. 2006 , 21-41	10
2102	Congo Red Staining of Amyloid: Improvements and Practical Guide for a More Precise Diagnosis of Amyloid and the Different Amyloidoses. 2006 , 239-276	25
2101	Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. 2006 , 26, 365-71	61
2100	Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. 2007 , 104, 18760-5	806
2099	Diagnostic imaging devices in Alzheimer's disease. 2007 , 4, 475-87	8
2098	Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. 2007 , 282, 23818-28	318
2097	In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. 2007 , 27, 10365-71	130
2096	Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. 2007 , 27, 10957-68	246
2095	Translational research in late-life mood disorders: implications for future intervention and prevention research. 2007 , 32, 1857-75	37
2094	Current experimental therapy for Alzheimer's disease. 2007 , 5, 127-34	10
2093	Positron emission tomography imaging in dementia. 2007 , 80 Spec No 2, S160-7	195
2092	Histological Validation of Dopamine Transporter PET Images in the Rat 6-OHDA Lesion Model of Parkinson's Disease. 2007 , 30, 123-129	1
2091	Longitudinal imaging in dementia. 2007 , 80 Spec No 2, S92-8	18
2090	Blueprint for imaging in biomedical research. 2007 , 244, 12-27	21
2089	Molecular neuroimaging: from conventional to emerging techniques. 2007 , 245, 21-42	57
2088	Role of imaging techniques in the diagnosis of dementia. 2007 , 80 Spec No 2, S71-7	75
2087	Computational anatomical methods as applied to ageing and dementia. 2007 , 80 Spec No 2, S78-91	51
2086	Cerebrovascular disease and dementia. 2007 , 80 Spec No 2, S121-7	46

2085	Structural magnetic resonance imaging-derived biomarkers for Alzheimer's disease. 2007 , 1, 79-92	4
2084	PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION. 2007 ,	4
2083	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. 2007 , 27, 6174-84	313
2082	Chapter 2 Alzheimer's Disease. 2007 , 33-58	1
2081	Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. 2007 , 27, 12721-31	81
2080	Imaging in dementia. 2007 , 19, 133-141	
2079	Visuospatial planning and problem solving in Alzheimer's disease patients: a study with the Tower of London Test. 2007 , 24, 424-8	24
2078	Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. 2007 , 322, 541-9	18
2077	Mild Cognitive Impairment. 2007 ,	
2076	Chapter 15 Advances in Neuroimaging. 2007 , 30, 381-410	
2075	PET and SPECT imaging in psychiatric disorders. 2007 , 52, 146-57	62
2074	[The concept of neuroprotective agents as a treatment modulator in the development of brain diseases]. 2007 , 62, 463-72	1
2073	Early detection of Alzheimer's disease. 2007 , 3, 449-456	2
2072	MILD COGNITIVE IMPAIRMENT. 2007 , 13, 15-38	21
2071	Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. 2007 , 21, S79-87	52
2070	NEUROIMAGING IN DEMENTIA. 2007 , 13, 180-203	1
2069	Amyloid imaging in Alzheimer's disease. 2007 , 20, 398-402	69
2068	Disease staging and milestones. 2007 , 34 Suppl 1, S62-6	2

2067	Imaging biomarkers and their role in dementia clinical trials. 2007 , 34 Suppl 1, S77-83	26
2066	Intelligence quotient-adjusted memory impairment is associated with abnormal single photon emission computed tomography perfusion. 2007 , 13, 821-31	13
2065	Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. 2007 , 28, 1465-80	100
2064	Disruption of large-scale brain systems in advanced aging. 2007 , 56, 924-35	1171
2063	18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. 2007 , 34, 89-97	95
2062	Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for beta-amyloid plaques. 2007 , 34, 681-9	16
2061	Impact of amyloid imaging on drug development in Alzheimer's disease. 2007 , 34, 809-22	105
2060	Quick assembly of 1,4-diphenyltriazoles as probes targeting beta-amyloid aggregates in Alzheimer's disease. 2007 , 50, 3380-7	51
2059	Aurones serve as probes of beta-amyloid plaques in Alzheimer's disease. 2007 , 361, 116-21	54
2058	Binding mode of Thioflavin T in insulin amyloid fibrils. 2007 , 159, 483-97	165
2057	[Neuroimaging in dementia]. 2007 , 36, 1453-63	6
2056	Imagerie moléculaire dans les démences. 2007 , 31, 272-277	1
2055	Human brain myelination and amyloid beta deposition in Alzheimer's disease. 2007 , 3, 122-5	100
2054	Longitudinal stability of CSF biomarkers in Alzheimer's disease. 2007 , 419, 18-22	145
2053	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. 2007 , 36, 298-312	75
2052	Assessment of Parkinson's disease with imaging. 2007 , 13 Suppl 3, S268-75	18
2051	Selective naming (and comprehension) deficits in Alzheimer's disease?. 2007 , 43, 921-34	26
2050	Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. 2007 , 13, 38-48	64

2049	Aspects of beta-amyloid as a biomarker for Alzheimer's disease. 2007 , 1, 59-78	65
2048	Positron Emission Tomography of the Brain. 2007 , 2, 1-13	1
2047	Brain imaging research: does the science serve clinical practice?. 2007 , 19, 541-58	29
2046	Imaging Parkinson's disease. 2007 , 83, 245-63	
2045	MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. 2007 , 20, 3-21	90
2044	Amyloid imaging in vivo: implications for Alzheimer's disease management. 2007 , 1, 337-49	3
2043	Donepezil: an update. 2007 , 8, 1011-23	132
2042	Metabolically stabilized benzothiazoles for imaging of amyloid plaques. 2007 , 50, 1087-9	72
2041	New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. 2007 , 50, 2415-23	28
2040	Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates. 2007 , 18, 238-46	56
2039	Neuroimaging in dementia. 2007 , 25, 843-57, viii	16
2038	Alzheimer's disease and mild cognitive impairment. 2007 , 25, 577-609, v	184
2037	The utility of PET brain imaging in the initial evaluation of dementia. 2007 , 8, 150-7	12
2036	Neuroimaging in Dementia. 2007 , 2, 15-24	1
2035	Cutting-edge brain imaging with positron emission tomography. 2007 , 17, 427-40, viii	6
2034	Cutting-Edge Brain Imaging with Positron Emission Tomography. 2007 , 2, 91-104	3
2033	Positron Emission Tomography Diagnosis of Alzheimer's Disease. 2007 , 2, 25-34	6
2032	Optical brain imaging in vivo: techniques and applications from animal to man. 2007 , 12, 051402	291

2031	Nanoimaging in protein-misfolding and -conformational diseases. 2007 , 2, 615-43		12
2030	Synthesis and structure-affinity relationships of new 4-(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-N-dimethylbenzeneamine derivatives as ligands for human beta-amyloid plaques. 2007 , 50, 4746-58		37
2029	The Molecular Basis of Alzheimer's Disease. 2007 , 241-255		
2028	Measuring disease modification in Alzheimer's disease. 2007 , 12, 11-4		12
2027	In vivo mouse imaging and spectroscopy in drug discovery. 2007 , 20, 154-85		88
2026	Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques. 2007 , 8, 1679-87		60
2025	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007 , 62, 229-34	9.4	420
2024	Molecules that target beta-amyloid. 2007 , 2, 1674-92		93
2023	Alzheimer's disease and essential tremor finally meet. 2007 , 22, 1525-7		19
2022	Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. 2007 , 58, 179-84		30
2021	The imaging continuum: bench to biomarkers to diagnostics. 2007 , 50, 746-769		11
2020	Structure-activity relationship of chalcones and related derivatives as ligands for detecting of beta-amyloid plaques in the brain. 2007 , 15, 6388-96		40
2019	Novel chalcones as probes for in vivo imaging of beta-amyloid plaques in Alzheimer's brains. 2007 , 15, 6802-9		64
2018	Radioiodinated aza-diphenylacetylenes as potential SPECT imaging agents for beta-amyloid plaque detection. 2007 , 17, 3581-4		12
2017	Synthesis and evaluation of a (99m)Tc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid beta. 2007 , 17, 6086-90		47
2016	Imaging treatment effects in Alzheimer's disease. 2007 , 25, 953-68		32
2015	Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?. 2007 , 4, 590-601		130
2014	Seeing what Alzheimer saw. 2007 , 13, 129-31		8

2013	The 23rd International Symposium on Cerebral Blood Flow, Metabolism and Function. 2007 , 27, BO01-01-BP59-08H	3
2012	Correlation between each task of the Mini-Mental State Examination and regional glucose hypometabolism in at-rest Alzheimer's disease patients. 2007 , 7, 124-130	3
2011	Binding and safety profile of novel benzoxazole derivative for in vivo imaging of amyloid deposits in Alzheimer's disease. 2007 , 7, 393-400	6
2010	Assessment of endothelial function in Alzheimer's disease: is Alzheimer's disease a vascular disease?. 2007 , 55, 1613-7	101
2009	Congo red and thioflavin-T analogs detect Abeta oligomers. 2008 , 104, 457-68	165
2008	Structural imaging in the dementias. 2007 , 6, 503-507	1
2007	Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. 2007 , 28, 3-15	78
2006	Differentiating Alzheimer disease-associated aggregates with small molecules. 2007 , 28, 251-60	58
2005	Disease-modifying trials in Alzheimer's disease: a European task force consensus. 2007 , 6, 56-62	118
2004	Getting a grip on Alzheimer's disease: imaging amyloid in the brain. 2007 , 6, 204-6	2
2003	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. 2007 , 6, 734-46	3067
2002	Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease. 2007 , 1097, 146-55	164
2001	Linking brain imaging and genomics in the study of Alzheimer's disease and aging. 2007 , 1097, 94-113	29
2000	Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. 2007 , 1097, 114-45	151
1999	Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease. 2007 , 1097, 239-58	16
1998	Magnetic resonance imaging of Alzheimer's disease. 2007 , 17, 347-62	47
1997	Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. 2007 , 17, 2441-57	42
1996	[Neurobiological early diagnosis of Alzheimer's disease]. 2007 , 78, 1310-8	3

1995	High-yield, automated radiosynthesis of 2-(1-{6-[(2-[¹⁸ F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([¹⁸ F]FDDNP) ready for animal or human administration. 2007 , 9, 6-16	66
1994	In vitro imaging techniques in neurodegenerative diseases. 2007 , 9, 161-75	24
1993	The application of positron-emitting molecular imaging tracers in Alzheimer's disease. 2007 , 9, 204-16	22
1992	The enigma of vascular cognitive disorder and vascular dementia. 2007 , 113, 349-88	175
1991	Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease. 2007 , 254, 1052-65	27
1990	Diagnosis and management of vascular cognitive impairment. 2007 , 9, 326-32	13
1989	Mild Cognitive Impairment [MCI]. 2007 , 1, 9-12	
1988	Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. 2008 , 5, 415-20	52
1987	Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. 2008 , 25, 1861-72	40
1986	Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. 2008 , 12, 61S-5S	22
1985	In vivo amyloid imaging with PET in frontotemporal dementia. 2008 , 35, 100-6	137
1984	Molecular imaging in dementia. 2008 , 35 Suppl 1, S1-3	10
1983	Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. 2008 , 35 Suppl 1, S4-11	15
1982	Amyloid plaque imaging in vivo: current achievement and future prospects. 2008 , 35 Suppl 1, S46-50	60
1981	Acetylcholine receptors in dementia and mild cognitive impairment. 2008 , 35 Suppl 1, S30-45	97
1980	Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. 2008 , 35 Suppl 1, S75-81	48
1979	MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. 2008 , 35 Suppl 1, S82-8	31
1978	In vivo imaging of axonal transport using MRI: aging and Alzheimer's disease. 2008 , 35 Suppl 1, S89-92	49

1977	Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. 2008 , 35 Suppl 1, S93-8		87
1976	Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's disease. 2008 , 35 Suppl 1, S107-13		23
1975	Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. 2008 , 35, 2169-81		217
1974	The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. 2008 , 38, 1-15		81
1973	A fusion PET-MRI system with a high-resolution research tomograph-PET and ultra-high field 7.0 T-MRI for the molecular-genetic imaging of the brain. 2008 , 8, 1302-23		70
1972	Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. 2008 , 62, 472-5		28
1971	Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience. 2008 , 23, 555-63		8
1970	Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. 2008 , 47, 8998-9033		711
1969	Thermodynamic and kinetic origins of Alzheimer's and related diseases: A chemical engineer's perspective. 2008 , 54, 1956-1962		11
1968	Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. <i>Annals of Neurology</i> , 2008 , 63, 112-8	9.4	184
1967	A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. <i>Annals of Neurology</i> , 2008 , 63, 377-87	9.4	329
1966	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. <i>Annals of Neurology</i> , 2008 , 63, 621-31	9.4	111
1965	Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2008 , 64, 388-401	9.4	363
1964	Primary progressive aphasia and the growing role of biomarkers in neurological diagnosis. <i>Annals of Neurology</i> , 2008 , 64, 361-4	9.4	6
1963	Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. <i>Annals of Neurology</i> , 2008 , 64, 587-91	9.4	77
1962	Synthese von 11C-, 18F-, 15O- und 13N-Radiotraceren für die Positronenemissionstomographie. 2008 , 120, 9136-9172		139
1961	Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. 2008 , 5, 381-90		17
1960	Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. 2008 , 172, 277-82		68

1959	Development of novel beta-amyloid probes based on 3,5-diphenyl-1,2,4-oxadiazole. 2008 , 16, 6867-72	42
1958	Synthesis and evaluation of stilbenylbenzoxazole and stilbenylbenzothiazole derivatives for detecting beta-amyloid fibrils. 2008 , 18, 1534-7	11
1957	Synthesis and biological evaluation of ^{99m} Tc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl)benzothiazole as potential probes for beta-amyloid plaques in the brain. 2008 , 18, 1442-5	42
1956	Isoindol-1,3-dione and isoindol-1-one derivatives with high binding affinity to beta-amyloid fibrils. 2008 , 18, 1628-31	14
1955	Synthesis and evaluation of indoliny- and indolylphenylacetylenes as PET imaging agents for beta-amyloid plaques. 2008 , 18, 4823-7	14
1954	[(18F)]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils. 2008 , 18, 5701-4	15
1953	Tau-based treatment strategies in neurodegenerative diseases. 2008 , 5, 443-57	109
1952	The brain's default network: anatomy, function, and relevance to disease. 2008 , 1124, 1-38	6450
1951	In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. 2008 , 18, 125-9	78
1950	Animal models of Alzheimer's disease and frontotemporal dementia. 2008 , 9, 532-44	535
1949	Beyond PIB: the next generation of amyloid-imaging ligands. 2008 , 8, 105-107	4
1948	Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. 2008 , 56, 920-34	102
1947	Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation. 2008 , 104, 1553-64	101
1946	In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. 2008 , 105, 1428-37	69
1945	MRI-based automated computer classification of probable AD versus normal controls. 2008 , 27, 509-20	115
1944	Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. 2008 , 582, 901-6	33
1943	Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. 2008 , 7, 129-35	551
1942	Imaging of amyloid comes of age. 2008 , 7, 114-5	3

1941	Current and future uses of neuroimaging for cognitively impaired patients. 2008 , 7, 161-72	110
1940	Biomarkers for cognitive impairment and dementia in elderly people. 2008 , 7, 704-14	64
1939	Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?. 2008 , 12, 1094-117	37
1938	Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. 2008 , 12, 1848-62	90
1937	DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. 2008 , 205, 57-63	27
1936	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. 2008 , 32, 412-9	395
1935	Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. 2008 , 46, 1597-612	90
1934	Functional imaging of cognition in Alzheimer's disease using positron emission tomography. 2008 , 46, 1613-23	30
1933	Recollection and familiarity in amnesic mild cognitive impairment: a global decline in recognition memory. 2008 , 46, 1965-78	88
1932	Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. 2008 , 46, 1688-97	239
1931	Amyloid imaging in Alzheimer's disease. 2008 , 46, 1636-41	58
1930	Clinical symptoms in Alzheimer's disease. 2008 , 89, 207-16	13
1929	Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. 2008 , 63, 609-18	182
1928	Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. 2008 , 64, 871-9	273
1927	Targeting cell death in vivo in experimental traumatic brain injury by a novel molecular probe. 2008 , 25, 569-80	30
1926	Early diagnosis and treatment of Alzheimer's disease. 2008 , 8, 769-80	20
1925	Synthesis and screening of a library of Re/Tc-based amyloid probes derived from beta-breaker peptides. 2008 , 19, 1087-94	28
1924	Variations in cortical thickness with dementia severity in Alzheimer's disease. 2008 , 436, 227-31	39

1923	Hippocampal hypometabolism predicts cognitive decline from normal aging. 2008 , 29, 676-92	239
1922	A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. 2008 , 29, 836-47	54
1921	PET imaging of amyloid deposition in patients with mild cognitive impairment. 2008 , 29, 1456-65	533
1920	In vivo site-directed radiotracers: a mini-review. 2008 , 35, 805-15	92
1919	[Near a biological diagnosis of Alzheimer's disease and related disorders]. 2008 , 29, 785-93	2
1918	[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results. 2008 , 14, 345-7	46
1917	An fMRI study of verbal episodic memory encoding in amnesic mild cognitive impairment. 2008 , 44, 869-80	40
1916	Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. 2008 , 38, 251-61	39
1915	Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. 2008 , 89, 245-60	100
1914	[11C]PIB binding in Parkinson's disease dementia. 2008 , 39, 1027-33	120
1913	Simplified parametric methods for [11C]PIB studies. 2008 , 42, 76-86	79
1912	Accuracy assessment of global and local atrophy measurement techniques with realistic simulated longitudinal Alzheimer's disease images. 2008 , 42, 696-709	31
1911	Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. 2008 , 43, 430-9	70
1910	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. 2008 , 4, 38-48	349
1909	Psychosocial determinants of intention to screen for Alzheimer's disease. 2008 , 4, 353-60	33
1908	Disease-modifying therapies in Alzheimer's disease. 2008 , 4, 65-79	103
1907	Optimizing phase II of drug development for disease-modifying compounds. 2008 , 4, S15-20	18
1906	Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. 2008 , 4, S29-36	20

1905	Eyes on the prize: federal Alzheimer's research effort aims to facilitate interventions. 2008 , 4, S37-47	6
1904	Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy. 2008 , 4, S88-90	
1903	Effect of parental family history of Alzheimer's disease on serial position profiles. 2008 , 4, 285-90	66
1902	Application of 18F-PET Imaging for the Study of Alzheimer's Disease. 2008 , 67-84	1
1901	Dementia of the Alzheimer type. 2008 , 30, 15-34	94
1900	Active and passive immunotherapy for neurodegenerative disorders. 2008 , 31, 175-93	202
1899	Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. 2008 , 43, 236-44	84
1898	KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. 2008 , 14, 215-26	62
1897	Investigation of Nonneoplastic Neurologic Disorders with PET and MRI. 2008 , 3, 317-34	3
1896	Automated (11)C-PiB standardized uptake value ratio. 2008 , 15, 1376-89	17
1895	Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly. 2008 , 16, 116-24	6
1894	Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. 2008 , 9, 172-82	111
1893	Frontotemporal lobar degeneration: clinical and pathologic overview. 2008 , 89, 343-64	7
1892	Mild cognitive impairment: believe it or not?. 2008 , 20, 357-63	34
1891	Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease. 2008 , 51, 148-58	24
1890	Strategies for using molecular neuroimaging in dementia. 2008 , 89, 87-95	
1889	Frequent amyloid deposition without significant cognitive impairment among the elderly. 2008 , 65, 1509-17	765
1888	Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. 2008 , 49, 1262-9	37

1887	Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. 2008 , 25, 423-32	21
1886	fMRI activation changes during successful episodic memory encoding and recognition in amnesic mild cognitive impairment relative to cognitively healthy older adults. 2008 , 26, 123-37	53
1885	Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. 2008 , 65, 1281-3	10
1884	Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. 2008 , 39, 349-54	114
1883	Generative atlases and atlas selection for C11-PIB PET-PET registration of elderly, mild cognitive impaired and Alzheimer disease patients. 2008 ,	2
1882	Imaging genetics of brain longevity and mental wellness: the next frontier?. 2008 , 246, 20-32	23
1881	Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. 2008 , 4, e1000100	813
1880	Animal and Translational Models of Neurological Disorders: An Industrial Perspective. 2008 , 1-20	
1879	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. 2008 , 131, 1630-45	714
1878	Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?. 2008 , 49, 1465-71	54
1877	Neuropsychological characterization of mild cognitive impairment. 2008 , 88, 499-509	4
1876	Technology insight: imaging neurodegeneration in Parkinson's disease. 2008 , 4, 267-77	28
1875	¹¹ C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. 2008 , 131, 665-80	716
1874	PET amyloid ligand [¹¹ C]PiB uptake shows predominantly striatal increase in variant Alzheimer's disease. 2008 , 131, 1845-53	99
1873	fMRI: use in early Alzheimer's disease and in clinical trials. 2008 , 3, 409-421	13
1872	Disclosure issues in neuroscience research. 2008 , 15, 226-41	2
1871	Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. 2008 , 20, 871-89	16
1870	[In-vivo imaging of amyloid plaques]. 2008 , 131, 333-7	

1869	Neuroimaging in dementia: in vivo amyloid imaging. 2008 , 215, 119-24	5
1868	Mild cognitive impairment: an overview. 2008 , 13, 45-53	397
1867	Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?. 2008 , 15, 303-25	97
1866	Molecular imaging and magnetic resonance imaging in early diagnosis of Alzheimer's disease. A literature review. 2009 , 21, 755-71	1
1865	Update on Alzheimer's Disease: One Hundred Years After Dr. Alois Alzheimer. 2008 , 13, 4-6	1
1864	Integrating symptomatic- and disease-modifying treatments. 2008 , 13, 28-30	3
1863	Neurodegenerative disorders. 39-89	0
1862	Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. 2008 , 22, 261-8	103
1861	Automated radiosynthesis of the Pittsburg compound-B using a commercial synthesizer. 2008 , 29, 920-6	25
1860	Whatever happened to Pittsburgh Compound-A?. 2008 , 22, 198-203	8
1859	The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. 2008 , 21, 683-7	73
1858	Introduction. 2008 , 13, 4-5	2
1857	Imaging of brain structure and function: relevance to psychiatric disorders. 68-79	
1856	FDG and amyloid positron emission tomography. 2008 , 13, 21-4	1
1855	Alzheimer's Disease, Diagnosis and the Need for Biomarkers. 2008 , 3, 317-323	9
1854	Molecular Aspects of Memory Dysfunction in Alzheimer's Disease. 2008 , 245-293	3
1853	Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. 2008 , 3, e2175	162
1852	Taking the next steps in the diagnosis of Alzheimer's disease: the use of biomarkers. 2008 , 13, 7-10	23

1851	Preclinical MRI and NMR Biomarkers of Alzheimer's Disease: Concepts and Applications. 2008 , 2, MRI.S971	
1850	Alzheimer's disease. 56-73	1
1849	Neuroimaging in dementia. 101-119	1
1848	Mild cognitive impairment. 172-187	1
1847	Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. 2009 , 5, 153-66	53
1846	Molecular Imaging in Neurodegenerative Diseases. 2009 , 52, 151	2
1845	Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. 2009 , 4, e7931	36
1844	Terahertz spectroscopy of misfolded proteins in bio-tissue. 2009 ,	3
1843	Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. 2009 , 50, 348-55	89
1842	Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. 2009 , 29, 14770-8	185
1841	Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. 2009 , 50, 1464-70	145
1840	Chapter 1 Amyloidosis. 2009 , 1-44	23
1839	Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. 2009 , 50, 818-22	175
1838	Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. 2009 , 50, 191-7	108
1837	Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. 2009 , 106, 6820-5	591
1836	Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?. 2009 , 5, 128-9	4
1835	Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. 2009 , 29, 1860-73	2076
1834	Examining the multifactorial nature of cognitive aging with covariance analysis of positron emission tomography data. 2009 , 15, 973-81	7

1833	Neurocognitive disorders: cluster 1 of the proposed meta-structure for DSM-V and ICD-11. 2009 , 39, 2001-12	25
1832	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. 2009 , 66, 1476-81	247
1831	Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. 2009 , 27, 458-64	96
1830	Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. 2009 , 66, 638-45	148
1829	Advances in molecular imaging for the diagnosis of dementia. 2009 , 3, 705-16	11
1828	Animal models for Alzheimer's disease and frontotemporal dementia: a perspective. 2009 , 1,	27
1827	Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. 2009 , 66, 888-93	89
1826	Personalized healthcare: how to improve outcomes by increasing benefit and decreasing risk through the use of biomarkers. 2009 , 3, 701-9	5
1825	Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. 2009 , 72, 56-62	274
1824	Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. 2009 , 66, 60-7	130
1823	Beta-amyloid, blood vessels, and brain function. 2009 , 40, 2601-6	205
1822	Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. 2009 , 66, 81-7	52
1821	Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. 2009 , 66, 1557-62	165
1820	Principal component analysis with pre-normalization improves the signal-to-noise ratio and image quality in positron emission tomography studies of amyloid deposits in Alzheimer's disease. 2009 , 54, 3595-612	9
1819	Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. 2009 , 73, 1571-8	196
1818	Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. 2009 , 132, 1310-23	526
1817	Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. 2009 , 6, 341-6	17
1816	Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. 2009 , 50, 1251-9	231

1815	The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. 2009 , 19, 497-510		669
1814	Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. 2009 , 66, 1469-75		350
1813	Relationships between biomarkers in aging and dementia. 2009 , 73, 1193-9		360
1812	Characterization of PiB binding to white matter in Alzheimer disease and other dementias. 2009 , 50, 198-204		76
1811	Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. 2009 , 50, 1887-94		342
1810	Comparison of 18F-FDG and PiB PET in cognitive impairment. 2009 , 50, 878-86		155
1809	Mild cognitive impairment: ten years later. 2009 , 66, 1447-55		887
1808	Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. 2009 , 66, 632-7		71
1807	Biomarkers of Alzheimer's disease. 2009 , 35, 128-40		134
1806	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. 2009 , 34, 107-12		158
1805	Patterns of brain activity during a semantic task differentiate normal aging from early Alzheimer's disease. 2009 , 173, 218-27		15
1804	Masked-Volume-Wise PCA and "reference Logan" illustrate similar regional differences in kinetic behavior in human brain PET study using [11C]-PIB. 2009 , 9, 2		4
1803	Small organic probes as amyloid specific ligands--past and recent molecular scaffolds. 2009 , 583, 2593-9		76
1802	In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. 2009 , 617, 54-8		70
1801	Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. <i>Annals of Neurology</i> , 2009 , 65, 176-83	9.4	272
1800	Amyloid imaging in mild cognitive impairment subtypes. <i>Annals of Neurology</i> , 2009 , 65, 557-68	9.4	276
1799	Cognition, reserve, and amyloid deposition in normal aging. <i>Annals of Neurology</i> , 2010 , 67, 353-64	9.4	246
1798	Die Alzheimer-Demenz: von der Pathologie zu therapeutischen Ansätzen. 2009 , 121, 3074-3105		37

1797	In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. 2009 , 4, 276-82	50
1796	Translational medicine perspective in development of disease modifying therapies for Alzheimer's disease: biomarkers to buy down the risk. 2009 , 70, 60-69	0
1795	Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. 2009 , 1, 371-80	278
1794	Synthesis and evaluation of two uncharged 99mTc-labeled derivatives of thioflavin-T as potential tracer agents for fibrillar brain amyloid. 2009 , 52, 227-235	13
1793	Neurochemical biomarkers in the differential diagnosis of movement disorders. 2009 , 24, 1411-26	31
1792	Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. 2009 , 24 Suppl 2, S742-7	69
1791	Radiolabelling with short-lived PET (positron emission tomography) isotopes using microfluidic reactors. 2009 , 84, 309-315	47
1790	Alzheimer's disease: from pathology to therapeutic approaches. 2009 , 48, 3030-59	467
1789	Beta-amyloid deposition and the aging brain. 2009 , 19, 436-50	112
1788	Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. 2009 , 11, 236-40	77
1787	Update on amyloid imaging: from healthy aging to Alzheimer's disease. 2009 , 9, 345-52	51
1786	Amyloid imaging in Alzheimer's disease and other dementias. 2009 , 3, 246-61	23
1785	Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data. 2009 , 13, 353-5	3
1784	Interest of the new criteria for drug trials in AD. 2009 , 13, 356-7	5
1783	Nuclear imaging in cardiac amyloidosis. 2009 , 36, 702-14	67
1782	Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. 2009 , 36, 1629-38	51
1781	Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data. 2009 , 36, 1651-60	22
1780	Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. 2009 , 36, 1859-63	73

1779	Does Alzheimer's disease begin in the brainstem?. 2009 , 35, 532-54	139
1778	Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment. 2009 , 86, 438-41	36
1777	Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. 2009 , 14, 469-86	179
1776	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. 2009 , 461, 916-22	474
1775	Molecular neuroimaging in rodents: assessing receptor expression and function. 2009 , 30, 1860-9	5
1774	The uses of biomarkers in drug development. 2009 , 1180, 1-10	24
1773	AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. 2009 , 108, 1177-86	111
1772	Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. 2009 , 109, 623-30	104
1771	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. 2009 , 110, 1129-34	585
1770	Classification and diagnosis of dementia: a mechanism-based approach. 2009 , 16, 168-73	10
1769	Noninvasive structural, functional, and molecular imaging in drug development. 2009 , 13, 360-71	40
1768	A simple, versatile, low-cost and remotely operated apparatus for [11C]acetate, [11C]choline, [11C]methionine and [11C]PIB synthesis. 2009 , 67, 581-9	20
1767	18F-labeled flavones for in vivo imaging of beta-amyloid plaques in Alzheimer's brains. 2009 , 17, 2069-76	31
1766	Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. 2009 , 19, 602-5	44
1765	Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. 2009 , 19, 2258-62	33
1764	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta. 2009 , 19, 4952-7	25
1763	Dementias. 2009 , 215-257	
1762	A review of imaging agent development. 2009 , 11, 286-99	77

1761	Current concepts in Alzheimer's disease: a multidisciplinary review. 2009 , 24, 95-121	193
1760	Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. 2009 , 73, 754-60	405
1759	Seizures in corticobasal degeneration: a case report. 2009 , 15, 352-6	10
1758	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. 2009 , 132, 1355-65	831
1757	Chapter 24 Discovery of Novel Positron Emission Tomography Tracers. 2009 , 44, 501-513	7
1756	Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of beta-amyloid plaques in Alzheimer's disease. 2009 , 52, 6394-401	57
1755	Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. 2009 , 4, 673-84	232
1754	Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment. 2009 , 84, 133-49	21
1753	Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. 2009 , 84, 105-31	18
1752	PET radiotracers: crossing the blood-brain barrier and surviving metabolism. 2009 , 30, 431-40	405
1751	On the multivariate nature of brain metabolic impairment in Alzheimer's disease. 2009 , 30, 186-97	41
1750	Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. 2009 , 30, 1902-9	74
1749	Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. 2009 , 30, 1026-36	485
1748	Amyloid deposition is associated with impaired default network function in older persons without dementia. 2009 , 63, 178-88	728
1747	Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques. 2009 , 36, 411-7	10
1746	Delivery of peptide and protein drugs over the blood-brain barrier. 2009 , 87, 212-51	219
1745	Imagerie moléculaire du transporteur vésiculaire de l'acétylcholine (VACh) par le [123I]-5-iodobenzovésiculaire dans la démence de type Alzheimer (DTA). 2009 , 33, 338-351	
1744	[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. 2009 , 54, 347-57	72

1743	Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. 2009 , 450, 336-9	59
1742	Trifluoromethoxy-benzylated ligands improve amyloid detection in the brain using (19)F magnetic resonance imaging. 2009 , 63, 76-81	20
1741	Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. 2009 , 65, 927-34	216
1740	Long-term exposure to magnetic fields and the risks of Alzheimer's disease and breast cancer: Further biological research. 2009 , 16, 149-56	34
1739	Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. 2009 , 285, 100-8	47
1738	Aging of the Brain and Alzheimer's Disease. 2009 , 187-195	3
1737	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents. 2009 , 52, 7090-102	12
1736	[Alzheimer disease: autosomal dominant forms]. 2009 , 165, 223-31	7
1735	Novel radioiodinated aurones as probes for SPECT imaging of beta-amyloid plaques in the brain. 2009 , 20, 95-101	56
1734	Molecular Imaging in Neurology and Psychiatry. 2009 , 255-298	1
1733	Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. 2009 , 180, 72-96	8
1732	APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. 2009 , 5, 343-62	75
1731	Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. 2009 , 29, 12686-94	444
1730	Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. 2009 , 17, 493-502	70
1729	Differential FDDNP PET patterns in nondemented middle-aged and older adults. 2009 , 17, 397-406	14
1728	Using the Artificial Neural Network to discriminate between normal controls with different APOE e4 genotypes and probable AD cases in PIB-PET studies. 2009 ,	
1727	Automation of the Logan plot based PiB-PET quantification over multiple subjects and multiple reference regions. 2009 ,	
1726	Push-pull benzothiazole derivatives as probes for detecting beta-amyloid plaques in Alzheimer's brains. 2009 , 17, 7002-7	43

1725	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). 2009 , 45, 1107-16	223
1724	Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. 2009 , 47, 1678-90	176
1723	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. 2009 , 48, 329-38	21
1722	Early risk assessment for Alzheimer's disease. 2009 , 5, 182-96	33
1721	Neuropathology of non-motor features of Parkinson disease. 2009 , 15 Suppl 3, S1-5	197
1720	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. 2009 , 15 Suppl 3, S13-6	16
1719	Dissecting molecular mechanisms in the living brain of dementia patients. 2009 , 42, 842-50	34
1718	Mettre la maladie d'Alzheimer en images. 2009 , 9, 196-202	
1717	Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. 2009 , 131, 15257-61	325
1716	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease. 2009 , 52, 1428-37	76
1715	Mapping brain beta-amyloid. 2009 , 22, 356-61	20
1714	[Pre-symptomatic detection of Alzheimer's disease and mild cognitive impairment]. 2009 , 49, 838-40	o
1713	[Molecular PET imaging for in vivo detection of amyloid in the human brain]. 2009 , 49, 922-4	
1712	Current and future treatments for Alzheimer's disease. 2009 , 14, 4-7; discussion 16-8	6
1711	The Early Detection of Alzheimer's Disease with Positron Emission Tomography. 2009 , 151-168	
1710	Differential Diagnosis of Dementia Using Functional Neuroimaging. 2009 , 245-260	3
1709	Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains. 2009 , 57, 1029-39	32
1708	[Molecular imaging by PET/SPECT]. 2009 , 129, 279-87	o

1707	Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. 2009 , 8, 144-59	30
1706	Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. 2009 , 8, 128-43	20
1705	Neuroimaging studies in Alzheimer's disease. A review. 2009 , 22, 525-33	
1704	The role of positron emission tomography imaging of beta-amyloid in patients with Alzheimer's disease. 2010 , 31, 4-11	15
1703	Biomarkers in frontotemporal lobar degeneration. 2010 , 23, 643-8	13
1702	Alzheimer disease update. 2010 , 16, 15-30	4
1701	Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development. 2010 , 221, 87-95	8
1700	Biomarkers and Surrogate Markers in Drug Development. 2010 , 101-166	
1699	Neurovascular photoacoustic tomography. 2010 , 2, 10	57
1698	Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. 2010 , 4, 170-93	66
1697	Plasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive decline.. 2010 ,	
1696	PET and SPECT in Drug Development. 2010 , 737-748	1
1695	Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. 2010 , 20, 843-54	187
1694	Pathobiology of Alzheimer's disease and biomarker development. 2010 , 135, 3-7	2
1693	Pittsburgh compound B as a marker of cognitive decline. 2010 , 5, 519-526	
1692	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. 2010 , 37, 1575-93	23
1691	In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET. 2010 , 37, 934-41	31
1690	Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. 2010 , 37, 1141-7	26

1689 [Neuroimaging in medicine]. **2010**, 53, 801-9

1688 [Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?]. **2010**, 81, 602-6

1687 Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for beta-amyloid plaques in Alzheimer's disease. **2010**, 18, 2777-84

1686 Binding research on flavones as ligands of β -amyloid aggregates by fluorescence and their 3D-QSAR, docking studies. **2010**, 29, 538-45

1685 Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. **2010**, 119, 221-33

1684 Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET. **2010**, 257, 721-7

1683 Potential biomarkers for vascular damage in Alzheimer's disease: thrombomodulin and von Willebrand factor. **2010**, 14, 439-41

1682 Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. **2010**, 14, 299-302

1681 Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease. **2010**, 14, 306-9

1680 Progression of atrophy in Alzheimer's disease and related disorders. **2010**, 18, 339-46

1679 Functional alterations in memory networks in early Alzheimer's disease. **2010**, 12, 27-43

1678 Amyloid-plaque imaging in early and differential diagnosis of dementia. **2010**, 24, 55-66

1677 Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. **2010**, 3, 1-18

1676 Metabolite analysis of [^{18}F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. **2010**, 284, 557-562

1675 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. **2010**, 9, 119-28

1674 ^{11}C -PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. **2010**, 9, 363-72

1673 The diagnosis of young-onset dementia. **2010**, 9, 793-806

1672 Revising the definition of Alzheimer's disease: a new lexicon. **2010**, 9, 1118-27

1671	A changing landscape for advance directives in dementia research. 2010 , 70, 623-30		34
1670	Diagnosis and biomarkers of predementia in Alzheimer's disease. 2010 , 8, 89		76
1669	Neuroimaging for Lewy body disease: is the in vivo molecular imaging of β -synuclein neuropathology required and feasible?. 2010 , 65, 28-55		35
1668	Multimodality imaging techniques. 2010 , 5, 180-9		83
1667	Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics. 2010 , 231-258		1
1666	Imaging of Misfolded Proteins. 2010 , 645-671		
1665	Current and Future Therapies for Alzheimer Disease. 2010 , 711-774		
1664	APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. <i>Annals of Neurology</i> , 2010 , 67, 122-31	9.4	618
1663	Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. <i>Annals of Neurology</i> , 2010 , 68, 535-40	9.4	112
1662	^{18}F -flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. <i>Annals of Neurology</i> , 2010 , 68, 319-29	9.4	475
1661	A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. <i>Annals of Neurology</i> , 2010 , 68, 521-34	9.4	549
1660	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. <i>Annals of Neurology</i> , 2010 , 68, 311-8	9.4	205
1659	Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. <i>Annals of Neurology</i> , 2010 , 68, 545-8	9.4	147
1658	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. <i>Annals of Neurology</i> , 2010 , 68, 446-53	9.4	98
1657	Amyloid imaging: coming to a PET scanner near you. <i>Annals of Neurology</i> , 2010 , 68, 277-8	9.4	7
1656	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A β -42. <i>Annals of Neurology</i> , 2010 , 68, 825-34	9.4	123
1655	Automated production of [^{18}F]FDDNP using a TRACERlab MXFDG. 2010 , 53, n/a-n/a		
1654	Examining Braak's hypothesis by imaging Parkinson's disease. 2010 , 25 Suppl 1, S83-8		19

1653	Reactions of the fac-[Re(CO) ₃] ⁺ and [ReO] ₃ ⁺ moieties with substituted benzothiazoles. 2010 , 363, 1292-1296	19
1652	Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridylbenzoxazole and 2-pyridylbenzofuran derivatives as ¹¹ C-PET imaging agents for beta-amyloid plaques. 2010 , 20, 1976-80	24
1651	Synthesis and evaluation of ¹⁸ F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease. 2010 , 68, 1066-72	14
1650	GMP-compliant automated synthesis of [(¹⁸ F)AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. 2010 , 68, 2293-7	45
1649	Molecular mechanism of Thioflavin-T binding to amyloid fibrils. 2010 , 1804, 1405-12	1123
1648	Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain. 2010 , 18, 1337-43	6
1647	Synthesis and characterization of novel phenylindoles as potential probes for imaging of amyloid plaques in the brain. 2010 , 18, 4740-6	21
1646	[(¹¹ C)Dimebon, radiosynthesis and lipophilicity of a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease. 2010 , 20, 2529-32	15
1645	Preparation of classical Re/ ^{99m} Tc(CO) ₃ (⁺) and novel ^{99m} Tc(CO) ₂ (NO) ₂ ⁺ cores complexed with flavonol derivatives and their binding characteristics for Abeta(1-40) aggregates. 2010 , 20, 5337-44	15
1644	^{99m} Tc/Re complexes based on flavone and aurone as SPECT probes for imaging cerebral amyloid plaques. 2010 , 20, 5743-8	35
1643	A novel ¹⁸ F-labeled pyridyl benzofuran derivative for imaging of amyloid plaques in Alzheimer's brains. 2010 , 20, 6141-4	26
1642	A convenient synthesis of ¹³ N-labelled azo compounds: a new route for the preparation of amyloid imaging PET probes. 2010 , 45, 5318-23	20
1641	Radiosynthesis of the candidate beta-amyloid radioligand [(¹¹ C)AZD2184: Positron emission tomography examination and metabolite analysis in cynomolgus monkeys. 2010 , 64, 733-41	24
1640	Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. 2010 , 114, 784-94	101
1639	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. 2010 , 9, 560-74	446
1638	REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. 2010 , 1184, 15-54	418
1637	In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. 2010 , 31, 99-109	19
1636	Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. 2010 , 19, 375-88	2

1635	Amyloid imaging using high-field magnetic resonance. 2010 , 9, 95-9	24
1634	Functional imaging of Alzheimer's disease. 332-350	
1633	In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?. 2010 , 2010,	11
1632	Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease. 2010 , 2010, 109618	4
1631	CSF Biomarkers for Alzheimer's Disease Diagnosis. 2010 , 2010,	61
1630	Vascular and Ischemic Disorders. 2010 , 527-550	4
1629	Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. 2010 , 75, 1381-7	133
1628	Combined PET/MR imaging--technology and applications. 2010 , 9, 5-20	52
1627	Target-specific PET probes for neurodegenerative disorders related to dementia. 2010 , 51, 1418-30	47
1626	Applications of Neuroimaging in Behavioral Medicine. 2010 , 783-802	
1625	Neuroimaging Methods in Behavioral Medicine. 2010 , 769-781	
1624	Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. 2010 , 23, 185-98	77
1623	Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. 2010 , 107, 6222-7	47
1622	Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. 2010 , 75, 42-8	39
1621	Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. 2010 , 24, 303-7	23
1620	Applications of molecular imaging. 2010 , 95, 237-98	16
1619	Challenges of High-resolution Diffusion Imaging of the Human Medial Temporal Lobe in Alzheimer Disease. 2010 , 21, 355-65	4
1618	Aging-Related Memory DisordersAlzheimer's Disease. 2010 , 292-319	1

1617	Functional imaging of cognitive impairment in Parkinson's disease. 2010 , 41, 119-26	3
1616	Alzheimer's disease and the amyloid-beta peptide. 2010 , 19, 311-23	806
1615	Advances in the application of MRI to amyotrophic lateral sclerosis. 2010 , 4, 483-496	51
1614	Imaging approaches to Parkinson disease. 2010 , 51, 596-609	139
1613	Increased fibrillar amyloid- β burden in normal individuals with a family history of late-onset Alzheimer's. 2010 , 107, 5949-54	107
1612	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. 2010 , 133, 3336-48	377
1611	Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. 2010 , 133, 1143-54	164
1610	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. 2010 , 133, 3290-300	77
1609	Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. 2010 , 133, 512-28	195
1608	Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. 2010 , 67, 440-6	10
1607	Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease. 2010 , 31, 847-55	27
1606	Differences in microstructural alterations of the hippocampus in Alzheimer disease and idiopathic normal pressure hydrocephalus: a diffusion tensor imaging study. 2010 , 31, 1867-72	34
1605	Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. 2010 , 74, 798-806	33
1604	Poststroke dementia--what's in a name?. 2010 , 6, 63-4	5
1603	Event Perception. 2010 , 53, 253-299	14
1602	In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. 2010 , 74, 77-84	148
1601	Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions?. 2010 , 107, 17459-60	10
1600	[The default mode network: cognitive role and pathological disturbances]. 2010 , 166, 859-72	21

1599	Structure-Function-Based Quantitative Brain Image Analysis. 2010 , 5, 155-68	8
1598	Beyond the dawning of the age of biomarkers. 2010 , 18, 955-8	2
1597	Evaluation of Early Dementia (Mild Cognitive Impairment). 2010 , 5, 15-31	2
1596	Amyloid PET Ligands for Dementia. 2010 , 5, 33-53	20
1595	Highly sensitive amyloid detection enabled by thioflavin T dimers. 2010 , 6, 1791-5	32
1594	Cerebrospinal fluid biomarkers of Alzheimer's disease. 2010 , 4, 51-63	58
1593	Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's A β peptide and reduce its cytotoxicity. 2010 , 132, 17015-22	69
1592	From mild cognitive impairment to prodromal Alzheimer disease: A nosological evolution. 2010 , 1, 146-154	4
1591	Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. 2010 , 67, 581-3	19
1590	Compensation and disease severity on the memory-related activations in mild cognitive impairment. 2010 , 68, 894-902	85
1589	Progression of cerebral amyloid load is associated with the apolipoprotein E ϵ 4 genotype in Alzheimer's disease. 2010 , 68, 879-84	83
1588	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. 2010 , 68, 903-12	298
1587	Twelve-month metabolic declines in probable Alzheimer's disease and amnesic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. 2010 , 51, 654-64	122
1586	Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. 2010 , 51, 586-98	38
1585	The episodic memory system: neurocircuitry and disorders. 2010 , 35, 86-104	362
1584	Primary progressive aphasia: clinicopathological correlations. 2010 , 6, 88-97	292
1583	Novel Benzofurans with (99m)Tc Complexes as Probes for Imaging Cerebral β Amyloid Plaques. 2010 , 1, 443-7	20
1582	Synthesis and evaluation of novel chalcone derivatives with (99m)Tc/Re complexes as potential probes for detection of β Amyloid plaques. 2010 , 1, 598-607	59

1581	Fluorinated Benzofuran Derivatives for PET Imaging of β -Amyloid Plaques in Alzheimer's Disease Brains. 2010 , 1, 321-5	29
1580	Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. 2010 , 6, 108-19	287
1579	The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: a post-mortem autoradiographic study. 2010 , 56, 789-98	51
1578	Imaging and biomarkers for Alzheimer's disease. 2010 , 65, 138-42	8
1577	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. 2010 , 1802, 373-88	16
1576	Mouse models in neurological disorders: applications of non-invasive imaging. 2010 , 1802, 819-39	37
1575	Potent inhibitors of amyloid β -fibrillization, 4,5-dianilinophthalimide and staurosporine aglycone, enhance degradation of preformed aggregates of mutant Notch3. 2010 , 402, 54-8	3
1574	[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. 2010 , 16, 666-70	62
1573	Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. 2010 , 31, 368-77	42
1572	Molecular polymorphism of Abeta in Alzheimer's disease. 2010 , 31, 542-8	43
1571	Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker. 2010 , 31, 889-900	25
1570	Distinctive alterations of the cingulum bundle during aging and Alzheimer's disease. 2010 , 31, 1582-92	51
1569	Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. 2010 , 31, 1669-78	83
1568	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. 2010 , 31, 1275-83	750
1567	Boosting power for clinical trials using classifiers based on multiple biomarkers. 2010 , 31, 1429-42	133
1566	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. 2010 , 31, 1263-74	105
1565	Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. 2010 , 31, 1463-80	125
1564	Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. 2010 , 59, 295-302	35

1563	Biomarkers in translational research of Alzheimer's disease. 2010 , 59, 310-22	46
1562	Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. 2010 , 37, 497-508	103
1561	Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. 2010 , 37, 917-25	30
1560	[Alzheimer's and related diseases: toward earlier and more accurate diagnosis]. 2010 , 31, 846-53	0
1559	Molecular pathways of frontotemporal lobar degeneration. 2010 , 33, 71-88	34
1558	Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. 2010 , 30, 6315-22	65
1557	Synthesis and In Vitro Evaluation of Imidazo[1,2-b]pyridazines as Ligands for β -Amyloid Plaques. 2010 , 1, 80-4	13
1556	Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. 2010 , 53, 1883-97	94
1555	Targeting Abeta and tau in Alzheimer's disease, an early interim report. 2010 , 223, 252-66	68
1554	Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. 2010 , 223, 311-21	92
1553	The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board. 2010 , 6, 286-90	7
1552	The use of PET in Alzheimer disease. 2010 , 6, 78-87	274
1551	2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations. 2010 , 18, 187; author reply 188	2
1550	Biomarkers in Parkinson's disease: a funder's perspective. 2010 , 4, 723-9	13
1549	Challenges for Developing PET Tracers: Isotopes, Chemistry, and Regulatory Aspects. 2010 , 5, 131-53	11
1548	Clinical practice. Early Alzheimer's disease. 2010 , 362, 2194-201	122
1547	Role of structural MRI in Alzheimer's disease. 2010 , 2, 23	76
1546	Values of default mode network to Alzheimer's disease call for consilience of multimodal neuroimaging and genetics. 2010 , 30, 3553-4	3

1545	Early detection of Alzheimer's disease with PET imaging. 2010 , 7, 131-5	37
1544	Imaging non-motor aspects of Parkinson's disease. 2010 , 184, 205-18	20
1543	Bapineuzumab. 2010 , 10, 1121-30	70
1542	Neuroimaging to assess safety and efficacy of AD therapies. 2010 , 19, 23-6	20
1541	Spatial correlation between brain aerobic glycolysis and amyloid- β deposition. 2010 , 107, 17763-7	275
1540	Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. 2010 , 107, 10256-61	172
1539	Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. 2010 , 24, 375-98	263
1538	Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. 2011 , 2, 596	31
1537	Sensing amyloid- β aggregation using luminescent dipyrrophenazine ruthenium(II) complexes. 2011 , 133, 11121-3	98
1536	PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. 2011 , 3, 11	32
1535	Technical aspects of amyloid imaging for Alzheimer's disease. 2011 , 3, 25	7
1534	Amyloid imaging in prodromal Alzheimer's disease. 2011 , 3, 26	18
1533	Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. 2011 , 3, 31	67
1532	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. 2011 , 3, 34	36
1531	Antibody-based therapy in Alzheimer's disease. 2011 , 11, 343-57	49
1530	Molecular dynamics effects on luminescence properties of oligothiophene derivatives: a molecular mechanics-response theory study based on the CHARMM force field and density functional theory. 2011 , 13, 17532-42	18
1529	Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. 2011 , 9, 5137-48	40
1528	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. 2011 , 134, 335-44	235

1527	Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. 2011 , 2, 269-75	58
1526	Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β Amyloid PET Ligands and Identification of MK-3328. 2011 , 2, 498-502	16
1525	[Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice]. 2011 , 167, 474-84	10
1524	Relationship of amyloid-burden with age-at-onset in Alzheimer disease. 2011 , 19, 627-34	23
1523	Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. 2011 , 41, 283-99	64
1522	Cognitively preserved subjects with transitional cerebrospinal fluid β amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. 2011 , 70, 183-90	75
1521	New imaging paradigms in drug development: the PET imaging approach. 2011 , 8, e63-9	5
1520	Clinical practice. Mild cognitive impairment. 2011 , 364, 2227-34	783
1519	Synthesis and evaluation of ^{11}C -labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β amyloid plaques in Alzheimer's disease. 2011 , 54, 949-56	62
1518	Epidemiology of Alzheimer disease. 2011 , 7, 137-52	1038
1517	Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. 2011 , 55, 933-41	45
1516	Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. 2011 , 54 Suppl 1, S204-17	405
1515	Differential effects of the APOE genotype on brain function across the lifespan. 2011 , 54, 602-10	149
1514	Correlation between baseline regional gray matter volume and global gray matter volume decline rate. 2011 , 54, 743-9	11
1513	β Amyloid affects frontal and posterior brain networks in normal aging. 2011 , 54, 1887-95	90
1512	Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). 2011 , 54, 2652-8	52
1511	Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. 2011 , 55, 574-89	306
1510	A kinetic aggregation assay allowing selective and sensitive amyloid- β quantification in cells and tissues. 2011 , 50, 1607-17	29

1509	Curcumin as the OO bidentate ligand in "2 + 1" complexes with the [M(CO) ₃] ⁺ (M = Re, ^{99m} Tc) tricarbonyl core for radiodiagnostic applications. 2011 , 50, 1295-303	69
1508	In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. 2011 , 31, 4720-30	111
1507	Amyloid imaging for Alzheimer's disease. 2011 , 5, 527-38	0
1506	Neuropsychological assessment of patients with dementing illness. 2011 , 7, 677-87	42
1505	Structural and Functional Neuroimaging Methods: Applications to Substance Abuse and Addiction. 2011 , 37-82	1
1504	The future: biomarkers, biosensors, neuroinformatics, and e-neuropsychiatry. 2011 , 101, 375-400	5
1503	Biomarkers: warning signs. 2011 , 475, S5-7	15
1502	The aging brain and neurodegenerative diseases. 2011 , 27, 629-44	23
1501	Functional neuroimaging in geriatric depression. 2011 , 34, 403-22, viii	13
1500	Dissecting axes of autonomic control in humans: Insights from neuroimaging. 2011 , 161, 34-42	112
1499	Conjugated polymers for enhanced bioimaging. 2011 , 1810, 286-96	43
1498	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β Amyloid Plaques. 2011 , 2, 673-7	48
1497	Cerebral lobar microhemorrhages detection by high magnetic field susceptibility weighted image: a potential diagnostic neuroimage technique of Alzheimer's disease. 2011 , 76, 840-2	6
1496	Activated MAO-B in the brain of Alzheimer patients, demonstrated by [¹¹ C]-L-deprenyl using whole hemisphere autoradiography. 2011 , 58, 60-8	137
1495	Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. 2011 , 32, 247-57	78
1494	Amyloid PET: Its diagnostic potential compared to FDG. 2011 , 35, 322-326	
1493	L'imagerie TEP-traceurs des plaques amyloïdes: le point de vue du clinicien. 2011 , 35, 608-612	1
1492	ANCA: A Family of Fluorescent Probes that Bind and Stain Amyloid Plaques in Human Tissue. 2011 , 2, 249-255	62

1491	Lifespan brain activity, β amyloid, and Alzheimer's disease. 2011 , 15, 520-6	151
1490	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. 2011 , 34, 430-42	235
1489	Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. 2011 , 17, 160-5	23
1488	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. 2011 , 95, 547-56	30
1487	Staging Alzheimer's disease progression with multimodality neuroimaging. 2011 , 95, 535-46	55
1486	PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. 2011 , 32, 223-34	74
1485	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. 2011 , 32, 1388-99	40
1484	Lack of association between ^{11}C -PiB and longitudinal brain atrophy in non-demented older individuals. 2011 , 32, 2123-30	37
1483	Amyloid imaging as a biomarker for cerebral β amyloidosis and risk prediction for Alzheimer dementia. 2011 , 32 Suppl 1, S20-36	103
1482	Potential of functional MRI as a biomarker in early Alzheimer's disease. 2011 , 32 Suppl 1, S37-43	105
1481	In vivo detection of amyloid β deposition using ^{19}F magnetic resonance imaging with a ^{19}F -containing curcumin derivative in a mouse model of Alzheimer's disease. 2011 , 184, 120-7	68
1480	Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier. 2011 , 190, 37-42	34
1479	Facile and rapid one-step radiosynthesis of $[(18)\text{F}]\text{BAY94-9172}$ with a new precursor. 2011 , 38, 121-7	10
1478	Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of β amyloid plaques in Alzheimer's disease. 2011 , 38, 313-20	41
1477	$[(18)\text{F}]\text{Fluoroazabenzoxazoles}$ as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. 2011 , 38, 1193-203	19
1476	Dementia and Alzheimer's disease: a new direction. The 2010 Jay L. Foster Memorial Lecture. 2011 , 7, 540-50	21
1475	Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods. 2011 , 33, 187-99	71
1474	Characterizing Alzheimer's disease using a hypometabolic convergence index. 2011 , 56, 52-60	122

1473	Synthesis and structure-affinity relationships of novel dibenzylideneacetone derivatives as probes for β -amyloid plaques. 2011 , 54, 2225-40	55
1472	Probing small molecule binding to amyloid fibrils. 2011 , 13, 20044-52	32
1471	PET applications in animal models of neurodegenerative and neuroinflammatory disorders. 2012 , 11, 45-64	3
1470	Evidence for ordering of Alzheimer disease biomarkers. 2011 , 68, 1526-35	170
1469	Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β -amyloid plaques in Alzheimer's brains. 2011 , 54, 2971-9	66
1468	Evolution of brain imaging instrumentation. 2011 , 41, 202-19	33
1467	A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?. 2011 , 41, 246-64	83
1466	Molecular Neuroimaging in the Study of Cognitive Impairment: Contribution of the Cerebral Blood Flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT Scan. 2011 , 30, 301-306	2
1465	Transforming cerebrospinal fluid A β 2 measures into calculated Pittsburgh Compound B units of brain A β amyloid. 2011 , 7, 133-41	70
1464	Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2. 2011 , 7, 35-52	46
1463	Revision of the criteria for Alzheimer's disease: A symposium. 2011 , 7, e1-12	27
1462	Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network. 2011 , 2011, 687945	20
1461	Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β -Amyloid. 2011 , 2011, 786264	3
1460	Biomarkers of Alzheimer's disease: from central nervous system to periphery?. 2010 , 2011, 342980	3
1459	Advances in structural and molecular neuroimaging in Alzheimer's disease. 2011 , 194, S20-3	3
1458	Plasma and CSF A β for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementia. 2011 ,	3
1457	Traditional Imaging Modalities in Clinical Medicine. 2011 , 11-46	
1456	BIOMARKERS AND PUBLIC-PRIVATE PARTNERSHIPS. 193-194	

1455	Functional MRI in Alzheimer's Disease and Other Dementias. 2011 , 535-556	1
1454	Molecular Neuroimaging of the Dementias. 2011 , 557-574	
1453	Paradigm shift in treatment of Alzheimer's disease: zinc therapy now a conscientious choice for care of individual patients. 2011 , 2011, 492686	14
1452	Biomarkers predicting Alzheimer's disease in cognitively normal aging. 2011 , 7, 60-8	26
1451	Bridging molecular genetics and biomarkers in lewy body and related disorders. 2011 , 2011, 842475	5
1450	Resting-state glucose metabolism level is associated with the regional pattern of amyloid pathology in Alzheimer's disease. 2011 , 2011, 759780	9
1449	Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring. 2011 , 2011, 481903	21
1448	IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES. 222-264	
1447	Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid- β Species in Alzheimer's Disease. 2010 , 2011, 623051	32
1446	Biomarkers in Alzheimer's disease. 2011 , 2, 46	14
1445	Fluorescence molecular tomography: principles and potential for pharmaceutical research. 2011 , 3, 229-74	101
1444	Automated detection of amyloid- β -related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. 2011 , 23, 221-37	24
1443	Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. 2011 , 7, 3-7	19
1442	Interview: Imaging in Alzheimer's Disease. 2011 , 3, 389-392	
1441	Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. 2011 , 6, 575-578	3
1440	Evolution of the diagnostic criteria for degenerative and cognitive disorders. 2011 , 24, 532-41	32
1439	In vivo human amyloid imaging. 2011 , 8, 366-72	30
1438	Asymptomatic Alzheimer's disease: a prodrome or a state of resilience?. 2011 , 8, 330-5	72

1437	Ask the experts: PET amyloid imaging: can its diagnostic potential be effectively realized in the clinic?. 2011 , 1, 445-451	
1436	Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. 2011 , 1, 19	67
1435	Frontotemporal Dementia. 2011 , 145-178	1
1434	Structure and function of medial temporal and posteromedial cortices in early Alzheimer's disease. 2011 , 34, 320-30	23
1433	Biomarkers and Alzheimer spectrum. 2011 , 65, 115-20	1
1432	Immunotherapy for Alzheimer's disease. 2011 , 269, 54-63	122
1431	PET/CT in diagnosis of dementia. 2011 , 1228, 81-92	54
1430	[F-18]FDDNP microPET imaging correlates with brain A β burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-A β antibody treatment. 2011 , 43, 565-75	32
1429	Where did I put that? Patients with amnesic mild cognitive impairment demonstrate widespread reductions in activity during the encoding of ecologically relevant object-location associations. 2011 , 49, 2349-61	41
1428	Face-name associative memory performance is related to amyloid burden in normal elderly. 2011 , 49, 2776-83	145
1427	[Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan]. 2011 , 30, 301-6	13
1426	Parallel findings in age-related macular degeneration and Alzheimer's disease. 2011 , 30, 217-38	183
1425	Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. 2011 , 10, 424-35	400
1424	Clinical amyloid imaging in Alzheimer's disease. 2011 , 10, 667-70	188
1423	A supervised method to assist the diagnosis and monitor progression of Alzheimer's disease using data from an fMRI experiment. 2011 , 53, 35-45	25
1422	Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future. 2011 , 46, 611-27	104
1421	Novel imaging agents for β amyloid plaque based on the N-benzoylindole core. 2011 , 21, 5594-7	5
1420	Synthesis and evaluation of 1-(4-[18 F]fluoroethyl)-7-(4'-methyl)curcumin with improved brain permeability for β amyloid plaque imaging. 2011 , 21, 5765-9	33

1419	A dual fluorinated and iodinated radiotracer for PET and SPECT imaging of β amyloid plaques in the brain. 2011 , 21, 6519-22	28
1418	From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivatives in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. 2011 , 1218, 7713-22	69
1417	Aggregation of amyloids in a cellular context: modelling and experiment. 2011 , 438, 415-26	45
1416	Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. 2011 , 91, 795-826	680
1415	Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems. 2011 , 105-110	
1414	Alzheimer's disease: the challenge of the second century. 2011 , 3, 77sr1	893
1413	In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. 2011 , 258, 1841-51	54
1412	The concept of FDG-PET endophenotype in Alzheimer's disease. 2011 , 32, 559-69	10
1411	In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. 2011 , 38, 343-51	123
1410	The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. 2011 , 38, 1104-19	191
1409	Individualized quantification of brain β amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. 2011 , 38, 1702-14	77
1408	In vivo imaging of astrocytosis in Alzheimer's disease: an ^{11}C -L-deuteriodeprenyl and PIB PET study. 2011 , 38, 2202-8	51
1407	Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. 2011 , 45, 366-71	5
1406	A modified method of 3D-SSP analysis for amyloid PET imaging using ^{11}C BF-227. 2011 , 25, 732-9	5
1405	On the emerging role of neuroimaging in determining functional and structural brain integrity induced by physical exercise: impact for predictive, preventive, and personalized medicine. 2011 , 2, 277-85	6
1404	Neuroimaging in Parkinson's disease. 2011 , 8, 72-81	49
1403	Neuroimaging in dementia. 2011 , 8, 82-92	50
1402	Reduced CSF turnover and decreased ventricular A β 2 levels are related. 2011 , 12, 42	11

1401	Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. 2011 , 6, 86		39
1400	N-heterocyclic carbenes as ligands in palladium-mediated [11C]radiolabelling of [11C]amides for positron emission tomography. 2011 , 54, 135-139		9
1399	Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro. 2011 , 54, 819-838		41
1398	Decreased brain stiffness in Alzheimer's disease determined by magnetic resonance elastography. 2011 , 34, 494-8		221
1397	Dissociation of β amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β amyloid-42 assembly. 2011 , 89, 815-21		8
1396	PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. 2011 , 226, 948-61		13
1395	Longitudinal assessment of A β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011 , 69, 181-92	9.4	576
1394	Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl- ^{11}C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole. <i>Annals of Neurology</i> , 2011 , 69, 673-80	9.4	144
1393	Amyloid- β associated cortical thinning in clinically normal elderly. <i>Annals of Neurology</i> , 2011 , 69, 1032-42	9.4	250
1392	Cerebral amyloid angiopathy in the elderly. <i>Annals of Neurology</i> , 2011 , 70, 871-80	9.4	367
1391	PET imaging of brain amyloid in dementia: a review. 2011 , 26, 991-9		105
1390	Altered default mode network connectivity in Alzheimer's disease--a resting functional MRI and Bayesian network study. 2011 , 32, 1868-81		141
1389	Amyloid precursor protein mutation E682K at the alternative β secretase cleavage β site increases A β generation. 2011 , 3, 291-302		84
1388	The reaction of a potentially N2S-donor bis[benzo(thiazole/imidazole)] with the fac-[Re(CO) $_3$] $^+$ and cis-[ReO $_2$] $^+$ cores. 2011 , 14, 1115-1118		7
1387	Aromatic radiofluorination and biological evaluation of 2-aryl-6-[^{18}F]fluorobenzothiazoles as a potential positron emission tomography imaging probe for β amyloid plaques. 2011 , 19, 2980-90		26
1386	Diphenylpropynone derivatives as probes for imaging β amyloid plaques in Alzheimer's brains. 2011 , 21, 117-20		13
1385	$^{99\text{m}}\text{Tc}$ - and Re-labeled 6-dialkylamino-2-naphthylethylidene derivatives as imaging probes for β amyloid plaques. 2011 , 21, 1064-8		15
1384	Synthesis and biological evaluation of indole-chalcone derivatives as β amyloid imaging probe. 2011 , 21, 980-2		33

1383	Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. 2011 , 21, 2655-8	55
1382	2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain. 2011 , 21, 2966-8	39
1381	Novel quinoxaline derivatives for in vivo imaging of β amyloid plaques in the brain. 2011 , 21, 4193-6	19
1380	Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[^{11}C]methylaminophenyl)-6-hydroxybenzothiazole ([^{11}C]PIB). 2011 , 69, 1212-7	20
1379	Novel (E)-5-styryl-2,2'-bithiophene derivatives as ligands for β amyloid plaques. 2011 , 46, 2908-16	13
1378	Synthesis and evaluation of benzofuran-2-yl(phenyl)methanone derivatives as ligands for β amyloid plaques. 2011 , 19, 4148-53	12
1377	Enhancement of precision and reduction of measuring points in tomographic reconstructions. 2011 , 375, 1167-1171	2
1376	Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. 2011 , 134, 1077-88	83
1375	Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. 2011 , 134, 1647-57	45
1374	Using biomarkers to improve detection of Alzheimer's disease. 2011 , 1, 127-139	22
1373	Positron emission tomography and neuropathologic estimates of fibrillar amyloid- β in a patient with Down syndrome and Alzheimer disease. 2011 , 68, 1461-6	50
1372	Globalization of P4 medicine: predictive, personalized, preemptive, and participatory--summary of the proceedings of the Eighth International Symposium of the International Society for Strategic Studies in Radiology, August 27-29, 2009. 2011 , 258, 571-82	14
1371	Brain Effective Connectivity Modeling for Alzheimer's Disease by Sparse Gaussian Bayesian Network. 2011 , 931-939	15
1370	Perspective: prevention is better than cure. 2011 , 475, S15	29
1369	Homogeneity-based feature extraction for classification of early-stage alzheimer's disease from functional magnetic resonance images. 2011 ,	2
1368	Nuclear medicine imaging in dementia: a practical overview for hospitalists. 2011 , 39, 149-60	7
1367	Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β amyloid imaging. 2011 , 134, 3030-43	243
1366	Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. 2011 , 25, 187-95	203

1365	Relationships between β -amyloid and functional connectivity in different components of the default mode network in aging. 2011 , 21, 2399-407	229
1364	Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. 2011 , 68, 51-7	421
1363	Use of florbetapir-PET for imaging beta-amyloid pathology. 2011 , 305, 275-83	760
1362	Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD. 2011 , 24, 123-6	14
1361	Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. 2011 , 52, 393-400	77
1360	Alzheimer's disease. 2011 , 22, 173-85	4
1359	SPECT Imaging Agents for Detecting Cerebral β -Amyloid Plaques. 2011 , 2011, 543267	37
1358	Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment. 2011 , 31, 276-83	24
1357	Instrumental activities of daily living impairment is associated with increased amyloid burden. 2011 , 31, 443-50	34
1356	Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. 2011 , 31, 17680-8	170
1355	Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. 2011 , 3, 89ra57	721
1354	Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. 2011 , 68, 1398-403	127
1353	Amyloid β and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. 2011 , 49, 367-74	51
1352	Comparison of analytical platforms for cerebrospinal fluid measures of β -amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. 2011 , 68, 1137-44	138
1351	Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLN patients. 2011 , 52, 173-9	60
1350	Longitudinal patterns of β -amyloid deposition in nondemented older adults. 2011 , 68, 644-9	77
1349	Positron emission tomography of brain β -amyloid and β -levels in adults with Down syndrome. 2011 , 68, 768-74	59
1348	Protein binding in patients with late-life depression. 2011 , 68, 1143-50	60

1347	Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis. 2011 , 5, 16-21	20
1346	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. 2011 , 134, 293-300	75
1345	Brain amyloid imaging. 2011 , 52, 1733-40	184
1344	Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE ϵ carriers: relationships with memory performance. 2011 , 31, 7775-83	136
1343	Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. 2011 , 52, 1210-7	267
1342	Effects of brain amyloid deposition and reduced glucose metabolism on the default mode of brain function in normal aging. 2011 , 31, 11193-9	26
1341	Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. 2011 , 108, 2528-33	90
1340	18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. 2011 , 134, 1089-100	255
1339	Challenges in the development of companion diagnostics for neuropsychiatric disorders. 2011 , 11, 829-37	8
1338	Serotonin signaling is associated with lower amyloid- β levels and plaques in transgenic mice and humans. 2011 , 108, 14968-73	218
1337	Amyloid imaging. 2011 , 23 Suppl 2, S41-9	23
1336	The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders. 2011 , 2011, 439397	6
1335	Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. 2011 , 76, 1797-803	99
1334	Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. 2011 , 77, 39-47	59
1333	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. 2011 , 134, 301-17	109
1332	Plasma A β and PET PiB binding are inversely related in mild cognitive impairment. 2011 , 77, 125-31	42
1331	Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. 2011 , 76, 1789-96	103
1330	Amyloid vs FDG-PET in the differential diagnosis of AD and FTL. 2011 , 77, 2034-42	230

1329	Failure to modulate attentional control in advanced aging linked to white matter pathology. 2012 , 22, 1038-51	57
1328	Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. 2012 , 9, 563-73	131
1327	Understanding the Pathophysiology of Alzheimer's Disease and Mild Cognitive Impairment: A Mini Review on fMRI and ERP Studies. 2012 , 2012, 719056	26
1326	Luminescent conjugated poly- and oligo-thiophenes: optical ligands for spectral assignment of a plethora of protein aggregates. 2012 , 40, 704-10	36
1325	Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. 2012 , 53, 37-46	287
1324	The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. 2012 , 22, 2653-61	91
1323	Molecular brain imaging in the multimodality era. 2012 , 32, 1377-92	14
1322	Effects of age and amyloid deposition on A β dynamics in the human central nervous system. 2012 , 69, 51-8	185
1321	Anomalous PiB enhancement in the superior sagittal and transverse venous sinuses. 2012 , 26, 186-90	1
1320	Neuroimaging in dementias. 2012 , 25, 473-9	19
1319	Neuroimaging insights into network-based neurodegeneration. 2012 , 25, 727-34	52
1318	Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. 2012 , 32, 127-38	14
1317	Association of lifetime cognitive engagement and low β amyloid deposition. 2012 , 69, 623-29	225
1316	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. 2012 , 64, 27-81	66
1315	Amyloid- β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 2012 , 79, 1636-44	174
1314	Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. 2012 , 9, 473-80	34
1313	Relationship between memory performance and β amyloid deposition at different stages of Alzheimer's disease. 2012 , 10, 141-4	33
1312	Imaging approaches for dementia. 2012 , 33, 1836-44	18

1311	Disrupted topological organization in white matter structural networks in amnesic mild cognitive impairment: relationship to subtype. 2012 , 265, 518-27	84
1310	Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. 2012 , 69, 215-22	59
1309	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. 2012 , 135, 2115-25	91
1308	APOE modifies the association between A β load and cognition in cognitively normal older adults. 2012 , 78, 232-40	128
1307	Neurobiology of Alzheimer's Disease. 2012 , 815-828	1
1306	Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical A β deposition. 2012 , 43, 1341-6	29
1305	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. 2012 , 4, 343-357	10
1304	Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid- β . 2012 , 53, 1794-801	18
1303	Noninvasive molecular imaging of neuroinflammation. 2012 , 32, 1393-415	192
1302	Blood-brain barrier P-glycoprotein function in Alzheimer's disease. 2012 , 135, 181-9	205
1301	Alzheimer's disease in the retina: imaging retinal A β plaques for early diagnosis and therapy assessment. 2012 , 10, 285-93	148
1300	Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. 2012 , 32, 16233-42	138
1299	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. 2012 , 2, 975-984	144
1298	Brain imaging in Alzheimer disease. 2012 , 2, a006213	336
1297	Indicators of amyloid burden in a population-based study of cognitively normal elderly. 2012 , 79, 1570-7	123
1296	Clinical validation of 18F-AZD4694, an amyloid- β -specific PET radioligand. 2012 , 53, 415-24	172
1295	Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. 2012 , 83, 923-6	80
1294	CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. 2012 , 22, 1993-2004	73

1293	Pain in people with Alzheimer disease: potential applications for psychophysical and neurophysiological research. 2012 , 25, 240-55	39
1292	Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. 2012 , 53, 59-71	212
1291	A pilot study of quantitative MRI measurements of ventricular volume and cortical atrophy for the differential diagnosis of normal pressure hydrocephalus. 2012 , 2012, 718150	26
1290	Aging and down syndrome. 2012 , 2012, 412536	59
1289	Different clinical phenotypes in siblings with a presenilin-1 P264L mutation. 2012 , 33, 132-40	5
1288	Clinical features of Pittsburgh compound-B-negative dementia. 2012 , 34, 112-20	12
1287	Functional neuroimaging in Parkinson's disease. 2012 , 2, a009274	54
1286	Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. 2012 , 69, 223-9	220
1285	Functional connectivity variations in mild cognitive impairment: associations with cognitive function. 2012 , 18, 39-48	40
1284	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. 2012 , 135, 2126-39	179
1283	Alzheimer's disease, cerebrovascular disease, and the β -amyloid cascade. 2012 , 39, 712-28	128
1282	Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions. 2012 , 25, 421-8	91
1281	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. 2012 , 69, 856-67	86
1280	Added Diagnostic Value of (11)C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis. 2012 , 2, 610-21	38
1279	Recent advances in imaging Alzheimer's disease. 2013 , 33 Suppl 1, S313-27	17
1278	Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease. 2013 , 33 Suppl 1, S427-38	12
1277	Microvascular perfusion based on arterial spin labeled perfusion MRI as a measure of vascular risk in Alzheimer's disease. 2012 , 32, 677-87	18
1276	Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: novel PET/SPECT imaging probes for diagnosis of Alzheimer's disease. 2012 , 118, 338-44	26

1275	Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease. 2012 , 118, 345-9	9
1274	Cerebrospinal fluid A β and tau level fluctuation in an older clinical cohort. 2012 , 69, 246-50	43
1273	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. 2012 , 17, 176-206	24
1272	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. 2012 , 2, 57-65	31
1271	Spectral discrimination of cerebral amyloid lesions after peripheral application of luminescent conjugated oligothiophenes. 2012 , 181, 1953-60	29
1270	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. 2012 , 7, 281-97	33
1269	Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: a simulation study. 2012 , 60, 1724-33	18
1268	CSF biomarking for diagnosis and treatment assessment in neurodegeneration. 2012 , 123, 339-41	
1267	Molecular neuroimaging in Alzheimer's disease. 2012 , 22, 57-65, viii	13
1266	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. 2012 , 367, 795-804	2272
1265	Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia. 2012 , 43, 671-6	45
1264	Alzheimer's disease. 2012 , 65, 329-52	176
1263	Novel 18 F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β amyloid plaques in Alzheimer's disease. 2012 , 55, 9136-45	37
1262	The frontal assessment battery in the differential diagnosis of dementia. 2012 , 25, 201-7	16
1261	Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- β plaques: a prospective cohort study. 2012 , 11, 669-78	532
1260	Tau as a therapeutic target in neurodegenerative disease. 2012 , 136, 8-22	84
1259	Mild cognitive impairment in older adults. 2012 , 14, 320-7	50
1258	Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. <i>Annals of Neurology</i> , 2012 , 72, 564-70	9.4 27

1257	Relation of neuropathology to cognition in persons without cognitive impairment. <i>Annals of Neurology</i> , 2012 , 72, 599-609	9.4	153
1256	Finding a pathological diagnosis for Alzheimer's disease: are inflammatory molecules the answer?. 2012 , 33, 3598-607		16
1255	Novel imaging strategies for assessment of cerebrovascular involvement. 2012 , 79, 674-82		
1254	Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. 2012 , 124, 823-31		86
1253	[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. 2012 , 124, 833-45		63
1252	Fluorescent 2-styrylpyridazin-3(2H)-one derivatives as probes targeting amyloid-beta plaques in Alzheimer's disease. 2012 , 22, 4106-10		8
1251	Dimers of the fac-[Re(CO) ₃] ⁺ core with benzothiazole derivatives of thiourea. 2012 , 24, 231-233		7
1250	Amyloid imaging in dementias with atypical presentation. 2012 , 8, 389-98		43
1249	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. 2012 , 8, S1-68		368
1248	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. 2012 , 8, 496-501		98
1247	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. 2012 , 8, 312-36		92
1246	New molecular targets for PET and SPECT imaging in neurodegenerative diseases. 2012 , 34 Suppl 2, S125-36		16
1245	L'imagerie moléculaire de la maladie d'Alzheimer. 2012 , 3, 366-368		
1244	[Early diagnosis of Alzheimer's disease]. 2012 , 168, 825-32		
1243	[Markers of prodromal Alzheimer's disease]. 2012 , 168, 815-24		
1242	Explaining the encoding/retrieval flip: memory-related deactivations and activations in the posteromedial cortex. 2012 , 50, 3764-74		82
1241	Resting state functional MRI in Alzheimer's Disease. 2012 , 4, 2		76
1240	Alzheimer's disease camouflaged by histrionic personality disorder. 2012 , 18, 75-9		2

1239	Synthesis and evaluation of ^{18}F -labeled styryltriazole and resveratrol derivatives for β -amyloid plaque imaging. 2012 , 55, 883-92	28
1238	(18)F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. 2012 , 3, 58-62	28
1237	Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. 2012 , 3, 936-41	46
1236	Technetium-99m labeled pyridyl benzofuran derivatives as single photon emission computed tomography imaging probes for β -amyloid plaques in Alzheimer's brains. 2012 , 55, 2279-86	58
1235	Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease. 2012 , 33, 75-82	78
1234	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. 2012 , 33, 215-25	108
1233	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. 2012 , 33, 198.e1-14	103
1232	Cholinergic system function and cognition in mild cognitive impairment. 2012 , 33, 867-77	82
1231	Age and amyloid-related alterations in default network habituation to stimulus repetition. 2012 , 33, 1237-52	62
1230	Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice. 2012 , 33, 1533-44	40
1229	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. 2012 , 33, 627.e1-627.e12	58
1228	Different β -amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. 2012 , 33, 825.e1-13	76
1227	Resting state fMRI in Alzheimer's disease: beyond the default mode network. 2012 , 33, 1564-78	367
1226	Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. 2012 , 33, 827.e11-9	84
1225	Cerebrovascular disease, β -amyloid, and cognition in aging. 2012 , 33, 1006.e25-36	88
1224	Lack of association between prior depressive episodes and cerebral [11C]PiB binding. 2012 , 33, 2334-42	51
1223	Toward a multifactorial model of Alzheimer disease. 2012 , 33, 2262-71	42
1222	Effects of age and β -amyloid on cognitive changes in normal elderly people. 2012 , 33, 2746-55	34

1221	Intercellular (mis)communication in neurodegenerative disease. 2012 , 73, 886-901	98
1220	Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. 2012 , 39, 315-23	15
1219	Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease. 2012 , 39, 484-501	23
1218	Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and Amyloid plaques in Alzheimer's disease models. 2012 , 55, 9170-80	58
1217	Amyloid deposition in patients with Parkinson disease at risk for development of dementia. 2012 , 79, 1161-7	84
1216	Molecular imaging of dementia. 2012 , 12, 106-14	16
1215	The challenges of tau imaging. 2012 , 7, 409-421	74
1214	Preventing Alzheimer's disease. 2012 , 337, 1488-92	280
1213	Synthesis and evaluation of novel ¹⁸ F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of Amyloid plaques. 2012 , 55, 9283-96	39
1212	Should Alzheimer's disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence. 2012 , 11, 104-22	16
1211	Distribution and binding of 18F-labeled and 125I-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: a whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer's disease patients. 2012 , 60, 153-62	8
1210	Imaging the default mode network in aging and dementia. 2012 , 1822, 431-41	181
1209	PET amyloid-beta imaging in preclinical Alzheimer's disease. 2012 , 1822, 370-9	102
1208	The use of PIB-PET as a dual pathological and functional biomarker in AD. 2012 , 1822, 380-5	41
1207	Synthesis and in vitro evaluation of Synuclein ligands. 2012 , 20, 4625-34	38
1206	Synthesis and biological evaluation of novel technetium-99m labeled phenylbenzoxazole derivatives as potential imaging probes for Amyloid plaques in brain. 2012 , 22, 4327-31	23
1205	Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as ¹⁸ F-PET imaging agents for Amyloid plaques. 2012 , 22, 4332-7	17
1204	Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. 2012 , 22, 5700-3	21

1203	Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia. 2012 , 48, 429-46	165
1202	Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders. 2012 , 48, 389-413	44
1201	A Phenylbenzothiazole Conjugate with the Tricarbonyl fac-[M(II)(CO) ₃]+ (M = Re, ⁹⁹ Tc, ^{99m} Tc) Core for Imaging of β Amyloid Plaques. 2012 , 2012, 4279-4286	22
1200	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. 2012 , 10, 127	37
1199	A molecular imaging primer: modalities, imaging agents, and applications. 2012 , 92, 897-965	713
1198	Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. 2012 , 26, 841-70	91
1197	Multiple findings in elderly adults with confirmed Alzheimer's disease. 2012 , 60, 2169-70	
1196	Current status of vaccination therapies in Alzheimer's disease. 2012 , 123, 647-51	14
1195	Apraxia of speech and phonological errors in the diagnosis of nonfluent/agrammatic and logopenic variants of primary progressive aphasia. 2012 , 55, S1562-72	67
1194	A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. 2012 , 57, R119-59	296
1193	Diagnosis of Alzheimer's disease. 2012 , 12-46	
1192	Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. 2012 , 64, 327-71	60
1191	Development of positron emission tomography β Amyloid plaque imaging agents. 2012 , 42, 423-32	132
1190	Florbetapir PET analysis of amyloid- β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. 2012 , 11, 1057-65	178
1189	Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. 2012 , 71, 792-7	82
1188	18 F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β Amyloid plaques. 2012 , 57, 51-8	7
1187	Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. 2012 , 59, 1152-60	116
1186	The serendipitous discovery of the brain's default network. 2012 , 62, 1137-45	200

1185	Brain imaging in the study of Alzheimer's disease. 2012 , 61, 505-16	83
1184	PET radiotracers for molecular imaging in the brain: past, present and future. 2012 , 61, 363-70	66
1183	Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?. 2012 , 60, 1716-23	32
1182	Measuring and comparing brain cortical surface area and other areal quantities. 2012 , 61, 1428-43	117
1181	Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. 2012 , 62, 1-8	70
1180	In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. 2012 , 39, 1042-8	45
1179	Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors. 2012 , 321, 11-6	81
1178	PET imaging in the differential diagnosis of vascular dementia. 2012 , 322, 268-73	40
1177	Emission Imaging in Dementia. 2012 , 223-247	
1176	Research Methods in Neuropsychology. 2012 ,	
1175	Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. 2012 , 8, 131-42	54
1174	PET/MRI for neurologic applications. 2012 , 53, 1916-25	189
1173	The molecular pathology of Alzheimer's disease. 2012 , 22, 11-22, vii	40
1172	Clinical and research diagnostic criteria for Alzheimer's disease. 2012 , 22, 23-32, viii	39
1171	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. 2012 , 262 Suppl 2, S71-7	19
1170	Local susceptibility causes diffusion alterations in patients with Alzheimer's disease and mild cognitive impairment. 2012 , 6, 426-36	3
1169	[18 FDG PET imaging of the brain in the analysis of a dementia syndrome]. 2012 , 43, 265-9	
1168	Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. 2012 , 39, 1927-36	35

1167	Pharmacokinetics of [¹⁸ F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. 2012 , 39, 1784-95	42
1166	Amyloid- β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. 2012 , 43, 514-23	165
1165	Gd(III) chelates for MRI contrast agents: from high relaxivity to β mart β from blood pool to blood-brain barrier permeable. 2012 , 3, 552	85
1164	Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease. 2012 , 37, 2627-58	52
1163	Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation. 2012 , 10,	1
1162	Anatomical and functional deficits in patients with amnesic mild cognitive impairment. 2012 , 7, e28664	68
1161	Galactic cosmic radiation leads to cognitive impairment and increased α l β plaque accumulation in a mouse model of Alzheimer's disease. 2012 , 7, e53275	136
1160	Small-animal PET imaging of amyloid-beta plaques with [¹¹ C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. 2012 , 7, e31310	94
1159	Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. 2012 , 28, 869-76	54
1158	Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. 2012 , 2012, 628070	55
1157	Practical management of heterogeneous neuroimaging metadata by global neuroimaging data repositories. 2012 , 6, 8	10
1156	(E)-5-styryl-1H-indole and (E)-6-styrylquinoline derivatives serve as probes for β amyloid plaques. 2012 , 17, 4252-65	11
1155	Dementia specialists and early adoption of amyloid imaging. 2013 , 33, 445-50	12
1154	Alzheimer's disease and related dementias. 17-31	
1153	Alzheimer's disease. 149-167	
1152	Clinical Diagnosis of Dementia. 2012 , 13, 133	1
1151	How Does the Patient Benefit from Clinical PET?. 2012 , 2, 427-36	10
1150	The use and importance of liposomes in positron emission tomography. 2012 , 19, 68-80	20

1149	Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. 2012 , 263, 344-61	166
1148	Biomarkers in dementia with Lewy bodies: a review. 2012 , 27, 443-53	41
1147	Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. 2012 , 78, 1576-82	202
1146	Investigation. 2012 , 107-137	
1145	BODIPY-based molecular probe for imaging of cerebral β amyloid plaques. 2012 , 3, 319-24	106
1144	Intrahippocampal administration of amyloid- β (1-42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. 2012 , 30, 413-22	65
1143	The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. 2012 , 112, 5147-92	636
1142	Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. 2012 , 79, 320-6	97
1141	An update on brain imaging in parkinsonian dementia. 2012 , 4, 201-213	12
1140	Automatic segmentation of amyloid plaques in MR images using unsupervised support vector machines. 2012 , 67, 1794-802	9
1139	Arterial spin labeling MRI study of age and gender effects on brain perfusion hemodynamics. 2012 , 68, 912-22	121
1138	An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2012 , 71, 765-75	9-4 435
1137	Novel indanone derivatives as potential imaging probes for β amyloid plaques in the brain. 2012 , 13, 1652-62	14
1136	Positronen-Emissions-Tomographie. 2012 , 46, 80-99	2
1135	Metal imaging in neurodegenerative diseases. 2012 , 4, 721-38	100
1134	The development, past achievements, and future directions of brain PET. 2012 , 32, 1426-54	96
1133	[Advances in the diagnostics of Alzheimer's disease]. 2012 , 83, 661-73	6
1132	Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina?. 2012 , 34, 633-49	63

1131	Molecular imaging of amyloidosis: will the heart be the next target after the brain?. 2012 , 14, 226-33	41
1130	Reduced interhemispheric inhibition in mild cognitive impairment. 2012 , 218, 21-6	20
1129	Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. 2012 , 39, 621-31	163
1128	Comparison of 11C-PiB and 18F-florbetaben for A β imaging in ageing and Alzheimer's disease. 2012 , 39, 983-9	143
1127	Longitudinal imaging of Alzheimer pathology using [11C]PiB, [18F]FDDNP and [18F]FDG PET. 2012 , 39, 990-1000	116
1126	The prognostic value of amyloid imaging. 2012 , 39, 1207-19	26
1125	Diagnostic accuracy of 18 F-FDG and 11 C-PiB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. 2012 , 66, 185-98	85
1124	National Institute on Aging at middle age--its past, present, and future. 2012 , 60, 1165-9	7
1123	Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. 2012 , 1253, 159-69	30
1122	Aberrant default mode network in subjects with amnesic mild cognitive impairment using resting-state functional MRI. 2012 , 30, 48-61	59
1121	Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. 2012 , 36, 297-309	149
1120	Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders. 2012 , 36, 1188-216	51
1119	Translatability scoring in drug development: eight case studies. 2012 , 10, 39	30
1118	Neuroimaging in the early diagnosis of neurodegenerative disease. 2012 , 1, 5	25
1117	A Synthetic Overview of Radiolabeled Compounds for β Amyloid Targeting. 2012 , 2012, 1279-1293	14
1116	Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. 2012 , 6, 1-15	39
1115	Amyloid- β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?. 2012 , 39, 202-8	27
1114	A β imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. 2012 , 39, 209-19	46

1113	Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. 2012 , 217, 115-25	53
1112	Mild cognitive impairment: pathology and mechanisms. 2012 , 123, 13-30	150
1111	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. 2012 , 123, 433-47	74
1110	A neuroimaging proof of principle study of Down's syndrome and dementia: ethical and methodological challenges in intrusive research. 2013 , 57, 105-18	8
1109	Heteroaromatic and aniline derivatives of piperidines as potent ligands for vesicular acetylcholine transporter. 2013 , 56, 6216-33	23
1108	(18)F-florbetaben Aβ imaging in mild cognitive impairment. 2013 , 5, 4	40
1107	Modeling of PET data in CNS drug discovery and development. 2013 , 40, 267-79	28
1106	Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimers disease through Suzuki-Miyaura cross-coupling reactions. 2013 , 69, 7345-7353	7
1105	Neuroimaging of dementia in 2013: what radiologists need to know. 2013 , 23, 3393-404	20
1104	Recent advances in neuroimaging biomarkers in geriatric psychiatry. 2013 , 15, 360	3
1103	Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. 2013 , 34, 2835-42	22
1102	Ushering in the study and treatment of preclinical Alzheimer disease. 2013 , 9, 371-81	103
1101	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. 2013 , 108, 21-43	368
1100	Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease. 2013 , 24, 407-59	41
1099	Identification of a common binding mode for imaging agents to amyloid fibrils from molecular dynamics simulations. 2013 , 135, 15114-28	38
1098	Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. 2013 , 40, 1122-5	12
1097	Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. 2013 , 40, 580-93	16
1096	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. 2013 , 40, 104-14	148

1095	Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. 2013 , 40, 125-32	91
1094	Development and screening of contrast agents for in vivo imaging of Parkinson's disease. 2013 , 15, 585-95	20
1093	Voxel-based analysis of amyloid-burden measured with [(11)C]PiB PET in a double transgenic mouse model of Alzheimer's disease. 2013 , 15, 576-84	16
1092	A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography. 2013 , 15, 497-506	22
1091	Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. 2013 , 125, 463-5	76
1090	Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. 2013 , 1, 217	154
1089	A new paradigm for testing AD drugs [neuroimaging biomarkers as surrogate outcomes homologous in animals and humans. 2013 , 10, e63-e71	
1088	The epidemiology of delirium: challenges and opportunities for population studies. 2013 , 21, 1173-89	76
1087	Decreased functional connectivity of the amygdala in Alzheimer's disease revealed by resting-state fMRI. 2013 , 82, 1531-8	58
1086	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. 2013 , 136, 2510-26	214
1085	Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer's disease. 2013 , 3, 487-93	27
1084	Preparation and stability of ethanol-free solution of [18F]florbetapir ([18F]AV-45) for positron emission tomography amyloid imaging. 2013 , 56, 295-300	6
1083	Impact of molecular imaging on the diagnostic process in a memory clinic. 2013 , 9, 414-21	137
1082	Emerging biomarkers in cognition. 2013 , 29, 809-28	11
1081	Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. 2013 , 135, 16397-409	211
1080	Amyloid imaging in atypical presentations of Alzheimer's disease. 2013 , 13, 412	29
1079	The common dementias: a pictorial review. 2013 , 23, 3405-17	26
1078	Apathy is associated with increased amyloid burden in mild cognitive impairment. 2013 , 25, 302-7	40

1077	An overview of PET neuroimaging. 2013 , 43, 449-61	34
1076	Glyconanoparticle aided detection of β amyloid by magnetic resonance imaging and attenuation of β amyloid induced cytotoxicity. 2013 , 4, 575-84	49
1075	Cerebral amyloid PET imaging in Alzheimer's disease. 2013 , 126, 643-57	79
1074	Amyloid PET Imaging: MCI and AD. 2013 , 8, 431-45	2
1073	Synaptic changes in Alzheimer's disease and its models. 2013 , 251, 51-65	206
1072	Biomarker modeling of Alzheimer's disease. 2013 , 80, 1347-58	586
1071	Meta-analysis of functional network alterations in Alzheimer's disease: toward a network biomarker. 2013 , 37, 753-65	81
1070	Alzheimer's disease biomarkers: correspondence between human studies and animal models. 2013 , 56, 116-30	15
1069	Molecular neuroimaging in degenerative dementias. 2013 , 32, 301-309	2
1068	Enhanced fluorescent assignment of protein aggregates by an oligothiophene-porphyrin-based amyloid ligand. 2013 , 34, 723-30	17
1067	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. 2013 , 12, 207-16	2557
1066	Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. 2013 , 21, 3356-62	24
1065	Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity?. 2013 , 1, 72	10
1064	Radiosynthesis and in vivo evaluation of a ^{18}F -labelled styryl-benzoxazole derivative for β amyloid targeting. 2013 , 82, 100-4	
1063	Molecular structure of β amyloid fibrils in Alzheimer's disease brain tissue. 2013 , 154, 1257-68	808
1062	Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. 2013 , 79, 1094-108	556
1061	Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. 2013 , 17, 510-6	27
1060	Pattern and predictability in memory formation: from molecular mechanisms to clinical relevance. 2013 , 105, 117-24	25

1059	A brief olfactory test for Alzheimer's disease. 2013 , 333, 19-24	62
1058	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. 2013 , 5, S3	20
1057	Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. 2013 , 34, 169-83	58
1056	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. 2013 , 34, 22-34	48
1055	Apolipoprotein E ϵ and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. 2013 , 34, 1-12	167
1054	A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease. 2013 , 34, 298-308	140
1053	A sparse structure learning algorithm for Gaussian Bayesian Network identification from high-dimensional data. 2013 , 35, 1328-42	43
1052	A two-photon fluorescent probe for amyloid- β plaques in living mice. 2013 , 49, 1303-5	47
1051	Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. 2013 , 9, 106-18	1770
1050	Resting state functional connectivity in preclinical Alzheimer's disease. 2013 , 74, 340-7	302
1049	Dementia and neuroimaging. 2013 , 260, 685-91	11
1048	Early neuropsychological discriminants for Lewy body disease: an autopsy series. 2013 , 84, 1326-30	44
1047	β -Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013 , 73, 155-69.4	209
1046	A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection. 2013 , 8, 127-39	9
1045	Synthesis, characterization and coordination chemistry of aminophenylbenzothiazole substituted 1,4,7-triazacyclononane macrocycles. 2013 , 52, 128-138	4
1044	Fast in vivo imaging of amyloid plaques using fMRI Gd-staining combined with ultrasound-induced blood-brain barrier opening. 2013 , 79, 288-94	24
1043	Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. 2013 , 9, 199-203	37
1042	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. 2013 , 2, 356-65	227

1041	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. 2013 , 9, e-1-16	330
1040	Cognitive aging in persons with minimal amyloid- β and white matter hyperintensities. 2013 , 51, 2202-9	26
1039	(99m)Tc-labeled dibenzylideneacetone derivatives as potential SPECT probes for in vivo imaging of β -amyloid plaque. 2013 , 64, 90-8	30
1038	Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer's disease. 2013 , 34, 1799-806	69
1037	Imagerie de l'Alzheimer : quoi de neuf ?. 2013 , 37, 212-214	
1036	Using neuroimaging to inform clinical practice for the diagnosis and treatment of mild cognitive impairment. 2013 , 29, 829-45	5
1035	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. 2013 , 9, e111-94	296
1034	Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. 2013 , 9, 602-8	215
1033	Disclosure of amyloid imaging results to research participants: has the time come?. 2013 , 9, 741-744.e2	34
1032	Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. 2013 , 71, 207-15	68
1031	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. 2013 , 2, 497-511	74
1030	Molecular neuroimaging in degenerative dementias. 2013 , 32, 301-9	3
1029	In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. 2013 , 34, 1790-8	52
1028	Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations. 2013 , 84, 154-62	41
1027	Effects of APOE ϵ 4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. 2013 , 34, 2482-7	14
1026	Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. 2013 , 21, 272-8	39
1025	Role of positron emission tomography/computed tomography in dementia. 2013 , 51, 927-34	2
1024	Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry. 2013 , 2, 620-9	17

1023	Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration - A combined MRI & FDG-PET study. 2013 , 2, 746-58		17
1022	Research and standardization in Alzheimer's trials: reaching international consensus. 2013 , 9, 160-8		16
1021	The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. 2013 , 76, 332-44		140
1020	L'imagerie cérébrale des plaques amyloïdes: le point de vue du clinicien. 2013 , 4, 59-63		
1019	Risk and resilience: A new perspective on Alzheimer's disease. 2013 , 1, 47-55		2
1018	Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture. 2013 , 79, 1035-7		11
1017	Aphasia with left occipitotemporal hypometabolism: a novel presentation of posterior cortical atrophy?. 2013 , 20, 1237-40		10
1016	The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. 2013 , 9, 687-698.e1		55
1015	Synthesis and applications of benzothiazole containing cyanine dyes. 2013 , 19, 1-11		17
1014	Synthesis and biological evaluation of radioiodinated quinacrine-based derivatives for SPECT imaging of A β plaques. 2013 , 60, 469-78		9
1013	Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. <i>Annals of Neurology</i> , 2013 , 73, 584-93	9-4	115
1012	Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. <i>Annals of Neurology</i> , 2013 , 73, 529-36	9-4	106
1011	Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β amyloid plaque binding agents. 2013 , 23, 1720-6		16
1010	Positron Emission Tomography in Alzheimer Disease. 2013 , 131-174		2
1009	Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. 2013 , 64, 367-83		76
1008	Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. 2013 , 124, 837-50		60
1007	[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. 2013 , 9, 666-76		421
1006	White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?. 2013 , 70, 455-61		137

1005	Brain β amyloid load approaches a plateau. 2013 , 80, 890-6	260
1004	Sporadic Alzheimer's disease begins as episodes of brain ischemia and ischemically dysregulated Alzheimer's disease genes. 2013 , 48, 500-15	82
1003	Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. 2013 , 70, 423-33	39
1002	Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid- β (1-42) and β proteins as Alzheimer disease biomarkers. 2013 , 59, 903-16	117
1001	Curcumin-conjugated nanoliposomes with high affinity for A β deposits: possible applications to Alzheimer disease. 2013 , 9, 712-21	112
1000	Neurodegenerative Diseases. 2013 , 151-173	1
999	Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β amyloid in cognitively normal older individuals. 2013 , 33, 5553-63	113
998	Substituted benzothiazoles: synthesis and medicinal characteristics. 2013 , 19,	14
997	Amyloid- β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. 2013 , 54, 70-7	275
996	Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. 2013 , 9, 192-200	197
995	Exercise counteracts declining hippocampal function in aging and Alzheimer's disease. 2013 , 57, 47-55	200
994	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of tau in cerebrospinal fluid. 2013 , 126, 631-41	103
993	Amyloid- β probes: Review of structure-activity and brain-kinetics relationships. 2013 , 9, 1012-44	28
992	Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. 2013 , 35, 106-17	43
991	Benzothiazole Schiff-bases as potential imaging agents for β amyloid plaques in Alzheimer's disease. 2013 , 22, 4069-4074	17
990	Synthesis and biological evaluation of ^{18}F -labeled 2-phenylindole derivatives as PET imaging probes for β amyloid plaques. 2013 , 21, 3708-14	5
989	Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. 2013 , 73, 422-8	66
988	Amyloid imaging with PET in early Alzheimer disease diagnosis. 2013 , 97, 377-98	45

987	Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. 2013 , 9, S72-83	157
986	Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β Amyloid Plaques. 2013 , 4, 596-600	21
985	Emotion recognition in the dementias: brain correlates and patient implications. 2013 , 3, 277-288	23
984	Contributions of academic laboratories to the discovery and development of chemical biology tools. 2013 , 56, 7161-76	36
983	Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. 2013 , 9, 621-48	84
982	Differential X-ray phase contrast tomography of Alzheimer plaques in mouse models: perspectives for drug development and clinical imaging techniques. 2013 , 8, C05005-C05005	
981	CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. 2013 , 16, 848-50	370
980	β Amyloid Fibril Structures, In Vitro and In Vivo. 2013 , 19-31	1
979	Vulnerable neural systems and the borderland of brain aging and neurodegeneration. 2013 , 77, 219-34	222
978	Automated synthesis of [18 F]Florbetaben as Alzheimer's disease imaging agent based on a synthesis module system. 2013 , 71, 41-6	18
977	Binary classification of [18 F]-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. 2013 , 64, 517-25	37
976	Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. 2013 , 65, 167-75	286
975	A non-linear mixed effect modelling approach for metabolite correction of the arterial input function in PET studies. 2013 , 66, 611-22	5
974	Radiotracers for positron emission tomography imaging. 2013 , 26, 149-58	8
973	Perseverations in Alzheimer's disease: memory slips?. 2013 , 49, 2028-39	17
972	Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases. 2013 , 211-226	3
971	Novel cyclopentadienyl tricarbonyl complexes of (99m)Tc mimicking chalcone as potential single-photon emission computed tomography imaging probes for β Amyloid plaques in brain. 2013 , 56, 471-82	46
970	Amyloid- β positron emission tomography imaging probes: a critical review. 2013 , 36, 613-31	56

969	Application of copulas to improve covariance estimation for partial least squares. 2013 , 32, 685-96	2
968	Cerebrospinal fluid A β 2, phosphorylated Tau181, and resting-state functional connectivity. 2013 , 70, 1242-8	68
967	Alterations in $\alpha 7$ nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. 2013 , 136, 3004-17	52
966	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. 2013 , 136, 2217-27	94
965	In vivo characterization of the early states of the amyloid-beta network. 2013 , 136, 2239-52	84
964	Neuroimaging and the search for a cure for Alzheimer disease. 2013 , 269, 671-91	37
963	In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. 2013 , 136, 2228-38	232
962	Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography. 2013 , 3, 472-81	6
961	Alzheimer's disease: Mapping the brain's decline. 2013 , 502, S84-5	14
960	Prevalence and topography of small hypointense foci suggesting microbleeds on 3T susceptibility-weighted imaging in various types of dementia. 2013 , 34, 984-9	37
959	Challenges of diagnosing dementia in the oldest old population. 2013 , 68, 1103-11	32
958	The role of β amyloid in alzheimer's disease-related neurodegeneration. 2013 , 33, 12910-1	19
957	Preclinical Alzheimer disease and risk of falls. 2013 , 81, 437-43	53
956	In vivo visualization of amyloid deposits in the heart with ^{11}C -PIB and PET. 2013 , 54, 213-20	166
955	Reference region automatic extraction in dynamic [^{11}C]PIB. 2013 , 33, 1725-31	18
954	Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. 2013 , 27, 4-15	86
953	PET quantification of ^{18}F -florbetaben binding to β amyloid deposits in human brains. 2013 , 54, 723-31	83
952	Amyloid imaging in dementia. 2013 , 23, 43-60	

951	Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. 2013 , 54, 1434-41	61
950	Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β -amyloid imaging in aging and dementia. 2013 , 54, 880-6	121
949	Neuroimaging biomarkers of neurodegenerative diseases and dementia. 2013 , 33, 386-416	87
948	PET molecular imaging to investigate higher brain dysfunction in patients with neurotrauma. 2013 , 118, 251-4	5
947	Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. 2013 , 54, 476-90	179
946	Verbal and visuospatial span in logopenic progressive aphasia and Alzheimer's disease. 2013 , 19, 247-53	34
945	Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. 2013 , 54, 1570-6	115
944	Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. 2013 , 54, 1472-8	79
943	Amyloid-load predicts medial temporal lobe dysfunction in Alzheimer dementia. 2013 , 54, 1909-14	18
942	Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. 2013 , 25, 699-710	10
941	Imaging in systemic amyloidosis. 2013 , 107, 41-56	33
940	Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: an exploratory study. 2013 , 4, 62	29
939	Small-molecule theranostic probes: a promising future in neurodegenerative diseases. 2013 , 2013, 150952	29
938	Alzheimer's disease clinical and research update for health care practitioners. 2013 , 2013, 207178	33
937	Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. 2013 , 8, e79378	59
936	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. 2013 , 136, 1399-414	148
935	Positron emission tomography radioligands for in vivo imaging of A β plaques. 2013 , 56, 89-95	47
934	Detection of brain amyloid β -deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B. 2013 , 27, 1026-31	40

933	In vivo assessment of amyloid- β deposition in nondemented very elderly subjects. <i>Annals of Neurology</i> , 2013 , 73, 751-61	9.4	80
932	Carbon-14 radiosynthesis of the benzofuran derivative and β -amyloid plaque neuroimaging positron emission tomography radioligand AZD4694. 2013 , 56, 321-4		2
931	Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. 2013 , 3, e233		167
930	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. 2013 , 80, 1784-91		175
929	Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. 2013 , 54, 887-93		14
928	Medial temporal lobe volume predicts elders' everyday memory. 2013 , 24, 1113-22		35
927	Unexpected finding of cerebral meningioma on (11)C-PiB PET. 2013 , 38, 292-3		6
926	Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. 2013 , 3, 219-229		39
925	Cognitive assessment in Parkinson's disease. 53-64		
924	Imaging and behavior in Parkinson's disease: functional imaging. 89-96		
923	Molecular Imaging of β -Amyloid Plaques with Near-Infrared Boron Dipyrromethane (BODIPY)-Based Fluorescent Probes. 2013 , 12, 7290.2013.00049		42
922	Atrophie corticale postleure. 2013 , 10, 1-6		1
921	Distribution of amyloid burden differs between idiopathic normal pressure hydrocephalus and Alzheimer's disease. 2013 , 26, 41-6		10
920	¹¹ C-PIB and PET for the detection of cardiac amyloid. 2013 , 5, 395-398		
919	¹¹ C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2013 ,		1
918	β -Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. 2013 , 28, 169-75		52
917	Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. 2013 , 3, 43		29
916	Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers. 2013 , 10, 790-6		21

915	Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. 2013 , 8, e57097	76
914	[New era of laboratory testing. Topics: II. Particulars; 10. Novel development of biomarker in nervous disease]. 2013 , 102, 3174-82	
913	Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. 2013 , 35, 284-94	14
912	Synapse stability in the precuneus early in the progression of Alzheimer's disease. 2013 , 35, 599-609	43
911	Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. 2013 , 18, 1150-73	15
910	Vascular risk and FDDNP-PET influence cognitive performance. 2013 , 35, 147-57	3
909	Clinical profile of PiB-positive corticobasal syndrome. 2013 , 8, e61025	38
908	Associations between white matter hyperintensities and β amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. 2013 , 8, e65175	63
907	Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. 2013 , 8, e66877	41
906	Quantitative analysis of PiB-PET with FreeSurfer ROIs. 2013 , 8, e73377	126
905	Development of novel 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of β amyloid plaques in Alzheimer's disease. 2013 , 8, e74104	30
904	Individual subject classification of mixed dementia from pure subcortical vascular dementia based on subcortical shape analysis. 2013 , 8, e75602	6
903	Washout allometric reference method (WARM) for parametric analysis of [(11)C]PIB in human brains. 2013 , 5, 45	11
902	Blood-brain transfer of Pittsburgh compound B in humans. 2013 , 5, 70	16
901	PiB Fails to Map Amyloid Deposits in Cerebral Cortex of Aged Dogs with Canine Cognitive Dysfunction. 2013 , 5, 99	15
900	Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. 2013 , 2013, 589308	7
899	Deconstructing mitochondrial dysfunction in Alzheimer disease. 2013 , 2013, 162152	86
898	Early assessment for Alzheimer's disease and dementia: comparison of two metamemory diagnostic tests. 2013 , 51, 17-21	4

897 Treatment of mood disorders in late life. 119-132

896 Management of adult major depressive disorder. 37-58

895 MR-less surface-based amyloid assessment based on ¹¹C PiB PET. **2014**, 9, e84777 29

894 Hippocampal neurochemical changes in senescent mice induced with chronic injection of D-galactose and NaNO₂ an in vitro high-resolution NMR spectroscopy study at 9.4T. **2014**, 9, e88562 16

893 RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. **2014**, 9, e89901 32

892 Widespread disruption of functional brain organization in early-onset Alzheimer's disease. **2014**, 9, e102995 40

891 Therapeutic and diagnostic challenges for frontotemporal dementia. **2014**, 6, 204 16

890 Regional Fluid-Attenuated Inversion Recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects. **2014**, 6, 240 12

889 Spread of activation and deactivation in the brain: does age matter?. **2014**, 6, 288 9

888 Allopregnanolone and neurogenesis in the nigrostriatal tract. **2014**, 8, 224 13

887 Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. **2014**, 4, 205 140

886 Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. **2014**, 4, 11

885 Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques. **2014**, 4, 23

884 Nuclear imaging of amyloidosis. **2014**, 79, 222-7 8

883 A Review of NIST Primary Activity Standards for (18)F: 1982 to 2013. **2014**, 119, 371-96 7

882 Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. **2014**, 42, 813-21 20

881 Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. **2014**, 407-416 5

880 (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). **2014**, CD010386 66

879	What have novel imaging techniques revealed about metabolism in the aging brain?. 2014 , 9, 341-354	26
878	Biological evaluation of the radioiodinated imidazo[1,2-a]pyridine derivative DRK092 for amyloid- β imaging in mouse model of Alzheimer's disease. 2014 , 581, 103-8	8
877	Biomarkers of Alzheimer's disease. 2014 , 801-815	
876	Amyloid imaging in Alzheimer's disease: a literature review. 2014 , 18, 723-40	8
875	Neurostatistical imaging for diagnosing dementia: translational approach from laboratory neuroscience to clinical routine. 2014 , 30, 755-64	2
874	Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain. 2014 , 3, 79-88	16
873	Synthesis of methoxy-X04 derivatives and their evaluation in Alzheimer's disease pathology. 2014 , 13, 209-13	8
872	[Clinically validated molecular biomarkers of neurodegenerative dementia]. 2014 , 85, 1372-81	4
871	Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid- β oligomers and no plaque pathology. 2014 , 9, 41	48
870	Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497. 2014 , 24, 355-60	9
869	Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. 2016 , 26, 695-707	63
868	Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 2014 , 19, 1044-51	143
867	Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI. 2014 , 87, 843-61	40
866	Novel 18 F-labeled dibenzylideneacetone derivatives as potential positron emission tomography probes for in vivo imaging of β -amyloid plaques. 2014 , 84, 628-38	7
865	Reduced glucose uptake and A β in brain regions with hyperintensities in connected white matter. 2014 , 100, 684-691	22
864	Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function?. 2014 , 24, 2210-8	30
863	Apathy correlates with prefrontal amyloid β deposition in Alzheimer's disease. 2014 , 85, 449-55	66
862	A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. 2014 , 2014, 785039	37

861	Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms. 2014 , 119, 229-35	15
860	The Default Network of the Brain. 2014 , 169-181	
859	Automated identification of dementia using FDG-PET imaging. 2014 , 2014, 421743	13
858	Quantitative characterization of brain β -amyloid using a joint PiB/FDG PET image histogram. 2014 ,	
857	Molecular imaging of Alzheimer disease pathology. 2014 , 35, S12-7	13
856	A data-driven model of biomarker changes in sporadic Alzheimer's disease. 2014 , 137, 2564-77	149
855	Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. 2014 , 71, 23-31	112
854	PET approaches for diagnosis of dementia. 2014 , 35, 2030-8	76
853	Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. 2014 , 57, 323-31	29
852	Biomedical Positron Emission Tomography (PET) imaging. 2014 , 3-40	4
851	Low-dose total-body carbon-ion irradiations induce early transcriptional alteration without late Alzheimer's disease-like pathogenesis and memory impairment in mice. 2014 , 92, 915-26	6
850	Biomarkers in the primary progressive aphasia. 2014 , 28, 922-940	13
849	Development of novel PET probe [^{11}C](R,R)HAPT and its stereoisomer [^{11}C](S,S)HAPT for vesicular acetylcholine transporter imaging: a PET study in conscious monkey. 2014 , 68, 283-92	6
848	Amyloid and its association with default network integrity in Alzheimer's disease. 2014 , 35, 779-91	28
847	Diagnostic methods and biomarkers for Alzheimer's disease. 2014 , 6, 133-147	8
846	Characteristics of the default mode functional connectivity in normal ageing and Alzheimer's disease using resting state fMRI with a combined approach of entropy-based and graph theoretical measurements. 2014 , 101, 778-86	72
845	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. 2014 , 1, 534-43	78
844	Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography. 2014 , 14, 110-7	5

843	In vivo optical signatures of neuronal death in a mouse model of Alzheimer's disease. 2014 , 46, 27-33	16
842	Radioligand development for molecular imaging of the central nervous system with positron emission tomography. 2014 , 19, 1936-44	45
841	Preoperative cerebrospinal fluid β Amyloid/Tau ratio and postoperative delirium. 2014 , 1, 319-328	36
840	Synthesis, characterization and (11) C-radiolabeling of aminophenyl benzothiazoles: structural effects on the alkylation of amino group. 2014 , 57, 566-73	4
839	Pittsburgh compound B retention and progression of cognitive status--a meta-analysis. 2014 , 21, 1060-1067	13
838	Radiation dosimetry of florbetapir F 18. 2014 , 4, 4	15
837	Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. 2014 , 45, 2825-9	78
836	Practical utility of amyloid and FDG-PET in an academic dementia center. 2014 , 82, 230-8	68
835	Synthesis and evaluation of a phenylbenzothiazole-based $^{99m}\text{Tc}(\text{CO})_3$ -radiotracer for possible application in imaging of β Amyloid plaques in Alzheimer's disease. 2014 , 302, 1339-1344	7
834	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. 2014 , 6, 226ra30	244
833	In vitro binding of [^3H]PIB to human amyloid deposits of different types. 2014 , 21, 21-7	14
832	Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications. 2014 , 4, 73-81	4
831	Imaging biomarkers for amyloid: a new generation of probes and what lies ahead. 2014 , 26, 703-7	1
830	Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond. 2014 , 35, 792-6	8
829	Mini-cognitive testing in patients with age-related macular degeneration. 2014 , 34, 868-73	9
828	Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. 2014 , 73, 72-80	31
827	Brain: positron emission tomography tracers beyond [^{18}F]fluorodeoxyglucose. 2014 , 9, 267-76	5
826	Applications of Small-Animal Imaging in Neurology and Psychiatry. 2014 , 517-546	1

825 Animal Models for Brain Research. **2014**, 3-46

824 Functional connectivity in autosomal dominant and late-onset Alzheimer disease. **2014**, 71, 1111-22 68

823 Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. **2014**, 55, 1623-8 116

822 Synergistic effects of ischemia and β amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment. **2014**, 71, 412-22 69

821 Effects of (-)Epicatechin on the Pathology of APP/PS1 Transgenic Mice. **2014**, 5, 69 28

820 PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. **2014**, 14, 79 34

819 Dementia. **2014**, 70-92

818 CSF levels of A β -38/A β -40/A β -42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer's disease. **2014**, 21, 238-45 16

817 Covarying alterations in A β deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. **2014**, 35, 297-308 66

816 The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. **2014**, 1842, 1219-31 411

815 Biomarkers in pharmacology and drug discovery. **2014**, 87, 172-88 45

814 High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. **2014**, 10, 530-540.e1 15

813 Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden. **2014**, 35, 1519-25 52

812 Detection of misfolded A β oligomers for sensitive biochemical diagnosis of Alzheimer's disease. **2014**, 7, 261-8 124

811 In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. **2014**, 24, 242-50 42

810 Homoisoflavonoids as potential imaging agents for β amyloid plaques in Alzheimer's disease. **2014**, 76, 125-31 13

809 Diagnosticare la malattia di Alzheimer. **2014**, 14, 1-14

808 Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. **2014**, 35, 143-51 85

807	Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. 2014 , 41, 836-43	28
806	[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. 2014 , 41, 290-300	73
805	Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI. 2014 , 41, 283-9	24
804	Plasma phospholipids identify antecedent memory impairment in older adults. 2014 , 20, 415-8	706
803	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. 2014 , 137, 1762-71	197
802	Imaging spectrum of sporadic cerebral amyloid angiopathy: multifaceted features of a single pathological condition. 2014 , 5, 375-85	12
801	PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [11C]MeDAS, [11C]CIC and [11C]PIB. 2014 , 41, 995-1003	37
800	Aerobic glycolysis in the primate brain: reconsidering the implications for growth and maintenance. 2014 , 219, 1149-67	57
799	Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. 2014 , 34, 753-8	42
798	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. 2014 , 41, 1190-8	7
797	Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. 2014 , 88, 640-51	693
796	Synthesis and evaluation of a (18)F-curcumin derivate for amyloid plaque imaging. 2014 , 22, 2753-62	27
795	Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. 2014 , 80, 175-83	156
794	Time for tau. 2014 , 137, 1570-1	10
793	Early detection of Alzheimer's disease using PiB and FDG PET. 2014 , 72 Pt A, 117-22	131
792	Early failure of the default-mode network and the pathogenesis of Alzheimer's disease. 2014 , 20, 692-8	36
791	Molecular neuroimaging: the basics. 2014 , 49, 225-33	3
790	Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. 2014 , 17, 304-11	336

789	Magnetization transfer contrast imaging reveals amyloid pathology in Alzheimer's disease transgenic mice. 2014 , 87, 111-9	18
788	Development of a quantitative structure activity relations (QSAR) model to guide the design of fluorescent dyes for detecting amyloid fibrils. 2014 , 89, 1-7	3
787	Neuroimaging of dementia. 2014 , 32, 59-93	17
786	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. 2014 , 10, 381-92	53
785	Neuroimaging biomarkers for Parkinson disease: facts and fantasy. <i>Annals of Neurology</i> , 2014 , 76, 769-834	29
784	Unbiased approaches to biomarker discovery in neurodegenerative diseases. 2014 , 84, 594-607	40
783	Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. 2014 , 24, 2800-9	20
782	Amyloid PET imaging in clinical practice. 2020 , 20, 451-462	7
781	Identification of a nanomolar affinity β -synuclein fibril imaging probe by ultra-high throughput screening. 2020 , 11, 12746-12754	11
780	Discovery of Diphenoxy Derivatives with Flexible Linkers as Ligands for β -Amyloid Plaques. 2020 , 17, 4089-4100	2
779	Decreased Alpha Reactivity from Eyes-Closed to Eyes-Open in Non-Demented Older Adults with Alzheimer's Disease: A Combined EEG and [18F]florbetaben PET Study. 2020 , 77, 1681-1692	1
778	Appropriate reference region selection of F-florbetaben and F-flutemetamol beta-amyloid PET expressed in Centiloid. 2020 , 10, 14950	6
777	PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction. 2020 , 9,	9
776	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI. 2020 , 20, 337	7
775	Comparative Study in Different Filters for Efficient Sterile Filtration. 2020 , 41, 824-828	0
774	Molecular Imaging of Tau Protein: New Insights and Future Directions. 2020 , 13, 586169	3
773	Evaluation of a visual interpretation method for tau-PET with F-flortaucipir. 2020 , 12, e12133	5
772	Recent advances in digital Positron Emission Tomography. 2020 , 15, C10029-C10029	1

771	Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting. 2020 , 74, 473-490	12
770	The application of stratified medicine to dementia care. 2020 , 26, 245-252	0
769	Down syndrome: Distribution of brain amyloid in mild cognitive impairment. 2020 , 12, e12013	4
768	Amyloid accumulation in Down syndrome measured with amyloid load. 2020 , 12, e12020	11
767	Advances in PET-Based Cardiac Amyloid Radiotracers. 2020 , 22, 40	4
766	Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study. 2020 , 61, 1814-1819	6
765	Differentiating A β 0 and A β 2 in amyloid plaques with a small molecule fluorescence probe. 2020 , 11, 5238-5245	12
764	Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. 2020 , 143, 1588-1602	50
763	Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias. 2020 , 11, 496	28
762	Older, non-demented apolipoprotein E carrier males show hyperactivation and structural differences in odor memory regions: a blood-oxygen-level-dependent and structural magnetic resonance imaging study. 2020 , 93, 25-34	1
761	Nuclear medicine and molecular imaging advances in the 21st century. 2020 , 93, 20200095	12
760	What to make of equivocal amyloid imaging results. 2020 , 26, 137-146	1
759	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. 2020 , 12, 74	18
758	Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. 2020 , 77, 1288-1298	17
757	Measuring peripheral markers of neuroinflammation in Alzheimer's disease - Challenges and opportunities. 2020 , 88, 840-841	1
756	Blood Biomarkers of Cognitive Health and Neurodegenerative Disease. 2020 , 568-586	
755	Residue-Specific Binding Mechanisms of Thioflavin T to a Surface of Flat β -Sheets within a Peptide Self-Assembly Mimic. 2020 , 59, 2782-2787	4
754	Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions. 2020 , 76, 281-290	8

753	AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. 2020 , 11, 459	6
752	Probing Estrogen Sulfotransferase-Mediated Inflammation with [11C]-PiB in the Living Human Brain. 2020 , 73, 1023-1033	4
751	Biochemical Markers in Alzheimer's Disease. 2020 , 21,	24
750	APOE- ϵ Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. 2020 , 30, 4110-4120	2
749	The effect of ApoE ϵ 4 on clinical and structural MRI markers in prodromal Alzheimer's disease. 2020 , 10, 464-474	9
748	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. 2020 , 124, 594-602	7
747	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. 2020 , 94, e1793-e1802	13
746	Topographical distribution of A β predicts progression to dementia in A β -positive mild cognitive impairment. 2020 , 12, e12037	4
745	Associations of [F]-APN-1607 Tau PET Binding in the Brain of Alzheimer's Disease Patients With Cognition and Glucose Metabolism. 2020 , 14, 604	9
744	[F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. 2020 ,	8
743	Neurological update: neuroimaging in dementia. 2020 , 267, 3429-3435	4
742	Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimer's disease mouse model. 2020 , 10, 10379	3
741	Sonochemistry and Copper Catalysis: An Efficient Duo in the Synthesis of Chalcogenylindolizines. 2020 , 9, 1631-1637	5
740	β -Secretase Activity Is Associated with Braak Senile Plaque Stages. 2020 , 190, 1323-1331	11
739	Amnesic and non-amnesic symptoms of dementia: An international study of Alzheimer's disease in people with Down's syndrome. 2020 , 35, 650-661	5
738	PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. 2020 , 25,	30
737	Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. 2020 , 11, 900-908	16
736	PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan. 2020 , 38, 343-357	6

735	Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. 2020 , 47, 2666-2680	12
734	Neuroimaging in Vascular Cognitive Impairment and Dementia: A Systematic Review. 2020 , 73, 1279-1294	20
733	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 87, 556-567	9.4 11
732	Validation of Iranian Smell Identification Test for screening of mild cognitive impairment and Alzheimer's disease. 2020 , 1-6	1
731	Diagnostic Value of Muscle [C] PIB-PET in Inclusion Body Myositis. 2019 , 10, 1386	0
730	Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis. 2020 , 75, 380-390	21
729	Synthesis and Characterization of Thiophene-based Donor-Acceptor-Donor Heptameric Ligands for Spectral Assignment of Polymorphic Amyloid- β Deposits. 2020 , 26, 7425-7432	3
728	Imaging biomarkers in neurodegeneration: current and future practices. 2020 , 12, 49	35
727	Temporal trajectories of in vivo tau and amyloid- β accumulation in Alzheimer's disease. 2020 , 47, 2879-2886	14
726	Design principles and fundamental understanding of biosensors for amyloid- β detection. 2020 , 8, 6179-6196	17
725	Brain amyloid, cortical thickness, and changes in activities of daily living. 2020 , 7, 474-485	1
724	Mapping the Binding Interface of PET Tracer Molecules and Alzheimer Disease A β Fibrils by Using MAS Solid-State NMR Spectroscopy. 2020 , 21, 2495-2502	7
723	Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo compared to Histology. 2020 , 73, 1481-1499	5
722	Tau PET imaging with F-PI-2620 in aging and neurodegenerative diseases. 2021 , 48, 2233-2244	20
721	Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [F] flutemetamol amyloid PET study. 2021 , 48, 302-310	9
720	[F]FDDNP PET binding predicts change in executive function in a pilot clinical trial of geriatric depression. 2021 , 33, 149-156	4
719	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. 2021 , 26, 309-321	19
718	Determining Amyloid- β Positivity Using F-AZD4694 PET Imaging. 2021 , 62, 247-252	20

717	Benzimidazole-based fluorophores for the detection of amyloid fibrils with higher sensitivity than Thioflavin-T. 2021 , 156, 1003-1019	3
716	Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer's disease. 2021 , 427, 213553	21
715	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. 2021 , 224, 117433	13
714	Cross-coupling of [C]methyl lithium for C-labelled PET tracer synthesis. 2021 , 57, 203-206	4
713	Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases. 2021 , 76, 121-126	
712	Amyloid: The known unknowns. 2021 , 65, 101212	13
711	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. 2021 , 96, e619-e631	13
710	Pharmacokinetic modelling for the simultaneous assessment of perfusion and F-flutemetamol uptake in cerebral amyloid angiopathy using a reduced PET-MR acquisition time: Proof of concept. 2021 , 225, 117482	1
709	An evaluation of the amyloid cascade model using in vivo positron emission tomographic imaging. 2021 , 21, 14-23	1
708	Attenuation correction using deep Learning and integrated UTE/multi-echo Dixon sequence: evaluation in amyloid and tau PET imaging. 2021 , 48, 1351-1361	8
707	Neurotransmitters and Neurometabolites in Late-Life Depression: A Preliminary Magnetic Resonance Spectroscopy Study at 7T. 2021 , 279, 417-425	7
706	P-tau/A β 2 and A β 2/40 ratios in CSF are equally predictive of amyloid PET status. 2021 , 13, e12190	5
705	The Role of Neuroimaging in Fall Prevention in Healthy Adults at Risk of Alzheimer's Disease. 2021 , 107-129	
704	Carbon-11: Radiochemistry and Target-Based PET Molecular Imaging Applications in Oncology, Cardiology, and Neurology. 2021 , 64, 1223-1259	9
703	Longitudinal cognitive and functional changes in primary progressive aphasia. 2021 , 268, 1951-1961	2
702	Camphor sulfonic acid catalyzed a simple, facile, and general method for the synthesis of 2-arylbenzothiazoles, 2-arylbenzimidazoles, and 3H-spiro[benzo[d]thiazole-2,3'-indolin]-2'-ones at room temperature. 2021 , 51, 1100-1120	3
701	Diagnostic Evaluation of Dementia. 2021 , 31-55	
700	Diagnóstico neuropsicológico diferencial en enfermedad de Alzheimer y demencia frontotemporal: una revisión sistemática cualitativa. 2021 , 1, 82-97	0

- 699 Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. **2021**, 30, 102625 1
- 698 β Amyloid PET and I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. **2021**, 3 3
- 697 Dual-phase F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer's disease. **2021**, 31, 102773 1
- 696 Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody. **2021**, 11, 2588 1
- 695 Vascular Cognitive Impairment. **2021**, 31-59
- 694 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. **2021**, 367-412
- 693 Tau: A Canonical Image Based Algorithm to Quantify Tau PET Scans. **2021**, 62, 1292-1300 6
- 692 PET and SPECT Imaging of Neurodegenerative Diseases. **2021**, 1309-1334
- 691 Neuroanesthesiology Update. **2021**, 33, 107-136 0
- 690 Clinical impact of ^{11}C -Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease. **2021**, 100, e23969 0
- 689 PET Chemistry: An Introduction. **2021**, 131-176
- 688 Journey's End A recap of the chapters, the final conclusions, and new directions to explore. **2021**, 261-270
- 687 Organometallic Chemistry of Drugs Based on Technetium and Rhenium. **2021**,
- 686 Combining bioscaffolds and iPSCs in the treatment of neural trauma and Alzheimer's disease. **2021**, 123-162
- 685 Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins. **2021**, 15, 56-69 3
- 684 Comprehensive review on design perspective of PET ligands based on β amyloids, tau and neuroinflammation for diagnostic intervention of Alzheimer's disease. **2021**, 9, 153-175 2
- 683 Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. **2021**, 48, 2200-2211 4
- 682 Detection of β amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. **2021**, 3, fcab008 14

681	Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. 2021 , 22,	13
680	Sulfur [F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis. 2021 , 143, 3753-3763	24
679	Inhalable Thioflavin S for the Detection of Amyloid Beta Deposits in the Retina. 2021 , 26,	5
678	[F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease. 2021 , 28, 1511-1519	0
677	The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis. 2021 , 22,	5
676	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. 2021 , 228, 117728	6
675	Amyloid burden quantification depends on PET and MR image processing methodology. 2021 , 16, e0248122	3
674	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. 2021 , 9, 48	6
673	Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study. 2020 , 17, 1145-1160	4
672	Comparison of [C]UCB-J and [F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. 2021 , 41, 2395-2409	10
671	Molecular Imaging Approaches in Dementia. 2021 , 298, 517-530	8
670	Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease. 2021 , 18, 709-727	1
669	The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease. 2021 , 35, 582-594	2
668	Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. 2021 , 18, 661-672	1
667	Elderly Man Repeating Questions about Upcoming Appointments. 2021 , 14-17	
666	The inappropriateness of brain MRI prescriptions: a study from Iran. 2021 , 19, 14	0
665	Precision health in Alzheimer disease: Risk assessment-based strategies. 2021 , 10, 54-70	
664	The Man Who Stopped Reading. 2021 , 78-83	

663	Investigating the Spatial Associations Between Amyloid- β Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer's Disease. 2021 , 80, 113-132	0
662	Improving contrast between gray and white matter of Logan graphical analysis' parametric images in positron emission tomography through least-squares cubic regression and principal component analysis. 2021 ,	2
661	Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography. 2021 , 1073858421997035	
660	Impact of Tracer Retention Levels on Visual Analysis of Cerebral [F]- Florbetaben Pet Images. 2021 , 14, 70-77	
659	News about the Role of Fluid and Imaging Biomarkers in Neurodegenerative Diseases. 2021 , 9,	4
658	EEG-fMRI Signal Coupling Is Modulated in Subjects With Mild Cognitive Impairment and Amyloid Deposition. 2021 , 13, 631172	1
657	Radionuclide Imaging of Cardiac Amyloidosis. 2021 , 16, 285-293	
656	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. 2021 , 11, 239-249	5
655	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. 2021 , 18, 728-752	2
654	Recent advances in pre-clinical diagnosis of Alzheimer's disease. 2021 , 1	
653	AMYQ: An index to standardize quantitative amyloid load across PET tracers. 2021 , 17, 1499-1508	4
652	Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy. 2021 , 22,	3
651	An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing. 2021 , 9,	1
650	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. 2021 , 151, 105247	1
649	The Diagnostic Potential of Amyloidogenic Proteins. 2021 , 22,	4
648	Multimodal, label-free fluorescence and Raman imaging of amyloid deposits in snap-frozen Alzheimer's disease human brain tissue. 2021 , 4, 474	5
647	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. 2021 , 80, 1723-1737	10
646	Biomarkers in neurological disorders: a fast-growing market. 2021 , 3, fcab086	1

645	Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly. 2021 ,	0
644	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. 2021 , 144, 2946-2953	10
643	Cerebral Microbleeds, Cerebrospinal Fluid, and Neuroimaging Markers in Clinical Subtypes of Alzheimer's Disease. 2021 , 12, 543866	2
642	Impact de l'imagerie TEP métabolique et moléculaire dans les maladies neurodégénératives cognitives. 2021 , 12, 180-189	
641	Alzheimer disease. 2021 , 7, 33	114
640	Molecular Imaging of Extrapyraxidal Movement Disorders With Dementia: The 4R Tauopathies. 2021 , 51, 275-285	2
639	Neuropsychiatric Symptoms of Alzheimer's Disease in Down Syndrome and Its Impact on Caregiver Distress. 2021 , 81, 137-154	1
638	On Gaps of Clinical Diagnosis of Dementia Subtypes: A Study of Alzheimer's Disease and Lewy Body Disease.	
637	Clinical Impact of PET With F-FDG and C-PIB in Patients With Dementia in a Developing Country. 2021 , 12, 630958	0
636	History in perspective: How Alzheimer's Disease came to be where it is?. 2021 , 1758, 147342	2
635	Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer's disease. 2021 , 10,	3
634	Network interdigitations of Tau and amyloid-beta deposits define cognitive levels in aging. 2021 , 42, 2990-3004	2
633	A Graph Gaussian Embedding Method for Predicting Alzheimer's Disease Progression With MEG Brain Networks. 2021 , 68, 1579-1588	5
632	Water exchange rate across the blood-brain barrier is associated with CSF amyloid-β42 in healthy older adults. 2021 ,	6
631	PET Agents in Dementia: An Overview. 2021 , 51, 196-229	10
630	Advances in Brain Amyloid Imaging. 2021 , 51, 241-252	10
629	Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. 2021 , 13, 99	5
628	Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease. 2021 , 5, 375-387	4

627	Imaging beta-amyloid (A β) burden in the brains of middle-aged individuals with alcohol-use disorders: a [C]PIB PET study. 2021 , 11, 257	
626	Translating amyloid PET of different radiotracers by a deep generative model for interchangeability. 2021 , 232, 117890	5
625	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. 2021 , 13, 624330	5
624	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. 2021 , 22,	6
623	Molecular imaging of beta-amyloid deposition in late-life depression. 2021 , 101, 85-93	8
622	Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?. 2021 , 12, 629442	7
621	C-PIB and I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention. 2021 ,	4
620	Early Impairment in the Ventral Visual Pathway Can Predict Conversion to Dementia in Patients With Amyloid-negative Amnesic Mild Cognitive Impairment. 2021 , 35, 298-305	1
619	Lessons in Organic Fluorescent Probe Discovery. 2021 , 22, 3109-3139	5
618	Following spatial A β aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. 2021 , 7,	3
617	Deep learning-based amyloid PET positivity classification model in the Alzheimer's disease continuum by using 2-[F]FDG PET. 2021 , 11, 56	4
616	A New Highly Deuterated [F]AV-45, [F]D15FSP, for Imaging β -Amyloid Plaques in the Brain. 2021 , 12, 1086-1092	2
615	Subcortical and Cortical Regions of Amyloid- β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. 2021 , 81, 1613-1624	0
614	Cognitively normal APOE ϵ carriers have specific elevation of CSF SNAP-25. 2021 , 102, 64-72	1
613	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. 2021 , 102, 151-160	1
612	Thiophene-Based Optical Ligands That Selectively Detect A β Pathology in Alzheimer's Disease. 2021 , 22, 2568-2581	1
611	Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. 2021 , 1	
610	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. 2021 , 142, 689-706	8

609	Generation of synthetic PET images of synaptic density and amyloid from F-FDG images using deep learning. 2021 , 48, 5115-5129	3
608	Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression. 2021 , 134, 1709-1719	0
607	The complexity of Alzheimer's disease: an evolving puzzle. 2021 , 101, 1047-1081	7
606	Past, present and future role of retinal imaging in neurodegenerative disease. 2021 , 83, 100938	16
605	Preclinical and clinical study on [F]DRKXH1: a novel β -amyloid PET tracer for Alzheimer's disease. 2021 , 1	4
604	When Does Alzheimer's Disease Really Start? The Role of Biomarkers. 2021 , 19, 355-364	
603	Dendritic Branching of Retinal Ganglion Cells as a Biomarker of Glaucomatous Optic Neuropathy and Alzheimer's Disease and a Target of Neuroprotective Therapy. 2021 , 18, 198-207	2
602	Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid β -Aggregates in Alzheimer's Disease. 2021 , 143, 10462-10476	6
601	Verbal Short-Term Memory Disturbance in the Primary Progressive Aphasias: Challenges and Distinctions in a Clinical Setting. 2021 , 11,	1
600	Postmortem Neocortical H-PiB Binding and Levels of Unmodified and Pyroglutamate A β in Down Syndrome and Sporadic Alzheimer's Disease. 2021 , 13, 728739	0
599	Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease. 2021 , 13, 718959	2
598	Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms. 2021 ,	7
597	Amyloid β -Binding Bifunctional Chelators with Favorable Lipophilicity for Cu Positron Emission Tomography Imaging in Alzheimer's Disease. 2021 , 60, 12610-12620	2
596	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. 2021 , 159, 211-233	8
595	Quantum dots as a theranostic approach in Alzheimer's disease: a systematic review. 2021 , 16, 1595-1611	7
594	Comparison of early F-18 Florbetaben PET/CT to Tc-99m ECD SPECT using voxel, regional, and network analysis. 2021 , 11, 16738	0
593	The Amyloid- β Pathway in Alzheimer's Disease. 2021 ,	63
592	Diagnosi clinicolaboratoristica della malattia di Alzheimer. 2021 , 21, 1-15	

- 591 Let's embrace optical imaging: a growing branch on the clinical molecular imaging tree. **2021**, 48, 4120-4128 2
- 590 Evaluation of [F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. **2021**, 3, fca190 4
- 589 Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. **2021**, 97, e1799-e1808 1
- 588 Clinical Implications of Amyloid-Beta Accumulation in Occipital Lobes in Alzheimer's Continuum. **2021**, 11, 1 1
- 587 Associations among vascular risk factors, neuroimaging biomarkers, and cognition: Preliminary analyses from the Multi-Ethnic Study of Atherosclerosis (MESA). **2021**, 2 2
- 586 Amyloid β oligomer selective antibodies for Alzheimer's therapeutics and diagnostics.
- 585 Novel Tracers and Radionuclides in PET Imaging. **2021**, 59, 887-918
- 584 Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates. **2021**, 11, 17977 4
- 583 Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares. **2021**, 11, 473 0
- 582 Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. **2021**, 97, e1823-e1834 5
- 581 and characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice. **2021**, 23, 100285 9
- 580 Distinguishing Amyloid β Protein in a Mouse Model of Alzheimer's Disease by Label-Free Vibrational Imaging. **2021**, 11, 0
- 579 Relationships between β Amyloid and tau in an elderly population: An accelerated failure time model. **2021**, 242, 118440 1
- 578 Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery. **2021**, 71, 101451 4
- 577 PET imaging in Down syndrome and Alzheimer's disease. **2022**, 173-192 0
- 576 Neurological Applications of Positron Emission Tomography Imaging in Healthcare and Research. **2022**, 136-141
- 575 [Cross-validation of Quantitative Analytical Software Using ^{18}F -florbetapir PET Imaging]. **2021**, 77, 32-40 2
- 574 Diagnostic and theranostic intranasal nanointerventions for brain diseases. **2021**, 287-303 0

573	PET Chemistry: Radiopharmaceuticals. 2021 , 177-199	
572	Mapping the binding site topology of amyloid protein aggregates using multivalent ligands. 2021 , 12, 8892-8899	0
571	Relationship between amyloid and tau levels and its impact on tau spreading. 2021 , 48, 2225-2232	8
570	Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease. 2020 , 3, e2027472	7
569	In Vivo Imaging Applications for the Nervous System in Animal Models. 253-269	1
568	Cognitive Impairment in Transgenic A β and Tau Models of Alzheimer's Disease. 2007 , 77-91	1
567	Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. 2009 , 119-147	4
566	What Have We Learned from the Tau Hypothesis?. 2009 , 49-62	1
565	Neuroimaging of Alzheimer's Disease, Mild Cognitive Impairment, and Other Dementias. 2011 , 309-339	3
564	Application of Neuroimaging Methods to Define Cognitive and Brain Abnormalities Associated with HIV. 2011 , 341-353	2
563	Brain Imaging in Behavioral Medicine and Clinical Neuroscience: Synthesis. 2011 , 383-393	2
562	Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET). 2012 , 271-304	1
561	Neuroreceptor Imaging. 2012 , 305-329	1
560	Cerebral Monitoring and Surveillance Using High-Resolution Functional Optical Imaging. 2014 , 307-330	1
559	Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography. 2018 , 1750, 221-229	1
558	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. 2018 , 1750, 231-251	14
557	Quantitative approaches to amyloid imaging. 2011 , 680, 201-25	3
556	The A β -centric Pathway of Alzheimer's Disease. 2007 , 5-36	1

555	PET Neuroimaging in Dementia Conditions. 2021 , 211-282	2
554	A Feature Selection Scheme for Accurate Identification of Alzheimer's Disease. 2016 , 71-81	1
553	ASL-incorporated Pharmacokinetic Modelling of PET Data With Reduced Acquisition Time: Application to Amyloid Imaging. 2016 , 406-413	4
552	Short Acquisition Time PET Quantification Using MRI-Based Pharmacokinetic Parameter Synthesis. 2017 , 737-744	2
551	Encyclopedia of Gerontology and Population Aging. 2020 , 1-8	2
550	Molecules that Disrupt Memory Circuits in Alzheimer's Disease: The Attack on Synapses by A β Oligomers (ADDLs). 2007 , 155-179	7
549	PET Tracers for Beta-Amyloid and Other Proteinopathies. 2014 , 199-212	2
548	Imaging of Dementia. 2008 , 215-218	1
547	18 Ziekte van Alzheimer. 2009 , 197-209	2
546	Tau PET Imaging. 2019 , 1184, 217-230	4
545	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. 2005 , 2, 348	1
544	[C]MODAG-001-towards a PET tracer targeting β synuclein aggregates. 2021 , 48, 1759-1772	16
543	Synthesis and applications of 18F-labeled compounds. 2020 , 215-278	1
542	The Dementias. 2008 , 1855-1907	1
541	PET Imaging in Parkinson's Disease and Other Neurodegenerative Disorders. 2007 , 821-828	4
540	Dementias. 2012 , 1534-1582	4
539	The Central Nervous System. 2010 , 1279-1344	18
538	Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. 2017 , 8, 131-138	57

537	ACR Appropriateness Criteria [®] Dementia. 2020 , 17, S100-S112	6
536	Diagnostic Accuracy of [C]PIB Positron Emission Tomography for Detection of Cardiac Amyloidosis. 2020 , 13, 1337-1347	23
535	Comparison of [F]Flutemetamol and [C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. 2017 , 16, 295-302	19
534	Troubles du langage et pathologies neurodégénératives. 2012 , 17, 16-20	1
533	The Molecularised Me. 245-260	2
532	Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. 2016 , 30, 624-30	42
531	Functional brain imaging in neuropsychology over the past 25 years. 2017 , 31, 954-971	15
530	Test may aid Alzheimer's diagnosis.	0
529	Parametric imaging of [11C]PIB studies using spectral analysis. 2005 , 25, S590-S590	1
528	Different patterns of PIB uptake in AD patients. 2005 , 25, S666-S666	1
527	Neuroimaging in Primary Progressive Aphasia. 2014 , 24, 145-156	1
526	Amyloid Imaging and (What is Normal) Aging. 2009 , 191-244	1
525	Brain Imaging in the Evaluation of Putative Alzheimer's Disease-Slowing, Risk-Reducing and Prevention Therapies. 2009 , 319-350	6
524	Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. 2021 , 144, 434-449	21
523	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. 2016 , 139, 2528-39	45
522	In-Vivo Imaging of Alzheimer Disease ¹⁸ F-Amyloid With [11C]SB-13 PET. 2004 , 12, 584-595	11
521	3D Mapping Reveals Network-specific Amyloid Progression and Subcortical Susceptibility.	1
520	OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease.	81

519	Evaluation of the potassium channel tracer [18F]3F4AP in rhesus macaques.	2
518	Reliability of P3 Event-Related Potential during Working Memory Across the Spectrum of Cognitive Aging.	2
517	Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study.	1
516	In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice.	2
515	Patterns of neurodegeneration in dementia reflect a global functional state space.	1
514	Label-free multiphoton imaging of α -amyloid plaques in Alzheimer's disease mouse models. 2019 , 6, 045008	2
513	Seeing how we smell. 2017 , 127, 447-449	1
512	Multimodal partial volume correction: Application to [C]PIB PET/MRI myelin imaging in multiple sclerosis. 2017 , 37, 3803-3817	14
511	Amyloid- β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. 2020 , 12, 169	10
510	Ageing and dementia. 2008 , 1031-1152	5
509	Beta-amyloid imaging in dementia. 2018 , 35, 1-6	5
508	Positron emission tomography for brain research. 2008 , 75, 68-76	9
507	Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. 2011 , 6, e18850	168
506	Metabolite profiling of Alzheimer's disease cerebrospinal fluid. 2012 , 7, e31501	122
505	Anti-amyloid- β mediated positron emission tomography imaging in Alzheimer's disease mouse brains. 2012 , 7, e51958	11
504	Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. 2012 , 7, e53547	105
503	Binding of the radioligand SIL23 to α -synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. 2013 , 8, e55031	75
502	Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. 2013 , 8, e58816	33

501	FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. 2013 , 8, e62471	75
500	Evaluating amyloid- β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. 2013 , 8, e66381	93
499	Cluster-based statistics for brain connectivity in correlation with behavioral measures. 2013 , 8, e72332	33
498	Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. 2014 , 9, e89998	36
497	Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value?. 2015 , 10, e0139926	21
496	A β levels in the jugular vein and high molecular weight A β oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease. 2017 , 12, e0174630	7
495	Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment. 2015 , 2, 64-70	17
494	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. 2018 , 11, 1-12	5
493	Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease. 2018 , 5,	4
492	Alzheimer's Disease Prevention and Treatment Using Herbal Agents. 2016 , 2,	1
491	Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. 2009 , 46, 717-57	69
490	A β Plaques. 2020 , 1,	8
489	Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy. 2012 , 7, 134-139	14
488	MS4A6A genotypes are associated with the atrophy rates of Alzheimer's disease related brain structures. 2016 , 7, 58779-58788	11
487	Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. 2008 , 14, 451-64	362
486	[F]-florbetaben PET/CT Imaging in the Alzheimer's Disease Mouse Model APPswe/PS1dE9. 2019 , 16, 49-55	8
485	Biomarkers for Alzheimer's Disease. 2019 , 16, 518-528	26
484	Radiosyntheses using fluorine-18: the art and science of late stage fluorination. 2014 , 14, 875-900	94

483	The Association between HbA1c Levels, Olfactory Memory and Cognition in Normal, Pre-Diabetic and Diabetic Persons. 2020 , 20, 198-212	6
482	Unidirectional Influx and Net Accumulation of PIB. 2008 , 2, 114-25	44
481	Performance of principal component analysis and independent component analysis with respect to signal extraction from noisy positron emission tomography data - a study on computer simulated images. 2009 , 3, 1-16	2
480	From Light to Sound: Photoacoustic and Ultrasound Imaging in Fundamental Research of Alzheimer's Disease. 2020 , 4,	4
479	Biomarkers to advance drug development for Alzheimer's disease. 2006 , 1, 409-415	1
478	Positron emission tomography in Alzheimer's disease: early prediction and differentiation. 2009 , 4, 23-38	1
477	Imaging as Biomarker for Decision-Making in Drug Development. 2006 , 31-44	5
476	Imaging of Neurotransmitter Systems in Dementia. 2016 , 271-296	9
475	Mild cognitive impairment: historical development and summary of research. 2004 , 6, 351-67	27
474	Biological markers for early detection and pharmacological treatment of Alzheimer's disease. 2009 , 11, 141-57	31
473	Imaging in Alzheimer's disease. 2009 , 11, 191-9	27
472	Is there a neuropathology difference between mild cognitive impairment and dementia?. 2009 , 11, 171-9	30
471	Memory loss in Alzheimer's disease. 2013 , 15, 445-54	242
470	Non-Alzheimer's disease-related memory impairment and dementia. 2013 , 15, 465-73	18
469	Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. 2009 , 21, 63-75	92
468	Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. 2009 , 21, 117-28	95
467	Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. 2013 , 26, 95-106	17
466	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. 2016 , 50, 249-60	39

465	Aberrant Hippocampal Functional Connectivity Is Associated with Fornix White Matter Integrity in Alzheimer's Disease and Mild Cognitive Impairment. 2020 , 75, 1153-1168	7
464	Progress on Aβ Targeted Therapeutic Strategies for Alzheimer's Disease*. 2012 , 39, 734-740	2
463	Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke. 2017 , 4, 1-16	22
462	PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. 2015 , 5, 433-47	72
461	Neuroimaging Approaches for Elderly Studies. 2015 , 47-86	2
460	Myelin positron emission tomography (PET) imaging in multiple sclerosis. 2020 , 15, 1842-1843	1
459	Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging. 2018 , 17, 21-26	7
458	Positron emission tomography agents. 2013 , 6-20	1
457	Iterative Image Processing for Early Diagnostic of Beta-Amyloid Plaque Deposition in Pre-Clinical Alzheimer's Disease Studies. 2017 , 6,	2
456	FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease. 2014 , 4, 15-26	23
455	Whole Brain Voxel-Wise Analysis of Cerebral Retention of Beta-Amyloid in Cognitively Normal Older Adults Using F-Florbetaben. 2017 , 14, 883-886	3
454	Amyloid positron emission tomography and cognitive reserve. 2015 , 7, 475-83	6
453	Chemometric Studies on Brain-uptake of PET Agents via VolSurf Analysis. 2008 , 29, 61-68	2
452	Synthesis of Thia(oxa)zopyridines and Their Inhibitory Activities for Aβ Amyloid Fibrillization. 2008 , 29, 2331-2336	8
451	Synthesis of Functionalized Benzoxazoles and Their Binding Affinities to Aβ2 Fibrils. 2008 , 29, 1765-1768	2
450	Novel Indole Derivatives as Potential Imaging Agents for Alzheimer's Disease. 2010 , 31, 177-180	1
449	Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. 2013 , 2, e00857	79
448	PET probes beyond (18)F-FDG. 2014 , 28, 435-46	15

- 447 Neuroimaging in Dementia: A Brief Review. **2020**, 12, e8682 4
- 446 Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease. **2011**, 9, 54-66 7
- 445 Cross-Sectional and Longitudinal Comparisons of Biomarkers and Cognition Among Asymptomatic Middle-Aged Individuals with a Parental History of Either Autosomal Dominant or Late Onset Alzheimer Disease.
- 444 Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling. **2021**, 13, 175 2
- 443 Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study.. **2022**, 57, 103331 2
- 442 Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnesic Mild Cognitive Impairment. **2021**, 18, 523-532 1
- 441 Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers. **2021**, 20, 5115-5130 2
- 440 Amyloid-IPET Classification on Cognitive Aging Stages Using the Centiloid Scale. **2021**, 1 1
- 439 Tau Protein Binding Modes in Alzheimer's Disease for Cationic Luminescent Ligands. **2021**, 125, 11628-11636 0
- 438 Möglichkeiten und Bedeutung nuklearmedizinischer Diagnostik: PET und SPECT. **2005**, 97-108
- 437 NEUROIMAGING ADVANCES. **2005**, 5, 36
- 436 FIELD NOTES. **2005**, 5, 56
- 435 Follow-up study of amyloid deposition and glucose metabolism in patients with Alzheimer's disease. **2005**, 25, S415-S415
- 434 Neuroimaging in Dementia: Structural Imaging. **2006**, 111-128
- 433 4. PET?AMS, ??????????. **2007**, 38, 149-154
- 432 5. ??????????. **2007**, 38, 155-159
- 431 PET Tracer Charts the Progress of Dementia. **2007**, 7, 24
- 430 Bibliographie. **2008**, 207-244

429 Molecular imaging research for efficient drug development and DDS. **2008**, 23, 49-60

428 Neuroimaging. **2008**, 681-686

427 MR-less high dimensional spatial normalization of ¹¹C PiB PET images on a population of elderly, mild cognitive impaired and Alzheimer disease patients. **2008**, 11, 442-9

11

426 Molecular Imaging in Biology and Pharmacology. **2008**, 457-XLV

425 Le diagnostic de la maladie d'Alzheimer : l'apport de la recherche préclinique. **2008**, 192, 345-361

424 Microstructural Imaging of Neurodegenerative Changes. **2009**, 95-117

423 Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia. **2009**, 103-127

422 Clinical Evaluation of Dementia and When to Perform PET. **2009**, 3-31

421 Neuroimaging Biomarkers in Alzheimer's Disease. **2009**, 3-15

420 Neurodegenerative Disorders. **2009**, 337-360

419 In Vivo Mouse Imaging and Spectroscopy in Drug Discovery. **2010**, 229-250

418 Bibliographie. **2009**, 337-358

417 Molecular Imaging of the CNS: Drug Actions. **2010**, 191-211

416 Imaging CNS Disease States: Alzheimer's Disease. **2010**, 303-318

415 Chapitre 2. Le rôle de l'imagerie Moléculaire dans le diagnostic des démences. **2009**, 31-41

414 Translational MRI in CNS Drug Discovery. **2010**, 215-228

413 Imaging of CNS Systems: Importance for Drug Development. **2010**, 11-28

412 Functional MRI Studies in Aging and Early Alzheimer's Disease: Predicting Clinical Decline. **2009**, 293-304

411 3.?????????????????. **2010**, 41, 101-106

410 PET Chemistry: Radiopharmaceuticals. **2010**, 103-118

409 Alzheimer's Disease. 1

408 Molecular and Functional Imaging for Drug Development and Elucidation of Disease Mechanisms Using Positron Emission Tomography (PET). **2010**, 222-234

1

407 Progression of Atrophy in Alzheimer's Disease and Related Disorders. **2012**, 167-174

406 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis. 1

405 Neuroimaging and Cognitive Assessments in early Drug Development. 167-186

404 The Toolbox. **2011**, 13-42

403 Functional MRI Studies in Ageing and Early Alzheimer's Disease. **2010**, 437-445

402 Physiological Neuroimaging in Ageing and Dementia: Metabolic and Molecular Scanning. **2010**, 257-261

401 Computational Anatomy in Alzheimer's Disease. **2010**, 262-270

400 In Vivo Imaging of Axonal Transport in Aging and Alzheimer's Disease. **2011**, 545-558

399 Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. **2011**, 419-453

398 Applications of fMRI to Neurodegenerative Disease. **2011**, 639-670

397 Closing the gap between research techniques and clinical practice in the treatment of dementia. **2011**, 2, 168

396 Encyclopedia of Clinical Neuropsychology. **2011**, 105-110

395 Simultaneous PET and MR Imaging of the Human Brain. **2011**, 867-892

394 Neurologie. **2011**, 985-1013

- 393 Molecular Imaging of the Brain with Positron Emission Tomography. **2011**, 376-392 2
- 392 Deterioro cognitivo leve. **2011**, 269-e52
- 391 Cognitive and Behavioral Neurology. **2012**, 161-215
- 390 Neuroimaging. **2012**, 549-555
- 389 Translational Research in Alzheimer's Disease for Development of Antibody-Based Therapeutics. **2012**, 341-354
- 388 Développement d'une batterie francophone pour l'évaluation des troubles du langage dans les maladies neurodégénératives: 10 ans de recherche sur les aphasies primaires progressives. **2012**, XVII, 117 0
- 387 Mild cognitive impairment. **2012**, 1534-1539
- 386 Dementia. 67-80 1
- 385 Imaging Biomarkers for Diagnosis, Prognosis and Treatment of Alzheimer's Disease. **2012**, 103-116
- 384 The Current Status of Alzheimer's Disease Treatment. **2012**, 117-161
- 383 Synthesis and Evaluation of Oleanolic Acid-Conjugated Lactoferrin for β -Amyloid Plaque Imaging. **2012**, 33, 3671-3675
- 382 Manifold Forests for Multi-modality Classification of Alzheimer's Disease. **2013**, 261-272
- 381 Cognition et imagerie cérébrale : contrastes entre vieillissement normal et maladie d'Alzheimer. **2013**, 89-109
- 380 Resting-State-fMRT. **2013**, 229-256 1
- 379 Progression of Atrophy in Alzheimer's Disease and Related Disorders. **2013**, 185-192
- 378 Enfermedad de Alzheimer: clínica y tratamiento. **2013**, 157-163
- 377 Apport de l'imagerie par résonance magnétique dans la maladie d'Alzheimer. **2013**, 45-61
- 376 Brain Hypometabolism, Oxidative Stress, Maternal Transmission, and Risk of Late-Onset Alzheimer's Disease. **2013**, 137-157

375 Hybrid Imaging: From Anatomy to Function. **2014**, 51-79

374 Vascular Dementia. **2014**, 417-435

1

373 Investigation. **2014**, 203-248

372 Nuclear Medicine Imaging Tracers for Neurology. **2014**, 3-30

371 Nuclear Imaging in Frontotemporal Dementia. **2014**, 339-357

370 Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets. **2014**, 3-14

369 Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. **2014**, 185-211

368 AI Imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. **2014**, 213-254

367 Cognitive Decline Associated with Aging, Alzheimer's Disease and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. **2014**, 657-676

366 SPECT/PET Findings in Lewy Body Dementia. **2014**, 373-415

1

365 In Vivo Imaging in Neurodegenerative Diseases. **2014**, 45-80

0

364 Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. **2015**, 179-225

363 Applications of fMRI to Neurodegenerative Disease. **2015**, 465-504

362 Alzheimer-Associated Pathology in the Extracellular Space. **2015**, 75-93

1

361 Amyloid imaging of dementia using the radioligand 18F-AV-45 (Florbetapir F 18). **2015**, 26, 11-18

360 Biomarkers in Alzheimer's Disease: From Pathogenic Initiation to Downstream Outcomes. **2015**, 341-354

359 Radiopharmaceuticals. **2016**, 31-57

1

358 Neurologische und dementielle Erkrankungen. **2016**, 765-794

- 357 Encyclopedia of Clinical Neuropsychology. **2016**, 1-8
- 356 FDG PET: Imaging Cerebral Glucose Metabolism with Positron Emission Tomography. **2016**, 247-270 1
- 355 Chemistry of PET Radiopharmaceuticals: Labelling Strategies. **2017**, 79-103 0
- 354 Hersenen. **2017**, 443-463
- 353 Small Molecule-Assisted PET: Approaches to Imaging of Conformational Diseases of the Brain. **2017**, 07, 106-139 1
- 352 Biological Markers in Nursing Research. **2017**, 25, 275-291 0
- 351 Neuroimaging Approaches for Elderly Studies. **2017**, 1576-1617
- 350 [Quantitative Assessment in Amyloid-PET Imaging]. **2017**, 73, 1165-1174
- 349 Brain Disorders. **2018**, 199-222
- 348 The Wisconsin Registry for Alzheimer's Prevention: A Review of findings and current directions. 0
- 347 CSF biomarkers are differentially related to structural and functional changes in dementia of the Alzheimer's type.
- 346 Encyclopedia of Clinical Neuropsychology. **2018**, 147-154
- 345 Investigation. **2018**, 207-240
- 344 Que penser de l'approche m'dicamenteuse pr'ventive de la maladie d'Alzheimer ?. **2018**, 202, 679-690
- 343 L'imagerie mol'culaire en m'decine nucl'aire, du biomarqueur au th'fanostique. **2018**, 202, 1501-1509
- 342 Imagerie m'tabolique et mol'culaire : l'exemple des maladies neurod'g'n'ratives. **2018**, 202, 1511-1521
- 341 Personalised Medicine, Individual Choice and the Common Good. **2018**, 2
- 340 Dynamic 11C-PiB PET shows cerebrospinal fluid flow alterations in Alzheimer's disease and multiple sclerosis. 0

- 339 Cognitive Decline Associated with Aging, Alzheimer's Disease, and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. **2019**, 1099-1119
- 338 Encyclopedia of Gerontology and Population Aging. **2019**, 1-9
- 337 Cognitive Decline Associated with Aging, Alzheimer's Disease, and Cerebrovascular Risk: Advantages of Dynamic Imaging with MEG. **2019**, 1-20 1
- 336 Primary progressive aphasia. **2019**, 11, 4-11 2
- 335 Neurobiology of Falls: Neuroimaging Assessment. **2020**, 165-188 0
- 334 Microglial activation and tau burden predict cognitive decline in Alzheimer's Disease.
- 333 The neuroscience of dementia. **2020**, 297-312
- 332 Nouvelles techniques d'imagerie cérébrale, potentiel pour la maladie d'Alzheimer. **2020**, 204, 232-236 1
- 331 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 330 Optical Coherence Tomography Angiography in Neuroophthalmology Review. **2020**, 5, 187-208
- 329 Bundle-specific associations between white matter microstructure and Aβ and tau pathology at their connecting cortical endpoints in older adults at risk of Alzheimer's disease.
- 328 The Role of APOE and NF-κB in Alzheimer's Disease. **2021**, 1, 391-399 1
- 327 Disclosing tau tangles using PET imaging: a pharmacological review of the radiotracers available in 2021. **2021**, 1 1
- 326 Positron Emission Tomography. **2020**, 285-312
- 325 Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets. **2021**, 3-15
- 324 Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. **2020**, 64, 414-421 3
- 323 Dementia with Lewy Bodies with Pure Agraphia for Kanji (Japanese Morphograms). **2020**, 59, 3217-3224
- 322 A simple and efficient automated microvolume radiosynthesis of [F]Florbetaben. **2020**, 5, 30 1

- 321 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 320 Butyrylcholinesterase as a biomarker in Alzheimer's disease. **2020**, 263-280 0
- 319 Optical Imaging Probes for Amyloid Diseases in Brain. **2020**, 157-182
- 318 Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. **2020**, 12, e12138 2
- 317 Neuroimaging Characteristics of Subcortical Vascular Cognitive Impairment. **2020**, 113-126
- 316 Radiopharmaceutical Sciences. **2020**, 49-191 1
- 315 Pathophysiology of Vascular Cognitive Impairment (II): Amyloid Contribution in Vascular Cognitive Impairment. **2020**, 87-97
- 314 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. **2020**, 6, e12098 0
- 313 Free-water metrics in medial temporal lobe white matter tract projections relate to longitudinal cognitive decline.
- 312 [Consideration of the Residual Radioactivity of Amyloid Imaging Agent F-flutemetamol Adsorbed on Materials Used in Amyloid PET]. **2020**, 76, 1276-1280
- 311 Study on structural atrophy changes and functional connectivity measures in Alzheimer's disease. **2020**, 7, 016002 0
- 310 Chapter 12: Radiopharmaceutical Chemistry: PET Agents. **2020**,
- 309 Iodine staining as a useful probe for distinguishing amyloid fibril polymorphs. 0
- 308 Chapter 24: Brain. **2020**,
- 307 Imaging cardiac sarcoidosis and infiltrative diseases: diagnosis and therapeutic response. **2020**, 64, 51-73 2
- 306 Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. **2021**, 178, 1014-1025 1
- 305 Academic Publication of Neurodegenerative Diseases From a Bibliographic Perspective: A Comparative Scientometric Analysis. **2021**, 13, 722944 3
- 304 The utility of positron emission tomography in cardiac amyloidosis. **2021**, 1 1

- 303 Neuroimaging in Alzheimer's Disease. 427-431 0
- 302 Noninvasive Detection of Misfolded Proteins in the Brain Using [11C]BF-227 PET. 438-445
- 301 A β Monomer, Oligomer and Fibril in Alzheimer's Disease. 1557-1563
- 300 Pharmacokinetic Challenges against Brain Diseases with PET. 997-1007
- 299 A β Monomer, Oligomer and Fibril in Alzheimer's Disease. 125-131
- 298 Pharmacokinetic Challenges against Brain Diseases with PET. 145-155
- 297 Noninvasive Detection of Misfolded Proteins in the Brain Using [11C]BF-227 PET. 212-219
- 296 Quantitative Analysis of Amyloid β Deposition in Patients with Alzheimer's Disease Using Positron Emission Tomography. 220-230 1
- 295 Neuroimaging in Alzheimer's Disease. 231-235
- 294 Amyloid imaging in alzheimer's disease: A literature review.
- 293 PET in Clinical Neurology. **2006**, 453-461
- 292 Radiopharmaceuticals: Recent Developments and Trends. **2006**, 247-274
- 291 Radiochemistry and Radiopharmacy. **2007**, 34-76
- 290 Spline based inhomogeneity correction for 11C-PIB PET segmentation using expectation maximization. **2007**, 10, 228-35 2
- 289 Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. **2005**, 2, 226-236
- 288 Development and evaluation of an automated quantification tool for amyloid PET images. **2020**, 7, 59 1
- 287 In vivo visualization of propagating β -synuclein pathologies in mouse and marmoset models by a bimodal imaging probe, C05-05. 2
- 286 Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics. **2021**, 60, 7-9 0

- 285 Nuclear Medicine Imaging Tracers for Neurology. **2021**, 3-35 1
- 284 AI Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. **2021**, 283-343
- 283 Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. **2021**, 427-451
- 282 Nuclear Imaging in Frontotemporal Dementia. **2021**, 469-490
- 281 SPECT/PET Findings in Dementia with Lewy Bodies.
- 280 The Default Network of the Brain. **2021**, 165-179
- 279 Animal Models for Brain Research. **2021**, 3-55
- 278 Quantitative multimodal imaging in traumatic brain injuries producing impaired cognition. **2020**, 33, 691-698 0
- 277 AβPET pathology accumulation index: Ready for the clinic?. **2020**, 95, 943-944
- 276 18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. **2021**, 144, 266-277 1
- 275 Combating the Trade in Organs. 77-112 1
- 274 Pathogenesis of Alzheimer's disease. **2007**, 2, 347-59 148
- 273 FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?. **2011**, 55, 250-64 29
- 272 Imaging astrocytosis with PET in Creutzfeldt-Jakob disease: case report with histopathological findings. **2012**, 5, 201-7 21
- 271 Current neuroimaging techniques in Alzheimer's disease and applications in animal models. **2012**, 2, 386-404 17
- 270 Deep brain stimulation: a novel strategy for treating Alzheimer's disease. **2012**, 9, 10-7 141
- 269 The default network: your mind, on its own time. **2010**, 2010, 19
- 268 Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging. **2013**, 3, 261-71 10

267	High-resolution optical tweezers for single-molecule manipulation. 2013 , 86, 367-83	21
266	Plasma acetylcholinesterase activity correlates with intracerebral β amyloid load. 2013 , 10, 48-56	22
265	Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?. 2013 , 3, 197-226	114
264	After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. 2014 , 39, 365-74	5
263	Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease. 2014 , 17, 93-9	24
262	AMYLOID CLEARING IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND THE RISK OF CEREBRAL AMYLOID ANGIOPATHY. 2007 , 1, 5-12	1
261	A review of neuroimaging biomarkers of Alzheimer's disease. 2013 , 18, 239-248	20
260	Separation of β amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis. 2015 , 5, 515-26	4
259	[(11)C]PiB PET in Gerstmann-Strüssler-Scheinker disease. 2016 , 6, 84-93	8
258	Increased Pittsburgh Compound-B Accumulation in the Subcortical White Matter of Alzheimer's Disease Brain. 2017 , 62, E136-E141	2
257	Correlation between two methods of florbetapir PET quantitative analysis. 2017 , 7, 84-91	4
256	Advances in Imaging: Brain Tumors to Alzheimer's Disease. 2015 , 10, 83-97	1
255	F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease. 2018 , 8, 268-281	18
254	Detection of misfolded protein aggregates from a clinical perspective. 2016 , 2, 11-26	3
253	Dementia and movement disorders. 2008 , 29, 204-6	9
252	Molecular Imaging Biomarkers in Dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias. 2020 , 19, 34-45	
251	PET imaging in dementia. 2021 ,	
250	ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods. 2021 ,	0

249 Vascular Cognitive Impairment. **2022**, 441-458

248 Amyloid Imaging in Dementia and Neurodegenerative Disease. **2022**, 99-110

247 Presenilin/secretase activity is located in acidic compartments of live neurons. **2021**, 1

246 F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies.. **2021**, 13, 761010 4

245 Qu'apporte l'imagerie hybride TEP-IRM dans l'étude des pathologies neuro-dégénératives ?. **2021**, 206, 28-28

244 What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. **2021**, 17, 1843-1854 1

243 Alzheimer's Disease. **2021**, 415-422

242 Dementia. **2021**, 1359-1367

241 The Therapeutic and Diagnostic Potential of Amyloid Oligomers Selective Antibodies to Treat Alzheimer's Disease.. **2021**, 15, 768646 0

240 Binding Sites of a Positron Emission Tomography Imaging Agent in Alzheimer's Amyloid Fibrils Studied Using F Solid-State NMR.. **2022**, 3

239 rPOP: Robust PET-Only Processing of community acquired heterogeneous amyloid-PET data. **2021**, 246, 118775 1

238 A review of the application of deep learning in the detection of Alzheimer's disease. **2022**, 3, 1-8 2

237 Connectivity and Patterns of Regional Cerebral Blood Flow, Cerebral Glucose Uptake, and Amyloid Deposition in Alzheimer's Disease (Early and Late-Onset) Compared to Normal Ageing. **2021**, 2

236 Application of Deep Learning Techniques to Diagnose Mild Cognitive Impairment: Functional Near-Infrared Spectroscopy Study. **2021**, 1

235 Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.. *Annals of Neurology*, **2022**, 9-4 3

234 60 Years of Achievements by KSNM in Neuroimaging Research.. **2022**, 56, 3-16

233 2-(4-Hydroxyphenyl)benzothiazole dicarboxylate ester TACN chelators for Cu PET imaging in Alzheimer's disease.. **2021**, 1

232 Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.. **2022**, 112, 181-190 1

- 231 Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease.. **2021**, 2
- 230 Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90.. **2022**, 1
- 229 An in vivo pig model for testing novel PET radioligands targeting cerebral protein aggregates. 0
- 228 Regional uptakes from early-frame amyloid PET and F-FDG PET scans are comparable independent of disease state.. **2022**, 6, 2 0
- 227 Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.. **2021**, 13, 751897 2
- 226 Salicylate metal-binding isosteres as fragments for metalloenzyme inhibition.. **2022**, 13, 2128-2136 0
- 225 Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future.. **2022**, 1
- 224 Neuroimaging of Mouse Models of Alzheimer's Disease.. **2022**, 10, 2
- 223 White matter microstructure associations to amyloid burden in adults with Down syndrome.. **2021**, 33, 102908
- 222 Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. **2022**, 4, fca017 2
- 221 Deep residual inception encoder-decoder network for amyloid PET harmonization.. **2022**, 1
- 220 In vivo imaging of alpha-synuclein with antibody-based PET.. **2022**, 208, 108985 1
- 219 Association of Performance on the Financial Capacity Instrument Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. 10.1212/CPJ.0000000000001157
- 218 Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment.. **2022**, 4, fca016 0
- 217 ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.. **2022**, 13, 826423 0
- 216 Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage.. **2022**, 14, 33 1
- 215 Strategic Design of Amyloid-Species Fluorescent Probes for Alzheimer's Disease.. **2022**, 0
- 214 Functional Molecular Imaging II. **2022**, 63-77

213 Amyloid Imaging. **2022**, 161-165

212 Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes for imaging of amyloid- β species.. **2022**, 12, 3178-3195

0

211 Current Progress in the Development of Probes for Targeting β -Synuclein Aggregates.. **2022**,

0

210 Impact of 40 Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series.. **2021**,

2

209 Synthesis of Novel Pyrazolo[3,4-b]pyridines with Affinity for β -Amyloid Plaques. **2022**, 2022, M1343

208 Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology.

207 Alzheimer's disease amyloid- β pathology in the lens of the eye.. **2022**, 108974

1

206 Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.. **2022**,

1

205 Dissection of the polygenic architecture of neuronal A β production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. **2022**, 2, 125-139

0

204 Examining a role for the retrosplenial cortex in age-related memory impairment.. **2022**, 189, 107601

0

203 An efficient combination of quadruple biomarkers in binary classification using ensemble machine learning technique for early onset of Alzheimer disease.

0

202 Causal evidence for the multiple demand network in change detection: auditory mismatch magnetoencephalography across focal neurodegenerative diseases.. **2022**,

0

201 Decreased imaging time of amyloid PET using [F]florbetapir can maintain quantitative accuracy.. **2022**, 1

200 Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer's Disease.. **2022**, 11,

0

199 Association of Indication for Hospitalization with Subsequent Amyloid PET and MRI Biomarkers.. **2022**,

198 Cerebellar and Cerebral Amyloid Visualized by [F]flutemetamol PET in Long-Term Hereditary V30M () Transthyretin Amyloidosis Survivors.. **2022**, 13, 816636

1

197 A computational model of neurodegeneration in Alzheimer's disease.. **2022**, 13, 1643

3

196 Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.. **2022**,

1

- 195 Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age.. **2022**, 14, 811146 1
- 194 An Pig Model for Testing Novel Positron Emission Tomography Radioligands Targeting Cerebral Protein Aggregates.. **2022**, 16, 847074 0
- 193 The meningeal lymphatic vasculature in neuroinflammation.. **2022**, 36, e22276 1
- 192 Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers.. **2022**, 10, 1
- 191 Quantification of amyloid PET for future clinical use: a state-of-the-art review.. **2022**, 1 1
- 190 Evaluation of MR-less in brain amyloid-PET Centiloid quantification. **2022**, 1
- 189 Tracer development for PET imaging of proteinopathies.. **2022**, 1
- 188 Pre-Diagnostic Cognitive and Functional Impairment in Multiple Sporadic Neurodegenerative Diseases. 0
- 187 Identifying Mild Alzheimer's Disease With First 30-Min C-PiB PET Scan.. **2022**, 14, 785495
- 186 New Horizons - Cognitive dysfunction associated with type 2 diabetes. **2021**, 0
- 185 Detection of Dementia Through 3D Convolutional Neural Networks Based on Amyloid PET. **2021**, 0
- 184 A longitudinal investigation of A β anxiety, depression, and mild cognitive impairment. **2021**, 1
- 183 The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis.. **2021**, 23, 0
- 182 Comparison of C-Pittsburgh compound-B and F-Flutemetamol White Matter Binding in PET.. **2021**, 1
- 181 Artificial intelligence for diagnosis and prognosis in neuroimaging for dementia; a systematic review. 1
- 180 In vivo alterations of mitochondrial activity and amyloidosis in early-stage senescence-accelerated mice: a positron emission tomography study. **2021**, 18, 288 0
- 179 Independent Prognostic Utility of C-Pittsburgh Compound B Positron Emission Tomography in Light-Chain Cardiac Amyloidosis Patients.. **2021**, 1
- 178 Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence. **2021**, 4

177 Tau and Alzheimer's Disease: Molecular Mechanisms and Treatment Approaches. **2021**, 4, 1

176 Cross-Modality Generation of Amyloid PET from FDG PET for Alzheimer's Disease Diagnosis. **2021**,

1

175 A Comparative Study of High-Contrast Fluorescence Lifetime Probes for Imaging Amyloid in Tissue. **2021**,

2

174 Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?. **2022**, 13, 74

0

173 High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimer's Disease.. **2022**, 12,

1

172 Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. **2022**, 143, 571

0

171 Neuroproteomics Chip-Based Mass Spectrometry and Other Techniques for Alzheimer's Disease Biomarkers - Update.. **2022**,

0

170 Fundamentals of Biostatistics. 28-41

169 Selecting Outcome Measures. 69-77

168 Table_1.DOCX. **2018**,

167 Image_1.TIF. **2019**,

166 Table_1.DOCX. **2019**,

165 Table_1.docx. **2019**,

164 Data_Sheet_1.pdf. **2019**,

163 Data_Sheet_1.PDF. **2019**,

162 Image_1.TIF. **2020**,

161 Image_1.JPEG. **2018**,

160 Image_2.JPEG. **2018**,

159 Table_1.XLSX. **2020**,

158 Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?. **2022**, 47,

2

157 Alzheimer's disease: Newer biomarkers.. **2021**, 30, S315-S319

156 PET Imaging of Amyloid and Tau in Alzheimer's Disease. **2022**, 307-323

0

155 The Role of Neuroimaging in Fall Prevention in Healthy Adults at Risk of Alzheimer's Disease. **2022**, 790-812

154 How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?. **2022**,

153 Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.. **2022**, 14, 838034

4

152 Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease.. **2022**, 27,

0

151 PET Imaging in Preclinical Anti-ADrug Development.. **2022**, 1

0

150 Deep learning-based brain age prediction in normal aging and dementia. **2022**, 2, 412-424

2

149 Artificial Intelligence Predictor for Alzheimer's Disease Trained on Blood Transcriptome: The Role of Oxidative Stress.. **2022**, 23,

148 PET Imaging of Dementia: Update 2022.. **2022**,

0

147 Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.. **2022**,

0

146 Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools. **2022**, 10,

1

145 Impact of cerebral blood flow and amyloid load on SUVR bias.. **2022**, 12, 29

0

144 The Broad Range of Research in Alzheimer's Disease and Related Dementias.. **2022**, 1

1

143 Molecular imaging: Techniques and current clinical applications. 10-21

3

142 Recognizing common PET patterns in neurodegenerative dementia. 06-12

- 141 The Association Between Acquired Color Deficiency and PET Imaging of Neurodegeneration in Mild Cognitive Impairment and Alzheimer Disease.. **2022**, 63, 20
- 140 PET Imaging in Animal Models of Alzheimer's Disease. **2022**, 16,
- 139 CSF Phosphorylated Tau as an Indicator of Subsequent Tau Accumulation. **2022**,
- 138 Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. **2022**, 12, 1357
- 137 A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413
- 136 Regiodivergent Synthesis of Benzothiazole-based Isosorbide Imidates by Oxidative N-Heterocyclic Carbene Catalysis.
- 135 The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. **2022**, 63, 13S-19S
- 134 68Ga-Labeled Benzothiazole Derivatives for Imaging A β Plaques in Cerebral Amyloid Angiopathy.
- 133 Face recognition from research brain PET: An Unexpected PET Problem. **2022**, 119357
- 132 Quantifying cerebrospinal fluid dynamics: A review of human neuroimaging contributions to CSF physiology and neurodegenerative disease. **2022**, 170, 105776
- 131 Recent Updates on PET Imaging in Neurodegenerative Diseases. **2022**, 83, 453
- 130 Tracers progress for positron emission tomography imaging of glial-related disease. **2022**, 36, 1
- 129 Longitudinal Consumption of Ergothioneine Reduces Oxidative Stress and Amyloid Plaques and Restores Glucose Metabolism in the 5XFAD Mouse Model of Alzheimer's Disease. **2022**, 15, 742
- 128 Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study.
- 127 Deep learning based low-activity PET reconstruction of [11C]PiB and [18F]FE-PE2I in neurodegenerative disorders. **2022**, 119412
- 126 Molecular PET Imaging in Alzheimer's Disease.
- 125 Spatial Distribution and Hierarchical Clustering of β -Amyloid and Glucose Metabolism in Alzheimer's Disease. 14,
- 124 Amyloid- and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study. 10.1212/WNL.0000000000200857

- 123 Alzheimer's disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM/PCA. **2022**, 12, 0
- 122 Differential Diagnosis Between Alzheimer's Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid- β Imaging?. **2022**, 1-7
- 121 The dense-core plaques of Alzheimer's disease are granulomas. **2022**, 219, 2
- 120 [18F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET Findings. **2022**, 18, 437 0
- 119 Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. **2022**, 8,
- 118 A Binary Classification Study of Alzheimer's Disease Based on a Novel Subclass Weighted Logistic Regression Method. **2022**, 10, 68846-68856
- 117 Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. 0
- 116 Utility of the Addenbrooke's Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. **2022**, 4, 1
- 115 Structure-specific amyloid precipitation in biofluids. 0
- 114 Brain Amyloid Index as a Probable Marker Bridging Between Subjective Memory Complaint and Objective Cognitive Performance. 16,
- 113 AMYLOID- β AND TAU DEPOSITION INFLUENCES COGNITIVE AND FUNCTIONAL DECLINE IN DOWN SYNDROME. **2022**,
- 112 If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. **2022**, 20, e3001694 3
- 111 The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. **2022**, 103125
- 110 Distribution and inter-regional relationship of amyloid-beta plaque deposition in a 5xFAD mouse model of Alzheimer's disease. 14, 1
- 109 DeepPVC: prediction of a partial volume-corrected map for brain positron emission tomography studies via a deep convolutional neural network. **2022**, 9,
- 108 Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amyloid load in Alzheimer's disease. 0
- 107 Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid- β Burden. **2022**, 1-10
- 106 Rational Design, Synthesis of Fluorescence Probes for Quantitative Detection of Amyloid- β in Alzheimer's Disease Based on Rhodamine-Metal Complex.

- 105 Proteophenes - amino acid functionalized thiophene-based fluorescent ligands for visualization of protein deposits in tissue sections with Alzheimer's disease pathology.
- 104 Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging. **2022**, 1-12
- 103 International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease.
- 102 Covariance-based vs. correlation-based functional connectivity dissociates healthy aging from Alzheimer disease. **2022**, 261, 119511
- 101 Phosphorus metabolism in the brain of cognitively normal midlife individuals at risk for Alzheimer's disease. **2022**, 2, 100121
- 100 Alzheimer's Drug PBT2 Interacts with the Amyloid β 42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs. **2022**, 61, 14626-14640
- 99 Association of B cell profile and receptor repertoire with the progression of Alzheimer's disease. **2022**, 40, 111391
- 98 Advances in Alzheimer's disease research over the past two decades. **2022**, 21, 866-869
- 97 How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. **2023**, 455-492
- 96 Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study. **2022**, 2, 100048
- 95 Uncertainties in the PET defined A-/T Neocortical + subtype. **2022**, 14,
- 94 Expression of Regional Amyloid Deposition in Centiloid Scale and Used for Quantitative Analysis in Alzheimer's Disease-A Multi-Site Study.
- 93 Future directions. **2023**, 175-209
- 92 Alzheimer's Disease Detection via a Surrogate Brain Age Prediction Task using 3D Convolutional Neural Networks. **2022**,
- 91 Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study.
- 90 Default-mode network connectivity changes during the progression towards Alzheimer's dementia: A longitudinal functional MRI study.
- 89 The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification. jnumed.122.264031
- 88 Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18F-THK5351. Publish Ahead of Print,

87	Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning.	0
86	Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers. 2022 , 23, 10490	0
85	Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management. 10.1212/WNL.0000000000001389	0
84	Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis. 1-10	1
83	Amyloid-beta biomarkers in Braak stages and their predictive relationships with cognitive impairment: Support vector machine and deep learning approaches.	0
82	Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer's disease. 2022 , 18, e1010294	0
81	Mental health care for older adults: recent advances and new directions in clinical practice and research. 2022 , 21, 336-363	1
80	A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia.	0
79	Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging.	0
78	Multipronged diagnostic and therapeutic strategies for Alzheimer's disease.	2
77	¹¹ C-PiB. 2022 , 120-121	0
76	Correlation of Global and Regional Amyloid Burden by ¹⁸ F-Florbetaben PET/CT With Cognitive Impairment Profile and Severity. 2022 , 47, 923-930	0
75	The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease. 13,	0
74	Early-stage differentiation between Alzheimer's disease and frontotemporal lobe degeneration: Clinical, neuropsychology, and neuroimaging features. 14,	0
73	Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease.	2
72	Dendritic Branching of Retinal Ganglion Cells as a Biomarker of Glaucomatous Optic Neuropathy and Alzheimer's Disease and a Target of Neuroprotective Therapy. 2022 , 19, 532-540	0
71	Brain Networks, Clinical Manifestations, and Neuroimaging of Cognitive Disorders. 2022 ,	1
70	Imaging Biomarkers for CNS Drug Development and Future Clinical Utility: Lessons From Neurodegenerative Disorders. jnumed.122.264773	0

- 69 Pre-diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases. 1
- 68 Can hippocampal subfield measures supply information that could be used to improve the diagnosis of Alzheimer's disease?. **2022**, 17, e0275233 0
- 67 Fast and accurate amyloid brain PET quantification without MRI using deep neural networks. *jnumed*.122.264414
- 66 Defining the clinical utility of PET or PET-CT in idiopathic inflammatory myopathies: A systematic literature review. **2022**, 57, 152107 0
- 65 Fluid biomarkers in Alzheimer's disease. **2022**, 0
- 64 Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer's disease in a feasibility study. 14, 0
- 63 In Vivo Preclinical Assessment of β -Amyloid-Affine [^{11}C]C-PIB Accumulation in Aluminium-Induced Alzheimer's Disease-Resembling Hypercholesterinaemic Rat Model. **2022**, 23, 13950 0
- 62 Case report: Non-Alzheimer's disease tauopathy with logopenic variant primary progressive aphasia diagnosed using amyloid and tau PET. 13, 0
- 61 Frontal and temporal lobe correlates of verbal learning and memory in aMCI and suspected Alzheimer's disease dementia. 1-17 0
- 60 Radiolabeled Thioflavin-T Derivative PET Imaging for the Assessment of Cardiac Amyloidosis. 0
- 59 Design, synthesis, and preliminary evaluation of [^{18}F]-aryl fluoro-sulfates PET radiotracers via SuFEx methods for β -amyloid plaques in Alzheimer's disease. **2022**, 75, 117087 0
- 58 Efficient synthesis of 2-aryl benzothiazoles mediated by *Vitreoscilla* hemoglobin. **2022**, 533, 112784 0
- 57 Design and synthesis of astatinated benzothiazole compounds for their potential use in Targeted Alpha Therapy (TAT) strategies to treat Alzheimer's disease-associated amyloid plaques. **2023**, 191, 110555 0
- 56 State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities. **2023**, 144, 104998 0
- 55 Aging Muscles, Myositis, Pain, and Peripheral Neuropathies: PET Manifestations in the Elderly. **2023**, 18, 149-160 0
- 54 A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. 1
- 53 An update on the use of gamma (multi)sensory stimulation for Alzheimer's disease treatment. 14, 0
- 52 Plasma phosphorylated tau181 predicts cognitive and functional decline. 0

- 51 Aβ Targeting Bifunctional Chelators (BFCs) for Potential Therapeutic and PET Imaging Applications. **2023**, 24, 236 ○
- 50 Update Amyloid-Bildgebung in der Diagnostik der Neurodegeneration. **2022**, 45, 256-265 ○
- 49 Handgrip Strength is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden. **2022**, 1-8 ○
- 48 Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. ○
- 47 Thiophene-Based Ligands for Histological Multiplex Spectral Detection of Distinct Protein Aggregates in Alzheimer's Disease. ○
- 46 Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. **2023**, 14, ○
- 45 Molecular Imaging of the Association between Serotonin Degeneration and Beta-Amyloid Deposition in Mild Cognitive Impairment. **2023**, 103322 ○
- 44 Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. 12, 1
- 43 Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer's disease. ○
- 42 Gender differences contribute to variability of serum lipid biomarkers for Alzheimer's disease. ○
- 41 Acute sleep loss decreases CSF-to-blood clearance of Alzheimer's disease biomarkers. ○
- 40 Data-Driven Phenotyping of Alzheimer's Disease under Epigenetic Conditions Using Partial Volume Correction of PET Studies and Manifold Learning. **2023**, 11, 273 ○
- 39 Differential effect of dementia etiology on cortical stiffness as assessed by MR elastography. **2023**, 37, 103328 1
- 38 A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease. ○
- 37 Hersenen. **2023**, 239-254 ○
- 36 Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline. n/a-n/a ○
- 35 The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact. 13, ○
- 34 Predicting continuous amyloid PET values with CSF and plasma Aβ₄₂/Aβ₄₀. **2023**, 15, ○

- 33 Predicting amyloid PET and tau PET stages with plasma biomarkers. ○
- 32 ExHiF: Alzheimer's disease detection using exemplar histogram-based features with CT and MR images. **2023**, 115, 103971 ○
- 31 Precise profiling of exosomal biomarkers via programmable curved plasmonic nanoarchitecture-based biosensor for clinical diagnosis of Alzheimer's disease. **2023**, 230, 115269 ○
- 30 The association of dietary and nutrient patterns on neurocognitive decline: A systematic review of MRI and PET studies. **2023**, 87, 101892 ○
- 29 Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. **2022**, 16, 25-39 ○
- 28 Multimodal comparisons of QSM and PET in neurodegeneration and aging. **2023**, 273, 120068 ○
- 27 . 306-308 ○
- 26 My Genome, My Right. 183-199 ○
- 25 Personalised Medicine and the Politics of Human Nuclear Genome Transfer. 17-36 ○
- 24 Index. 302-305 ○
- 23 Bibliography. 261-301 ○
- 22 I Run, You Run, We Run. 226-244 ○
- 21 Personalising Future Health Risk through Biological Insurance 52-76 ○
- 20 The Best Me I Can Possibly Be 200-225 ○
- 19 When There Is No Cure. 113-132 ○
- 18 Plantainoside B in *Bacopa monniera* Binds to A β Aggregates Attenuating Neuronal Damage and Memory Deficits Induced by A β **2023**, 46, 320-333 ○
- 17 Design and feasibility of an Alzheimer's disease blood test study in a diverse community-based population. ○
- 16 Development of ATR-FTIR spectroscopy for the diagnosis of Alzheimer's disease using oral buccal cells. ○

- 15 Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment. 19, ○
- 14 Leveraging the regulatory framework to facilitate drug development in Parkinson's disease. **2023**, 347-360 ○
- 13 Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging. **2023**, 13, ○
- 12 Synthesis and In Vitro and In Vivo Evaluation of 18F-Labeled Positron Emission Tomography Tracers for Imaging Aβ Plaques. **2023**, 14, 988-1003 ○
- 11 Harnessing the potential of machine learning and artificial intelligence for dementia research. **2023**, 10, ○
- 10 Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. **2022**, 16, 25-39 ○
- 9 Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort. ○
- 8 Thiophene-based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphic Disease Associated Protein Aggregates. ○
- 7 Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects. ○
- 6 Fluorine-18-Labeled Diaryl-azines as Improved Aβ Amyloid Imaging Tracers: From Bench to First-in-Human Studies. **2023**, 66, 4603-4616 ○
- 5 Neurodegeneration: Cerebrum. **2013**, 947-947.e19 ○
- 4 Psychometry in Dementia. ○
- 3 Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. ○
- 2 Aβ42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson's disease. 15, ○
- 1 30 years of [11C]methyl triflate. **2023**, 197, 110812 ○